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I.  Abbreviations 
AA      arachidonic acid 
aa   amino  acid 
ADP   adenosine  diphosphate 
AKBA  3-O-acetyl-11-keto-β-boswellic acid 
AM   alveolar macrophages 
AMP   adenosine  monophosphate 
ATP   adenosine  triphosphate 
BLT   LTB4 receptors 
C5a     complement C5a 
CaMK   calcium/calmodulin-dependent kinase 
cAMP   cyclic AMP 
CLP   coactosin-like  protein 
COX   cyclooxygenase 
cPLA2   cytosolic phospholipase A2 
CTP   cytidine triphosphate 
cysLT   cysteinyl leukotriene 
DMSO dimethylsulfoxide 
DNA   desoxyribonucleic  acid 
DTT   dithiothreitol   
EDTA  ethylendiaminetetraacetate 
ERK    extracellular signal-regulated kinase 
F-actin filamentous  actin 
FLAP   5-lipoxygenase activating protein 
fMLP  N-formyl-methionyl-leucyl-phenylalanine 
GFP    green fluorescent protein 
GM-CSF   granulocyte/macrophage colony-stimulating factor 
GPCR   G protein-coupled receptor 
GPx   glutathione  peroxidase 
Grb2    growth factor receptor-bound protein 2  
GSH   glutathione 
H(p)ETE hydro(pero)xyeicosatetraenoic  acid 
HeLa cells  epithelial cells derived from a human cervix carcinom Abbreviations 
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HL-60 cells  promyeloic leukemic cell line 
HL-60TB  HL-60 cells negative for 5-LO 
HpODE hydroperoxyoctadecadienoic  acid 
Hsp27   heat shock protein 27 
IL   interleukin 
kDa   kilo  Dalton 
LO   lipoxygenase 
LOOH  lipid hydroperoxide 
LPS   lipopolysaccharide 
LT   leukotriene 
LTA4H LTA4-hydrolase 
LTC4S   LTC4-synthase 
MAPEG membrane-associated  proteins  in  eicosanoid and glutathione metabolism 
MAPK  mitogen-activated protein kinase 
MAPKAPK  mitogen-activated protein kinase-activated protein kinase 
MBP   myelin basic protein 
MEK    MAPK kinase  
MEKK MEK  kinase 
MGST  microsomal  GSH-S-transferase 
MK    MAPKAPK (mitogen-activated protein kinase-activated protein kinase) 
MKK   MAPK  kinase 
MM6   Mono  Mac  6 
MNK   MAP  kinase-interacting  kinase 
NFκB   nuclear factor κB 
NES   nuclear export signal 
NIS    nuclear import sequence 
NLS    nuclear localization sequence 
NO   nitric oxide 
OAG   1-oleoyl-2-acetylglycerol 
PAF   platelet-activating  factor 
PC   phosphatidylcholine 
PG   prostaglandin 
PhGPx  phospholipid hydroperoxide glutathione peroxidase 
PI 3-K   phosphatidyl inositol 3-kinase Abbreviations 
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PK   protein kinase  
PL   phospholipase 
PM   peritoneal  macrophages 
PMA     phorbol-12-myristate-13-acetate 
PMNL   polymorphonuclear leukocytes 
PPAR   peroxisome proliferator-activated receptor 
RBL-1   rat basophilic leukemia 
RNA   ribonucleic  acid 
ROS    reactive oxygen species 
SA   sodium arsenite  
SH   src-homology   
sPLA2  secretory  phospholipase  A2 
TGFβ   transforming growth factor beta 
TNFα   tumor necrosis factor alpha 
TRAP  TGFβ receptor-I-associated protein 
U937 cells  lymphoblostoid cell line 
UFA   unsaturated  fatty  acid 
UTP   uridine triphosphate 
-/-   double knock outIntroduction 
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II.  Introduction 
A.  Lipoxygenases 
1.  Definition and nomenclature 
Lipoxygenases (LOs) constitute a family of dioxygenases that catalyze the oxygenation of free 
and esterified polyunsaturated fatty acids containing a (1Z,4Z)-penta-1,4-diene system to 
produce the corresponding hydroperoxy derivatives [175]. They are widely expressed in plants, 
fungi, and animals but not in bacteria or yeast. In plants, they are involved in diverse aspects of 
plant physiology as growth and development, pest resistance and senescence or responses to 
wounding [346]. LOs are named according to the position in which molecular oxygen is 
incorporated in the main substrate arachidonic acid (AA). In some cases, also the 
stereoconfiguration and the tissue of occurrence are specified. 
2.  Family 
When discovered in 1947 the first LO was referred to as lipoxidase, isolated and crystallised 
from soybean [336]. 12-(S)-hydroxyeicosatetraenoic acid (12-HETE) was the first product 
derived from a mammalian LO detected in 1974 when human platelets were treated with AA 
[129]. The first 5-LO was discovered in rabbit polymorphonuclear leukocytes (PMNL) [29]. To 
date, 18 different sequences of mammalian LOs are known and the enzymes are separated into 
four groups based on their enzymatic properties [176]. In humans, there are five enzymes, noted 
as reticulocyte-type 15(S)-LO [317], platelet-type 12(S)-LO [157], epidermis-type 12(R)-LO 
[27], epidermis-type 12(S)-LO [33], and 5(S)-LO (see figure 1) [216]. The whole family 
comprises enzymes with a molecular weight of 75-80 kDa in mammals and 94-104 kDa in 
plants. Introduction 
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Figure 1: Phylogenetic tree of lipoxygenases 
5-LOs consist of an N-terminal β-barrel domain plus a C-terminal catalytic domain containing a 
single atom of nonheme iron [32]. In general, LOs exert their biological functions via three 
different routes: First, mobilisation of lipids, second, peroxidation reactions resulting in 
structural and pathophysiological changes, and third, signalling pathways leading to formation of 
LTs and HETEs (see figure 2) (for detailed review see [32]). 
 
Figure 2: Biological roles of lipoxygenases Introduction 
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B.  5-lipoxygenase 
1.  Gene and protein expression 
The human 5-LO protein is derived from a gene which is located on chromosome 10q11.2 
whereas most other human LOs are located on 17p13 [329]. The 5-LO gene has a length of 82 kb 
separated into 14 exons and 13 introns [110]. Within the gene, numerous consensus binding sites 
are obvious including sp1/3, Egr–1/2, NFκB, GATA, myb, AP-2 [147] as well as response 
elements for vitamin D receptor, and TGFβ [326]. The 5-LO promoter shows no TATA or 
CCAAT sequence, is highly G+C rich and contains 10 sp1 binding sites. Five of them exist in 
overlapping tandem sites and are necessary for basal transcription [147]. There are promoter 
polymorphisms, consisiting of three to eight sp1 binding sites [88, 89]. These polymorphisms are 
connected to altered transcription efficacy of the gene [153] and to decreased response of asthma 
patients to 5-LO inhibitors [88]. The polymorphisms are no indication for the susceptibility of 
humans for asthma [308] but seems to be implicated in atherogenesis [89]. 
Expression of 5-LO is mainly limited to cells derived from bone marrow, but among 
granulocytes, monocytes, macrophages, mast cells, and B-lymphocytes [325], there are also 
human skin keratinocytes [162], and epidermal Langerhans cells that express 5-LO [324]. 
Differentiation of the myeloid cell lines MM6 and HL-60 with calcitriol and TGFβ yields an 
extensive increase of 5-LO mRNA, protein level, and enzyme activity [39, 40]. Also DMSO, 
phorbol-12-myristate-13-acetate (PMA), granulocyte macrophage-colony stimulating factor 
(GM-CSF), interleukin (IL)-3, or LDL elevate the level of mRNA in several leukocyte cell lines 
[318]. 
DNA methylation and histone acetylation regulate 5-LO expression. Treatment of the 
5-LO-negative cell lines U937 and HL-60TB with the demethylating agent 5-aza-2'-
deoxycytidine upregulates expression of 5-LO primary transcripts and mature mRNA in a 
similar manner [340]. By means of reporter gene assays it was shown that the histone 
deacetylase inhibitor trichostatin A induces 5-LO promoter activity in MM6 cells [169]. 
2.  Structure 
So far only four crystal structures of LOs are available, three of them are from plants and the 
fourth is 15-LO from the rabbit reticulocyte. Using the latter as template, a model of human 
5-LO was calculated [142]. As for all LOs, the secondary structure of 5-LO reveals a protein 
with two domains. A N-terminal β-barrel domain consisting of the first 120 amino acids (aa) and 
a C-terminal catalytic domain spanning from aa 121 to 673. Since LOs contain a nonheme iron 
within the catalytic domain there are residues important for iron binding in 5-LO, namely Introduction 
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His372, His550, and the terminal Ile673 [133, 377]. His367, Asn554, and a water molecule are 
supposed to be flexible ligands [130]. 
Different methods showed that Ca
2+ binds to the β-barrel domain with a stoichiometry of 2 mol 
Ca
2+ per mol protein with a Kd of 6 µM. Asn34, Asp44, and Glu46 are involved in Ca
2+ binding 
[131, 132]. Recently, in a theoretical approach two Ca
2+ binding sites were revealed, namely site 
1 consisting of Phe14, Ala15, Gly16, Asp79, and site 2 consisiting of Asp18, Asp19, Leu76 [21]. 
The N-terminal region of 5-LO acts as a genuine C2-domain. C2-domains are conserved 
structural motifs which form an eight strand anti-parallel β-sandwich and mediate Ca
2+-
dependent membrane association [151]. This applies for the β-barrel domain of 5-LO. Binding of 
Ca
2+ to 5-LO leads to phosphatidylcholine (PC) selectivity of the protein in which the aromatic 
residues Trp13, 75, and 102 play an essential role [178]. Furthermore, the β-barrel domain of 
5-LO is essential for nuclear membrane translocation and reveals similarity to the C2-domain of 
protein kinase (PK)C and cytosolic phospholipase (cPL)A2 [53]. 
ATP stimulates 5-LO activity and the protein can be purified via ATP affinity chromatography. 
The DNA sequence shows no obvious NTP binding site [110] but affinity studies on ATP-
agarose revealed binding of one mol ATP per mol 5-LO [92, 376]. Trp75 and Trp201 seem to be 
involved in this affinity to ATP and to other nucleotides [376]. 
5-LO is found in the cytosol but also in the nucleus. Also, the protein exerts (a) nuclear import 
sequence(s) (NIS). In 1998, a region of basic aa spanning residues 639-656 was found to be 
involved in 5-LO translocation [191]. In particular, Arg651 seemed to play an essential role in 
nuclear import of 5-LO [138]. However this residue is important for structural integrity and 
5-LO activity and therefore the same authors rejected their assumption followed by a proposal 
for aa 518-530 as a “real” NIS [165]. Recently, Arg112 and Lys158 were identified as NISs 
[166]. One study showed that the N-terminal region mediates entering of 5-LO into the nucleus 
[55]. But this is controversial because the fusionprotein used for this study allows free diffusion 
between nucleus and cytosol [138]. 
Moreover, 5-LO contains a functional Src homology (SH)3-binding motif, a short, proline-rich 
region spanning residues 566-577. This suggests a role for 5-LO in tyrosin kinase signalling 
[192]. 
3.  Catalysis 
5-LO catalyses the first two steps in the biosynthesis of LTs from its main substrate AA (see 
figure 3). The nonheme iron of 5-LO cycles through different redox states and was shown to be 
necessary for the enzyme catalysis. Within the oxygenase reaction, 5-LO converts AA in a 
stereospecific manner to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5(S)-Introduction 
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HpETE). The process starts with the oxidation of the iron from the ferrous state to the ferric form 
via lipid hydroperoxides (LOOH), followed by a homolytic cleavage of the pro-S hydrogen at C7 
of AA. This results in the formation of a pentadienyl radical and the iron is again reduced to the 
ferrous form. Subsequently, molecular oxygen is inserted antarafacial at C5, yielding the 
intermediate product 5(S)-HpETE while iron is converted to the ferric form [63]. In the LTA4 
synthase reaction, 5-HpETE is converted to the unstable epoxide LTA4. After the homolytic 
cleavage of the pro-R hydrogen at C10 of 5-HpETE and the reduction of the iron followed by 
allylic shifts, an electron and a proton are transferred to the cleared hydroxyl moiety, resulting in 
H2O, LTA4, and oxidized iron of 5-LO [316]. The mechanism indicates the necessity of LOOH 
and a correct redox cycling of the iron during the catalytic reaction. The sequence of the 
reactions is made up of the initial phase where 5-LO is converted to the active state, followed by 
a high conversion rate, and finally an irreversible inactivation phase [103]. The latter phase has 
to be considered as an activity of the enzyme and is also referred to as suicide inactivation. 
LOOH are discussed to be responsible for this inactivation [3]. 
 
Figure 3: 5-LO catalysis Introduction 
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It was shown that AA and 5-HpETE compete with each other, suggesting that both reactions, 
oxygenase and LTA4 synthase, take place at the same catalytic site. The rate of produced 
5-HpETE to LTA4 depends on several conditions, e.g. presence of FLAP and membrane 
association of 5-LO, amount of 5-LO, concentration of AA or 5-HpETE. 
Another enzyme property is described as a pseudoperoxidase activity. Reducing agents, like 
N-hydroxyurea-derivatives or hydroxamic acids, are oxidized via fatty acid hydroperoxides, e.g. 
5-HpETE. This reaction, catalyzed by 5-LO, is a one electron transfer and therefore termed as a 
pseudoperoxidase activity. The reducing agents are redox-type inhibitors of 5-LO, and those 
which exhibit a better substrate ability for the pseudoperoxidase reaction are more potent 
inhibitors. Thus, the compounds attain their potency from reducing the ferric enzyme to the 
ferrous form and as an alternative substrate for 5-LO. For an extensive overview of 5-LO 
kinetics see [103]. 
4.  Stimulating factors 
a)  Calcium 
Effects of Ca
2+ on LT formation were first reported when human PMNL were treated with the 
ionophore A23187 [30]. A variety of other stimuli, such as thapsigargin (TG), N-formyl-
methionyl-leucyl-phenylalanine (fMLP), platelet-activating factor (PAF), leukotriene B4 (LTB4), 
or antigen-stimulation, also lead to an increase of free intracellular Ca
2+-levels and subsequently 
to activation of 5-LO [309, 365, 366]. Although other LOs do not require Ca
2+ and Ca
2+ is not 
absolute essential for 5-LO activity, it strongly stimulates LT formation [242, 269]. For purified 
5-LO, half maximal activity is obtained at concentrations of 1  -  2  µM Ca
2+ [259], maximal 
activity at 4 - 10 µM [242]. In intact cells, 150 - 350 nM intracellular free Ca
2+ are sufficient for 
activation of 5-LO [309]. The enzyme is capable of binding two Ca
2+ ions with a Kd = 6 µM 
whereas mutation of Asn43, Asp44, and Glu46 impairs the affinity of 5-LO to Ca
2+ [131, 132]. 
Ca
2+ promotes all three described enzyme activities of 5-LO [279], increases the hydrophobicity 
[132], and triggers binding of 5-LO to phosphatidylcholine [242]. Moreover, binding of Ca
2+ to 
the N-terminal β-barrel domain facilitates translocation of cytosolic 5-LO to the nuclear 
envelope as well as membrane binding [178, 286, 290]. Also Ca
2+ confers 5-LO resistant against 
inhibition by glutathione peroxidase (GPx)-1, suggesting an increased affinity of 5-LO to LOOH 
at a regulatory fatty acid binding site in presence of Ca
2+ [42, 44]. Regarding kinetics, Ca
2+ 
shortens the initial lag-phase, enhances the steady state velocity, and decreases the KM for AA 
[4]. Introduction 
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The environment of 5-LO dictates the necessity of Ca
2+ for enzyme activity. In cell free systems, 
high concentrations of PC or AA render 5-LO activity Ca
2+ independent [275, 320]. Mg
2+ as a 
bivalent cation can also bind to 5-LO and activates the enzyme within a range of 0.1 – 1 mM. To 
raise hydrophobicity at least 4 mM Mg
2+ are required. Additionally, Mg
2+ and Ca
2+ bind to the 
same site of 5-LO [21, 274], indicating that Mg
2+ substitutes for Ca
2+ in a less efficient manner. 
In a model, using the mast cell line PT-18, it was shown that Ca
2+ is not required for LT 
synthesis [348]. In human PMNL, 5-LO shows only a partial dependence on extracellular Ca
2+ 
[309] and AA-induced LT formation is mediated by Ca
2+ and/or phosphorylation [45, 330, 360, 
paper I]. 
Recent studies revealed that there are two independent ways of 5-LO activation, namely by Ca
2+ 
and by phosphorylation [45]. Hyperosmotic, stress-induced 5-LO activation is completely 
Ca
2+-independent and can be blocked by specific kinase inhibitors, implying that 
phosphorylation is operative [353]. 
b)  ATP 
ATP is a well-known stimulation factor which is able to potentiate the enzymatic activity of 
crude 5-LO up to 6-fold. Also other nucleotides including AMP, ADP, cAMP, CTP, UTP, and 
the nonhydrolyzable γ-S-ATP stimulate 5-LO activity [92, 241, 244]. The effect of ATP is Ca
2+ 
independent and has a maximum impact at 0.1 mM ATP [103, 241, 320]. Within intact cells, 
ATP occurs in complex with Mg
2+ as MgATP
2-, suggesting the latter as physiological stimulus 
[274]. ATP has Ka values of 30 - 100 µM for stimulating and binding to 5-LO is estimated one 
mol ATP per one mol enzyme (for detailed review see [272]). 
c)  Membrane fractions 
Since the ratio of AA to phospholipids is an important factor for the rate of 5-LO reaction, there 
is basic evidence that the enzymatic reaction of purified 5-LO takes place at a lipid-water 
interface [280]. Thus, it is reasonable that microsomal membrane fractions stimulate the catalytic 
activity of 5-LO [289, 291]. They can be replaced by synthetic lipids like PC or by Tween 20 but 
not by phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, or diacylgycerol 
[240, 269]. The stimulating effect can be observed both in the presence and absence of Ca
2+ 
[274, 320]. Nevertheless, the C2-like domain of 5-LO is a genuine Ca
2+-dependent membrane-
targeting domain, which directs the enzyme selectively to PC rich membranes, conferred by the 
tryptophan residues Trp13, Trp75, and Trp102 [178]. Introduction 
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d)  Lipid hydroperoxides 
Initial oxidation of the active site iron within the centre of 5-LO by LOOH is essential for the 
catalytic activity of the enzyme. Consequently, LOOH like 5-HpETE, 12-HpETE, 15-HpETE, or 
13(S)-HpODE shorten the lag-phase and stimulate 5-LO, whereas H2O2 and other peroxides 
without long chain fatty acyl moiety fail [278, 288]. In PMNL homogenates, dithiothreitol 
(DTT) counteracts this effect [278, 288], and in intact cells, GPx-1 reduces LOOH, thus 
suppressing 5-LO activity [350]. 
Of considerable interest, addition of 13(S)-HpODE or inhibition of GPx by iodoacetate or 
selenium-deficiency, leads to impaired efficacy of nonredox-type 5-LO inhibitors [359, 
paper IV]. 
5.  Subcellular distribution and translocation of 5-LO 
The subcellular distribution of 5-LO in resting cells is a puzzling issue, since 5-LO is a rather 
mobile enzyme. In resting cells, 5-LO resides in the cytosol or the soluble compartment of the 
nucleus. The distribution depends on the cell-type: in peripheral blood neutrophils and 
monocytes, differentiated HL-60 and MM6 cells, and in peritoneal macrophages (PM), the 
enzyme is located in the cytosolic fraction. However, in alveolar macrophages (AM), rat 
basophilic leukaemia cells (RBL-1), mouse bone marrow-derived mast cells, and in Langerhans 
cells of human skin, 5-LO is mainly in the soluble intranuclear region [352]. For transfected cells 
like RAW macrophages, HEK 293, COS, CHO and NIH-3T3 cells, nuclear localization was 
reported [352]. A dynamic regulation seems to be responsible for compartmentalization of 5-LO. 
During the course of monocyte differentiation into PM, 5-LO is localized in the cytoplasm, but 
migration of the PM into the alveolar compartment is linked to an import of 5-LO into the 
nucleus [64]. Nuclear import of cytosolic 5-LO was also shown for PMNL after in vitro 
adherence [37]. With respect to the molecular mass of 5-LO, the ability for a nuclear import of 
the enzyme should depend on nuclear localization sequences (NLS) [36, 202]. Moreover, 
mutation of the phosphorylation site Ser271 results in  reduced 5-LO nuclear localization [202]. 
In contrast, Leptomycin B, a specific inhibitor of nuclear export signal (NES)-dependent 
transport, diminished the cytosolic localization of 5-LO in HL-60 and GFP-5-LO in CHO-K1 
cells [134]. 
Nuclear import of 5-LO is not automatically associated with an increase in LT formation. For 
adherent PMNL an increased ability for 5-LO activity is reported [37], whereas adherent 
eosinophils show a decreased LT formation because of failed translocation to the membrane 
[35]. Introduction 
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LT formation from endogenous AA serving as substrate implies translocation of either cytosolic 
or nuclear 5-LO to the outer or inner nuclear envelope. Upon stimulation of intact cells, an 
increase of intracellular Ca
2+ leads to an association of soluble 5-LO with cellular membranes 
[286, 290, 365]. In addition, phosphorylation of 5-LO is an alternative impulse for translocation, 
shown in PMNL and differentiated MM6 cells [194, 353, 356]. 
Factors like protein-protein interactions via the SH3 domain-binding region of 5-LO and tyrosine 
kinase signalling [192, 194, paper VII] as well as cellular interacting proteins [265, 267] may 
play an important role in 5-LO translocation. Unlike earlier reports, translocation seems to be 
independent of FLAP [167]. 
6.  Regulation of cellular 5-LO activity 
There are some critical steps during activation of cellular 5-LO. (i) Oxidation of the ferrous, 
resting state to the ferric, active state of 5-LO via LOOH. (ii) Mobilisation of intracellular Ca
2+ 
and/or phosphorylation of 5-LO. (iii) Redistribution of activated 5-LO from cytoplasm to the 
NE/ER accompanied with translocation of activated cPLA2. (iiii) Release of endogenous AA via 
cPLA2 and transfer of the substrate via FLAP to 5-LO for production of 5-HpETE and LTA4, 
respectively. These individual schematic steps can be carried out upon different stimuli and 
activation pathways. Depending on the experimental setup or the conditions in vivo, respectively, 
the importance of the different steps is weightened variable. 
a)  Ca
2+ mobilisation 
Treatment of cells with ionophore A23187 [30] or TG [249] results in Ca
2+ mobilisation and 
subsequently in LT formation. But also natural ligands such as fMLP, complement C5a (C5a), 
LTB4, PAF, IL-8 or particles like zymosan and phosphate crystals cause an elevation of 
intracellular Ca
2+ and LT formation [352]. The resulting degree of 5-LO activity corresponds to 
the extent of Ca
2+ mobilisation. Thus, Ca
2+-ionophore A23187 leads to a prominent LT 
formation. In contrast, fMLP, PAF, or LTB4, which interact with specific G protein coupled 
receptors (GPCRs), cause moderate 5-LO activity. Since LT formation depends on the 
availability of free AA, cPLA2 activity is a determinant for 5-LO product synthesis [306]. For 
this reason, minor LT formation upon stimulation with natural ligands could be due to low 
amounts of free AA. Supporting evidence is given by the observation that co-addition of 
exogenous AA to cells stimulated by natural agents yields in increased LT synthesis [57, 309]. 
Growth factors, cytokines, phorbol esters or lipopolysaccharide (LPS) do not cause 5-LO activity 
by themselves. However, priming of cells with these agents leads to an augmented LT formation 
after stimulation with natural ligands [68, 84, 310]. Introduction 
  15
Whether these priming effects are based on increased supply of AA, a pronounced mobilisation 
of Ca
2+ or a higher degree of phosphorylated 5-LO depends on the priming agent or is still 
unclear. For detailed review see [352]. 
b)  Phosphorylation of 5-LO 
Mammals exhibit a well-characterized family of mitogen-activated protein kinases (MAPK). 
This family consists of four subgroups including extracellular signal-regulated kinases (ERK 
1/2), c-Jun amino-terminal kinases (JNKs), p38 MAPKs, and ERK5. They all control a huge 
variety of physiological processes. In general, these enzymes are regulated by an upstream relay 
of two protein kinases which phosphorylate and subsequently activate one another [163]. 
Especially ERKs and p38 MAPK are in the focus of 5-LO research (see figure 4). 
p38 MAPK is activated in immune cells in response to inflammatory cytokines but also by 
hormones, ligands for GPCRs, cell stress or heat shock. ERKs are mainly activated by growth 
factors, cytokines, virus infection, transforming agents, and also by activators of GPCRs [163, 
180]. p38 MAPK has been shown to phosphorylate several cellular targets including 
MAPKAPK-2/3 (MK2/3). p38 activity is involved in macrophage and neutrophil responses, 
including adhesion, degranulation, oxidative burst, chemotaxis, and also cytokine production 
[188, 285]. Activated ERKs phosphorylate numerous substrates in all cellular compartments and 
ERK1/2 signalling has been implicated as a key regulator of cell survival and proliferation [285]. 
In the primary sequence of human 5-LO several phosphorylation motifs including motifs for 
PKA, PKC, Ca
2+/calmodulin-dependent kinase (CaMKII), MAPKAPK-2 (MK2) and -3, S6 
kinase, MAPK1/2, and Cdc2 are obvious [352]. Already in 1996, phosphorylated 5-LO was 
discovered in the nucleus of Ca
2+-ionophore-stimulated HL-60 cells. However, the group failed 
to phosphorylate 5-LO by MAP kinase, Cdc-2 or Lyn in vitro [194]. The same group showed 
that PD098059, a potent and selective inhibitor of MAP kinase kinase (MEK), inhibits 5-LO 
translocation as well as 5-LO activity, independent of cPLA2 [193]. Introduction 
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Figure 4: MAPK phosphorelay system 
By means of an in-gel kinase assay, MK-2 was found to phosphorylate 5-LO [355]. Stimuli like 
Ca
2+-ionophore, TG, fMLP, PMA, TNFα, or sodium arsenite (SA) lead to activation of MK-2 
and finally also to activation of 5-LO [354]. Specific inhibitors, targeting designated 5-LO 
kinases, block redistribution and activation of 5-LO. If PKC, which is upstream of ERKs, is 
inhibited by calphostin C, PMA-induced 5-LO translocation and activation is potently blocked 
[356]. Also SB203580, a specific p38 MAPK inhibitor, diminishes LT formation upon 
stimulation of PMNL with Ca
2+-ionophore [355]. Because cell stress is capable of activating the 
p38 MAPK cascade, treatment with hyperosmotic stress (NaCl, sorbitol) or genotoxic stress 
(SA) leads to 5-LO translocation and activation in B-lymphocytes and PMNL [353, 354]. 
Moreover, the p38 MAPK inhibitor SB203580 blocked stress-induced 5-LO product formation 
efficiently. Intriguingly, cell stress activates 5-LO in isolated PMNLs independent of Ca
2+ [353]. 
However, if stimuli that increase intracellular Ca
2+ like Ca
2+-ionophore are combined with 
stimuli that cause cell stress, then 5-LO activity is strongly suppressed [43]. 
Ser271 of 5-LO is a phosphorylation site of several Ser/Thr-kinases. Thus, in vitro kinase assays 
revealed that not only MK2 but also CaMKII and PKA are capable of phosphorylating 5-LO 
[203, 355, 360]. Mutation of Ser271 to Ala in 5-LO sequence showed the necessity of this 
residue for phosphorylation in vitro. In gel kinase assays prove that the enzyme is 
phosphorylated at Ser271 [360]. HeLa cells transfected either with wt 5-LO or with a Ser271Ala 
mutant showed the same LT formation when cells were treated with Ca
2+-ionophore plus Introduction 
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exogenous AA. However, when cells were stimulated with AA alone, conditions which promote 
phosphorylation of 5-LO (see below), 5-LO activity of the Ser271Ala mutant was significantly 
lower as compared to wt-5-LO [360]. 
Compared to heat shock protein (Hsp)27, 5-LO is a weak substrate for MK2. However, addition 
of unsaturated fatty acids up to 50 µM results in similar phosphorylation by MK-2 as for Hsp27 
[360]. In contrast, this was not observed for CaMKII and PKA. The role of ERKs regarding 
5-LO activation are addressed in papers I, II. Paper III-VI show the consequences of 
phosphorylated 5-LO for inhibition of LT formation by pharmacological inhibitors. 
c)  Induction of 5-LO activity by 1-oleoyl-2-acetylglycerol (OAG) 
OAG was found to function as a direct agonist for PMNL stimulating 5-LO product formation. 
OAG (i) does not increase the release of endogenous AA, (ii) does not promote the redistribution 
of 5-LO from the cytosol to the nuclear envelope (NE), (iii) and does not alter the mobilisation 
of intracellular Ca
2+-level. Moreover, specific kinase inhibitors for p38 MAPK and ERKs fail to 
inhibit OAG induced 5-LO activity [7]. In addition, OAG mimics the stimulatory effects of Ca
2+ 
on 5-LO catalysis. Thus, under optimized assay conditions where Ca
2+ is present, OAG caused 
no stimulation of 5-LO. However, after omission of Ca
2+  by chelation using EDTA, OAG 
strongly and concentration-dependently stimulated crude 5-LO. In contrast, phospholipids or 
cellular membranes abolished the effects of OAG. In analogy to Ca
2+, OAG could render 5-LO 
activity resistant against inhibition by GPx activity, which again was reversed by phospholipids 
[14]. 
7.  Proteins binding to 5-LO 
Until today, there are four proteins in total known to bind 5-LO. Three of them had been detected 
by the yeast two-hybrid system using a human lung cDNA as screening system [267]. FLAP, 
often assumed to serve as an anchor for 5-LO, was not demonstrated to bind to the enzyme. 
a)  Growth factor bound receptor protein 2 (Grb2) 
As mentioned above, 5-LO contains a short proline-rich region which is able to serve as a 
binding motif for SH3 domains. There is a high specificity for interaction of 5-LO with Grb2, a 
protein involved in tyrosine kinase-mediated cell signalling. Purified 5-LO binds to a GST-Grb2 
fusion protein and a corresponding peptide to the SH3-binding motif of 5-LO inhibits the 
formation of a 5-LO/Grb2 complex [192]. The peptide inhibited also the translocation of 5-LO 
from the cytosol to the NE after activation by Ca
2+ ionophore A23187. Furthermore, it was 
shown that 5-LO associates to actin-sepharose, and α-actinin-sepharose respectively [192]. These Introduction 
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associations can also be revoked by the mentioned peptide. The data imply a role of 5-LO in 
tyrosine kinase signalling as well as a link to dynamics of the cytoskeleton. 
b)  TGFβ receptor-I-associated protein-1 (TRAP-1) 
TRAP-1, a 96-kDa cytoplasmic protein, binds to the activated TGFβ receptor. It plays a role in 
the Smad-mediated signal transduction pathway, interacting with the common mediator, Smad4, 
in a ligand-dependent fashion [272].  Binding of 5-LO to the C-terminal end of TRAP-1 was 
shown by the yeast two-hybrid system [267]. Based on the fact that TGFβ and calcitriol increase 
5-LO expression and activity [39], a connection of 5-LO and TRAP-1 seems to be reasonable. 
c)  Coactosin like protein (CLP) 
CLP, similar to coactosin, is a 17 kDa actin-binding protein from Dictyostelium discoidium. CLP 
itself binds to F-actin and has no effect on actin polymerization [266]. The yeast two-hybrid 
system revealed association of 5-LO with CLP [267], confirmed by coimmunoprecipitation 
experiments. CLP binds 5-LO in a 1:1 molar stoichiometry in a Ca
2+-independent but 
pH-dependent manner [265]. Lys131 is involved in 5-LO binding [265] whereas Lys75 is linked 
to the association with actin [266].  No ternary F-actin/CLP/5-LO complex could be detected but 
5-LO competes with F-actin for binding to CLP. Moreover, 5-LO was found to interfere with 
actin polymerization [265]. 
d)  Ribonuclease (RNase) III, dicer 
Long dsRNA is processed by a RNase III enzyme called dicer into small interference RNAs 
(siRNAs), which subsequently serve as the sequence determinants of the RNAi pathway by 
directing cleavage of homologoues mRNA via an RNA-induced silencing complex (RISC) 
[338]. A protein containing a RNase III motif and a dsRNA binding domain was identified via 
two-hybrid system to associate with 5-LO [267]. A functional connection between dicer and 
5-LO could not be displayed so far. 
8.  Targeted disruption of the 5-LO gene 
Studies were performed using 5-LO knockout mice to determine how LTs contribute to different 
physiological and pathophysiological actions. 
In general, 5-LO 
-/
- mice develop normally and are healthy [54]. Only slight differences with 
respect to bone constitution are described [107]. After treating isolated cells, levels produced of 
prostaglandin(PG)s are equal to wild type mice [108]. Introduction 
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5-LO knockout mice displayed reduced signs of inflammation in AA-induced ear oedema, 
zymosan-induced peritonitis, or ovalbumin-induced airway inflammation [47, 54, 117, 154]. 
5-LO deficient mice are also able to recover from PAF-induced shock [54]. In contrast, 
inflammation induced by PMA did not differ in the absence of 5-LO products [107]. 
In an allergic airway inflammation model, 5-LO deficient mice displayed a decreased airway 
hyperresponsiveness and also a reduced amount of eosinophils in the airway after treatment 
[109]. 
C.  Proteins involved in LT formation 
1.  Phospholipase A2 
The numerous members of the phospholipase(PL)A2 family are defined by their ability to 
catalyze the hydrolysis of the centre (sn-2) ester bond of the phospholipid substrate. PLA2 
products such as AA or oleic acid (OA) operate as stores of energy, but AA mainly acts as a 
second messenger [113] and as a precursor of eicosanoids [22]. Lysophospholipids are also 
products of PLA2 and can be acetylated to PAF. They are also important in cell signalling, 
phospholipid remodelling and membrane perturbation [226]. 
Up to now there are 11 groups of PLA2, subdivided into further subgroups, disposed dependent 
on the enzyme activity, sequence, homology, and splice variants. For detailed review see [319]. 
Mammalian cells contain a variety of PLA2 enzymes which can be found together in the same 
cell. Among these enzymes, the low-molecular-weight 14 kDa secreted PLA2 (sPLA2) requires 
millimolar levels of Ca
2+ and has no fatty acid specificity. sPLA2 are involved in digestion of 
lipids (group I), chronic inflammatory diseases (group IIa), and are implicated in AA release 
(group V) (more details in [113]). The second family in mammals belongs to the 
Ca
2+-independent PLA2 with a molecular mass of 85 kDa. They are expressed ubiquitously, 
exhibit also no sn-2 specificity and might be involved in phospholipid remodelling [18]. 
In 1986 the first member of a cytosolic PLA2 family was reported from human neutrophils [11] 
and platelets [171]. After sequencing [59], [315], the 85 kDa enzyme was classified into group 
IVA. The structure is based on two domains, a C2 domain and an α/β hydrolase PLA2 domain 
[77]. This cPLA2 is the only member with specificity to sn-2 AA [80] but has also a strong 
lysophospholipase [195] and weak transacylase activity [276]. Human cPLA2 is expressed in a 
variety of tissues and its levels are regulated by cytokines and growth factors [198]. 
Posttranslational events like binding of Ca
2+ to the C2 domain and phosphorylation of the 
enzyme dominate the regulation of cPLA2 activity. Thus, Ca
2+-mobilizing agents like ionophore 
A23187 and zymosan induce AA release by promoting translocation of cPLA2 from the cytosol Introduction 
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to the nuclear envelope and endoplasmatic reticulum, respectively [311]. Phosphorylation of 
cPLA2 on Ser505 and Ser727 by MAPK and MNKs, respectively, is also important for activation 
of the enzyme activity [75, 199]. However it is not clear how phosphorylation affects cPLA2 
function. cPLA2 
-/
- mice develop normally but females have reproductive defects leading to 
reduced fertility [28]. A more rapid recovery from allergen-induced bronchoconstriction and no 
airway hyperresponsiveness was observed. PM of cPLA2 
-/
- mice fail to produce PGs, LTB4 and 
cysLTs after stimulation. Bone marrow-derived mast cells also fail to generate eicosanoids (for 
detailed review see [306]). Targeted disruption of cPLA2 revealed the importance of the enzyme 
in inflammation and tissue injury. Therefore, the control of AA production by inhibiting PLA2 
could be beneficial for treatment of diseases caused by eicosanoids. 
2.  5-lipoxygenase activating protein 
5-lipoxygenase activating protein (FLAP) is an 18 kDa membrane protein which belongs to the 
MAPEG-family (see below) and therefore it is no surprise that there is a sequence identity of 31 
% to LTC4S. ALOX5AP encoding FLAP is located on chromosome 13q12 including 5 exons 
and 4 introns with a size of 31 kbp [168].  
FLAP is co-expressed with 5-LO in myeloid cells like PMNL, monocytes/macrophages and B-
lymphocytes. However, some cell lines negative for 5-LO protein express FLAP, e.g. T-cells, 
undifferentiated MM6 or U937 cells, indicating substantial differences in gene activation [351]. 
The observation that MK886 blocks only LT formation in intact cells but not in the 
corresponding homogenates [114] led to the discovery of FLAP. It was shown that MK886 sticks 
to FLAP [225] and co-transfection of osteosarcoma cells with 5-LO/FLAP demonstrates that 
both proteins are necessary for LT formation [83]. 
125I-labelled AA binds to the protein [208], 
and AA and other cis-unsaturated fatty acids compete with MK886 for binding to FLAP [272]. 
Further studies revealed that FLAP resides at the nuclear envelope and the neighbouring 
perinuclear endoplasmatic reticulum [261, 367]. 
The precise function of FLAP has still to be elucidated but so far it is known that the protein 
stimulates the utilization of AA by 5-LO and promotes the conversion of 5-HpETE to LTA4 [1]. 
FLAP can also facilitate the conversion of 12-HETE to 5, 12-diHETE by 5-LO [211].  
Lately the presence of two distinct multimeric complexes that organize the biosynthesis of LTC4 
and LTA4 in RBL-2H3 cells was demonstrated by using fluorescence lifetime imaging 
microscopy and immunoprecipitation. One complex including LTC4S and FLAP is responsible 
for the formation of LTC4. The other one consists of multimers of FLAP, providing LTA4 for 
LTB4 formation [212]. Regarding the FLAP gene it was reported that variants of ALOX5AP are 
associated with greater risk of myocardial infarction and stroke [141]. FLAP-binding inhibitor Introduction 
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MK886 induces apoptosis in U937 cells and in cultured malignant cells from patients with 
chronic myelogenous leukaemia [12]. In addition MK886 significantly increased caspase-3 
activity [74] but acts independent of the FLAP protein [73]. Moreover, FLAP seems to be 
involved in cell division [368].  
Targeted disruption of FLAP in mice results in reduced responses to AA, an increased resistance 
to PAF-induced shock, less edema in zymosan-induced peritonitis [46] as well as collagen-
induced arthritis [118]. Thus, FLAP 
-/
- resembles the 5-LO 
-/
- phenotype. 
3.  Leukotriene A4 hydrolase 
LTB4 is generated by hydrolyzing the unstable epoxide LTA4, catalysed by leukotriene 
A4-hydrolase (LTA4H) [123]. LTA4H has been purified from a variety of species as a soluble 
monomeric enzyme [273]. LTA4H, consisting of 610 aa with a calculated molecular weight of 69 
kDa, have been cloned and sequenced from human, mouse, rat, and guinea pig [123]. The 
corresponding gene is located on chromosome 12q22 with a size of >35 kbp and contains 19 
exons. The promoter contains a phorbol ester response element (AP2) and two xenobiotic 
response elements (XRE), but no definitive TATA box [209]. From sequence comparisons with 
certain zinc proteases and exopeptidases, a zinc-binding motif was discovered which lies in the 
catalytic domain [207, 345]. One mol of zinc per mol of protein binds to the three binding 
ligands His295, His299, and Glu318 [124, 221]. Beside the epoxide hydrolase activity LTA4H 
shows a peptide-cleaving activity towards the synthetic substrates alanine-4-nitroanilide and 
leucine-4-nitroanilide [125]. This aminopeptidase properties can be activated by monovalent 
anions like thiocyanate and chloride as well as albumin [361]. 
A characteristic feature of LTA4H is the inactivation of both enzyme activities by covalent 
binding of its substrate LTA4 [91, 250] in the active site [229]. Also divalent cations inhibit 
LTA4H activity with different potency and specificity for the two enzyme activities [362]. 
The crystal structure of LTA4H in complex with the inhibitor bestatin was recently solved and 
revealed a protein folded into three domains, N-terminal, catalytic and C-terminal. Together 
these three domains form a zinc-binding cleft from where a deep hydrophobic pocket leads into 
the enzyme where LTA4 fits in via a L-shaped binding conformation [337]. 
In addition to bestatin, other aminopeptidase and angiotensin-converting enzyme inhibitors such 
as captopril were found to suppress LTA4H activity [252]. The LTA4H inhibitor SC-57461, N-
methyl-N-[3-[4-(phenylmethyl)-phenoxy]propyl]-b-alanine, blocked ionophore-induced LTB4 
production in human whole blood with an IC50 of only 49 nM [375], is orally active, and showed 
promising results in an animal model of colitis. Introduction 
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LTA4H is widely spread in mammalian species and found in almost all tissues and blood cells. 
Basophils express only small levels of LTA4H and platelets seem to be virtually devoid of the 
enzyme. Many of the cells expressing LTA4-hydrolase lack 5-LO, thus giving evidence for 
transcellular metabolism [123]. The enzyme is generally thought to reside in the cytosol and has 
been reported only once with a membrane bound activity in liver cells [122]. 
Mice deficient in LTA4H means to lose the ability to convert LTA4 into LTB4. They develop 
normally and are healthy. Treating mice with proinflammatory stimuli revealed that LTA4H is 
required for LTB4 formation. LTA4H 
-/
- mice are resistant against the lethal effects of systemic 
shock induced by PAF [47], as found for 5-LO 
-/
- mice. 
4.  Leukotriene C4 synthase 
Leukotriene C4-synthase (LTC4S) conjugates LTA4 with glutathione (GSH) to form LTC4, the 
parent compound of the cysteinyl LTs [373]. Sequential cleavage of glutamatic acid and glycine 
from the GSH moiety of LTC4 yields LTD4 and LTE4 respectively [251]. The enzyme is 
expressed in eosinophils, mast cells, basophils, monocytes/macrophages, and some leukemic cell 
lines (THP-1, KG-1) as well as platelets which lack 5-LO [183]. The 150 aa of the LTC4S gives 
an 18 kDa membrane protein, existing as a homodimer [236]. The enzyme activity is augmented 
by Mg
2+ and inhibited by Co
2+ and MK-886 [183]. 5 Exons plus 4 introns, in conjunction 2.5 
kbp, constitute the human LTC4S gene located on chromosome 5q35. LTC4S and FLAP exhibit 
similar genomic organization [257]. The deduced amino acid sequence demonstrated that FLAP 
and LTC4S are homologs with 31 % amino acid sequence identity. Also the LTC4S polypeptide 
displayed a similar hydropathy pattern compared to FLAP [161]. LTC4S 
-/
- mice grow normally 
and fail native and adaptive immune inflammatory permeability responses [183]. 
5.  MAPEG-family 
FLAP and LTC4S belong to the widespread MAPEG (membrane  associated  proteins in 
eicosanoid and GSH metabolism)-superfamily which is defined according to enzymatic activity, 
sequence motifs, and structural properties [160]. The six human proteins FLAP, LTC4S, 
microsomal glutathione S transferase (MGST)1–3, and MGST1-L1 as well as several 
homologues from different sources can be subdivided into four groups, based on sequence 
alignment. FLAP, LTC4S, and MGST2 are part of the first subfamily. The second consists of 
MGST3 together with the members found in plants and fungi. Subfamily three and four include 
proteins identified in bacteria and MGST1/MGST1-L1 [160]. 
Properties of FLAP are described in section II.C.2. LTC4S conjugates LTA4 with GSH, but also 
from MGST2 and 3, LTC4S activity is reported. Additionally, for both enzymes a peroxidase Introduction 
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activity was discovered [158, 159]. They are sequence homologues of FLAP and LTC4S but 
possess a broader substrate specificity. It is discussed that both, MGST2 and 3, are involved in 
detoxification and oxidative stress because of their occurrence in liver and their enzyme 
activities. 
Also MGST1 has a wide substrate specificity and is broadly expressed, with the highest 
concentration in liver [227]. In addition to MGST2 and 3, the substrates for MGST1 include 
halogenated arenes like CDNB and various polyhalogenated hydrocarbons whereas LTA4 and 
other epoxides are poor substrates for the enzyme. Interestingly, LTC4 is a binding inhibitor of 
MGST1 but the function is not known so far [161]. MGST1-L1 as well is involved in redox 
regulation and has been reported to be controlled by p53 [263]. 
D.  Eicosanoids and their functions 
1.   Oxoeicosanoids 
Oxoeicosanoids are a family of biologically active AA derivates. Among other compounds, 
5-HETE and its corresponding keto derivate 5-oxo-ETE form this group as well as 
oxoeicosanoids from the 12- and 15-LO pathway (12- and 15-HETE, hepoxilins). Formation and 
release of 5-oxo-ETE has been shown in platelets [105], eosinophils [264], and neutrophils 
[246]. 5-oxo-ETE is capable of inducing chemotaxis in vitro [116] and in vivo via mobilisation 
of Ca
2+ [247]. It also provokes degranulation [247] and stimulates oxygen radical formation after 
GM-CSF treatment [245]. Recently, a G-protein-coupled receptor was isolated which is activated 
by 5-oxo-ETE and to a lesser extent by the related 5-HpETE and 5-HETE. [148, 164]. 
An increase in glucagon release from isolated pancreatic islets and an augmented occurrence in 
early diabetic processes are impacts of 12-HETE. It also plays a role in regulating cell growth 
and apoptosis, is enhanced in hypertensive rats and in patients with essential hypertension [374]. 
15-HETE is involved in cell differentiation and maturation, and in humans, superoxid anion 
formation, migration of PMNL, and LTB4 formation is inhibited. Contraction of human 
bronchial smooth muscle cells and pro-athereogenic properties has also been shown [177]. 
Hepoxilins, constituting epoxy-hydroxy eicosanoids, are biosynthesized via the 12(S)-LO 
pathway. Recently, it was shown that rat leukocyte-type 12(S)-LO exhibits an intrinsic hepoxilin 
A3 synthase activity [239]. This eicosanoid causes strong chemotaxis of human neutrophils at 
submicromolar concentrations and leads to a prominent Ca
2+ release [331]. Furthermore, 
hepoxilin A3 is required in neutrophil migration across intestinal epithelia [228]. Introduction 
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2.  Leukotriene B4 
LTB4 (5(S), 12(R)-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic acid, LTB4) is a potent lipid 
mediator biosynthesized by metabolizing the precursor LTA4 via LTA4H to LTB4 (see figure 5). 
Its all-trans isomers are produced by non-enzymatic hydrolysis of the unstable epoxide LTA4 
[303]. In contrast to the ubiquitous expression of LTA4H, 5-LO is limited to haematopoietic 
cells. Therefore, LTB4 is thought to be produced mainly by leukocytes under normal conditions. 
During inflammation, LTB4 production occurs also in other cell types. Transcellular metabolism 
of the precursor LTA4 seems to be prerequisite [299]. Recent data suggest that also FLAP has an 
influence on the extent of LTB4 generation [212]. Several metabolizing mechanisms for LTB4 
are known including ω-oxidation by cytochrome P450 4F3, dehydrogenation, and β-oxidation. 
All reactions lead to inactivation of the biological function of LTB4 [370]. Most actions of LTB4 
are mediated by cell surface GPCRs, namely BLT1 and BLT2 (see below, [369]). It is discussed 
that LTB4 is a ligand of the orphan nuclear receptor PPARα implying a role in gene expression 
[78]. 
Initially, LTB4 was identified as an activator of granulocytes [305] with biological characteristics 
comparable to classical chemoattractants such as IL-8, C5a, and fMLP. In CHO cells transfected 
with BLT1, LTB4 increases the intracellular Ca
2+-level [369] and upon stimulation, leukocytes 
show potent chemotactic and chemokinetic activities. Leukocyte rolling and adhesion to the 
venous endothelium [71] is as much increased as secretion of superoxid anion and release of 
lysosomal enzymes [126]. Moreover, LTB4 contracts the guinea pig aorta via an indirect 
mechanism involving the release of histamine and thromboxane [17]. Experiments using bone 
marrow cultures suggest that LTB4 stimulates bone resorption by enhancing the formation of 
osteoclasts [111]. LTB4 has been also implicated in the development of atherosclerosis [76] and 
is discussed to be involved in cell-survival signalling [248]. A release of anti-HIV mediators 
after administration of LTB4 to humans has been revealed recently [100]. Introduction 
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Figure 5: The AA cascade with emphasis on the 5-LO pathway 
3.  Cysteinyl leukotrienes 
Slow-reacting substance of anaphylaxis (SRS-A) was the first name given to the cysteinyl LTs. 
In 1979 the SRS-A was identified as LTC4, D4, and E4 [304]. Conjugation of reduced GSH with 
LTA4 via LTC4S leads to LTC4 which is metabolized to LTD4 and E4 by cleavage of glutamic 
acid and glycine, respectively. Also MGST-2 is capable of catalyzing this conjugation step. 
Thus, formation of cysLTs is controlled by both enzymes [322]. 
CysLTs are inactivated by formation of the corresponding sulfoxides or, similar to LTB4, by ω-
hydroxylation followed by β-oxidation [238]. CysLTs are formed by eosinophils, mast cells, 
monocytes, macrophages but not by PMNL [322]. In contrast to LTB4, cysLTs primarily affect 
smooth muscle and other cells with contractile capacity. In analogy to LTB4, cysLTs exert their Introduction 
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biological effects via GPCRs, namely cysLT1 and 2. CysLTs are potent inducers of 
bronchoconstriction in guinea pig airways with a 100-1000 fold higher potency than histamine 
[85, 139] and also cause contraction of isolated human bronchi [72]. Depending on the 
concentrations, they contract or relax vascular smooth muscle cells [10]. CysLTs also promote 
plasma exudation [71], stimulate mucus secretion [215], and possess a high capacity to promote 
eosinophil recruitment [341]. In addition they are reported to reduce myocardial contractibility 
and coronary blood flow [224]. 
4.  Lipoxins 
Lipoxins (LX) are trihydroxytetraene-containing eicosanoids and may act as endogenous 
anti-inflammatory lipid mediators [217]. LXA4 and LXB4 are the principal molecules formed in 
mammals [312, 313]. The 15R-enantiomers of LXA4 and LXB4 are referred to as 
aspirin-triggered LXs (ATLs) [58]. The LXs are generated via cell-cell interactions. Enzyme 
activity of 5-LO combined with activity of 12-LO (→ LXA4), 15-LO (→ LXA4/B4), or COX-2 
(→ ATLs) is necessary. There is a variety of effects mediated by LXs in vitro dependent on the 
cell type. In human PMNL, they inhibit chemotaxis, Ca
2+ mobilisation [189] as well as cell 
adhesion, and PMNL-mediated vascular permeability [255, 334]. In contrast, chemotaxis and 
adhesion are stimulated in monocytes [206]. In nonmyeloid cells like endothelium, proliferation, 
chemotaxis, and P-selectin mobilisation is inhibited. For detailed review see [217]. Thus, 
lipoxins exhibit anti-inflammatory effects through their own GPCR but also via antagonizing 
LTD4 effects on cysLT1 [218]. 
E.  Receptors 
The actions of eicosanoids are mediated mainly by specific receptors. All known LT receptors 
belong to the family of the seven transmembrane-spanning GPCRs. They are classified into two 
main groups: The LTB4-receptors BLT1 and 2 which mediate the actions of LTB4, as well as the 
cysLT1 and 2 receptor group which is mainly responsible for the effects of LTC4, D4 and E4. 
BLT1 was first cloned from differentiated HL-60 cells in 1997 [369] and from mouse in 1998 
[150]. The human gene is located on chromosome 14q11.2-q12 and encodes for a 352 aa protein 
with an approximate mass of 43 kDa [253]. The human BLT1 shares a 78 % homology with the 
corresponding receptor from mice and 45.2 % to BLT2 which was identified in 2000. 
Surprisingly, the open reading frame of human BLT2 was located within the promoter of the 
BLT1 gene suggesting a common transcriptional regulation of these two receptors [372]. BLT2 
is expressed ubiquitously in contrast to BLT1 which is mainly expressed in leukocytes [333]. 
LTB4 is the main ligand of these receptors with a 20 fold higher affinity to BLT1 than to BLT2 Introduction 
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[372]. Other ligands such as 12-H(p)ETE or 15-HETE compete with LTB4 binding to BLT2, but 
not BLT1 [371], suggesting that BLT2 functions as a low affinity receptor with broader ligand 
specificity for various eicosanoids. Generation of a BLT1 
-/
- mice strain revealed that the major 
activities of LTB4 are mediated by BLT1 [136, 332]. The BLT1 
-/
- mice are viable, fertile and 
develop normally. In contrast to BLT1 positive mice, recruitment of neutrophils and PM failed 
as well as LTB4-induced Ca
2+ flux and chemotaxis. In addition, oedema and protein 
extravasation in response to AA is reduced and also BLT1 
-/
- mice show a reduced mortality 
towards PAF induced shock [136, 332]. 
In 1999 two groups cloned the cysLT1, a GPCR consisting of a 337 aa protein yielding a 
molecular mass of 38 kDa [204, 307]. CysLT1 is expressed in leukocytes, mast cells, endothelial 
cells as well as in lung and nasal mucosa [90]. Among the cysLTs, binding of LTD4 and LTC4 to 
cysLT1 follows the much strongest contraction of human bronchial smooth muscle. LTE4 is less 
potent [16]. Radio binding studies revealed that selective antagonists, such as montelukast and 
zafirlukast, potently block LTD4 binding to cysLT1, but not to cysLT2. The solubilized receptor 
is associated with a PTX-sensitive G-protein (for detailed review see [238]). 
Less is known about the cysLT2 receptor which was cloned in 2000. Located on chromosome 
13q14, a region linked to atopic asthma, the gene encodes for a protein consisting of 346 aa with 
a 38% homology to the cysLT1 receptor [140]. CysLT2 mRNA shows a strong expression in the 
human heart, adrenals, peripheral blood leukocytes, spleen, lymph nodes and a weak expression 
in smooth muscle cells [140]. The rank order of agonist potency on human pulmonary venous 
smooth muscle preparations is LTC4 = LTD4 > LTE4, with LTE4 as a partial agonist [181]. In 
contrast for cysLT1-receptor, there is no selective inhibitor but with BAY u9773 a dual 
antagonist towards both cysLT-receptors. A further class of cysLT-receptor is discussed [16, 
238]. 
Human cDNA encoding for LXA4R was identified on basis of high affinity to LXA4. Like all LT 
receptors, it is a seven transmembrane-spanning protein with PTX-sensitivity [97]. Binding of 
LXA4 to LXA4R results in a subsequently activation of phospholipase D [98]. LXA4 competes 
with LTD4 for binding with cysLT1 on endothelial cells [218]. 
F.  Clinical implications of 5-LO products 
Asthma is a chronic inflammatory disorder of the airways in which the inflammatory response 
contributes to the airway hyperresponsiveness (AHR) and the episodic, widespread, reversible 
airway narrowing that is characteristic of the disease [13]. Symptoms of an asthma attack include 
coughing, wheezing, shortness of breath, chest tightness. Asthma occurs in people who are Introduction 
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predisposed to develop asthma because of genetic and environmental factors that determine 
susceptibility. A variety of "triggers" may start or worsen an asthma attack, including, exposure 
to allergens, viral respiratory infections, airway irritants, such as tobacco smoke and certain 
environmental pollutants, and exercise (National Institute of Allergy and Infectious Diseases, 
NIH). The inflammatory response is characterized by an increased number of leukocytes such as 
eosinophils, basophils, neutrophils, mast cells and lymphocytes in the epithelium, submucosa or 
bronchoalveolar lavage fluid (BALF). Pronounced mucus secretion and mast cell degranulation 
are other clinical symptoms [13]. 
The role of LTs in asthma contributes to the observed actions of LTs in vivo and in vitro [305]. 
The amount of LTs is increased in BALF and also the urinary LTE4 levels are higher in asthma 
patients in contrast to healthy subjects [87, 185]. Moreover, anti-LT therapy leads to an increased 
bronchodilatation, reduced asthmatic response to triggering factors as well as a decreased AHR 
[70, 155, 156, 190, 234]. 
The properties of LTs imply also a significant role in other inflammatory diseases like arthritis, 
psoriasis, inflammatory bowel disease or allergic rhinitis [352].  Another clinical implication of 
5-LO products is the involvement in atherogenesis. Atherosclerosis is associated with 
hypercholesterinaemia combined with an increased oxidation of low-density lipoproteins (LDL) 
which stick to the subendothelial layer of the artery wall, finally resulting in inflammation of the 
vessel wall [284]. 5-LO was identified as a gene contributing to atherosclerosis susceptibility in 
LDL receptor 
-/
- mice [223]. There is also evidence that variations of 5-LO genotypes may be 
responsible for an increased atherosclerotic vulnerability [89]. 5-LO expressing cells, such as 
monocytes and dentritic cells, are markedly increased in advanced atherosclerotic lesions [323]. 
LTB4 is responsible for monocyte infiltration in these lesions, and this can be counteracted by 
specific LTB4 receptor antagonists [5]. In contrast to non-atherosclerotic coronary arteries, 
challenging of atherosclerotic coronary arteries with LTC4 or LTD4 results in contraction [9, 10]. 
Recent data show that 5-LO contributes to the formation of aortic aneurysms induced by an 
atherosclerotic diet in Apo 
-/
- mice and that 5-LO links hyperlipidemia and the production of 
systemic inflammatory chemokines in several mouse models of hyperlipidemia [378]. For 
detailed review see [271]. 
In addition to these diseases 5-LO products may contribute to carcinogenesis and cell survival 
[15, 82, 96, 121] as well as bone metabolism [54, 111, 186]. Therefore, anti-LT therapy is 
salutary in the treatment of inflammatory diseases [325] but may also be beneficial in the therapy 
of cancer [82, 112, 282], osteoporosis [6, 186] and atherosclerosis [89, 222]. Introduction 
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G.  5-LO inhibitors 
1.  Endogenous Inhibitors 
a)  Glutathione peroxidase 
A certain level of LOOH is required for 5-LO to enter the redox cycle which is necessary for its 
activation [103]. The cellular peroxide level is mainly regulated by GPx, particularly in cells 
devoid of catalase [343]. The family of GPx consists of three tetrameric GPx (1-3) and the 
monomeric phospholipid (Ph)GPx (GPx-4) [344]. Their biosynthesis strictly depends on the 
availability of selenium. They become inactivated if their selenocysteins are carboxymethylated 
by iodoacetate or if the selenium is eliminated [343]. Reducing agents like GSH, DTT, or β-
mercaptoethanol act as cofactors of GPx [102]. 
Phospholipid hydroperoxide glutathione peroxidase (PhGPx) activity is primarily responsible for 
the reduction of 5-HpETE and therefore governs the actual activity of leukocyte 5-LO via 
regulating the tone of endogenous hydroperoxides [350, 358]. PhGPx suppresses 5-LO activity 
in A431 and RBL2H3 cells [149, 152]. After differentiation of MM6 cells by TGFβ and 
calcitriol, the induction of 5-LO protein is obvious but an increase in activity is not prominent 
[40]. Later it was discovered that GPx-1, not only PhGPx, is an efficient inhibitor of 5-LO and is 
involved in the regulation of cellular 5-LO activity in various cell types [328]. Moreover, GPx-1 
confers 5-LO activity Ca
2+-dependent and further data suggest that interaction of Ca
2+ at the C2-
like domain of 5-LO protects the enzyme against the effect of GPx-1 [42, 45]. 
b)  Adenosine 
Adenosine plays an important role in biochemical processes, such as energy transfer - as ATP 
and ADP - but also in signal transduction as cAMP. Effects of adenosine on leukocytes are 
inhibition of phagocytosis, generation of toxic oxygen metabolites, and adhesion without 
inhibiting degranulation or chemotaxis [66]. Concerning LT formation, fMLP-induced synthesis 
of LTB4 in whole blood pretreated with LPS and TNFα is concentration-dependently inhibited 
by adenosine [172]. The removal of endogenous adenosine with either adenosine deaminase or 
the blockade of its action by an adenosine A2a receptor antagonist, markedly reversed the effect 
on LTB4 synthesis upon ligand stimulation [173]. Adenosine inhibits AA release and LTB4 
synthesis via cAMP [101]. cAMP-elevating agents such as isoproterenol, PGE2, adenosine A2a 
receptor agonist, type IV phosphodiesterase inhibitors, and forskolin, all inhibit LT biosynthesis 
and 5-LO translocation to the nucleus in human PMNL stimulated with TG [101]. These effects 
are mediated by direct activation of PKA by cAMP. It was shown that the catalytic subunit of Introduction 
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activated PKA directly phosphorylates 5-LO in vivo and in vitro and inhibits 5-LO activity in 
intact cells and in cell free systems by phosphorylation of Ser523 [203]. 
c)  Nitric oxide (NO) 
NO is a radical produced by NO synthase and has pleiotrophic activities in health and disease. In 
a model using soybean LO, NO-releasing agents inactivated the enzyme by reducing the 
catalytic iron to the inactive ferrous form and counteracted the H2O2-mediated activation of the 
LO-catalyzed dioxygenase reaction. [205]. Prolonged exposure of AM to LPS impairs LT 
production via NO-mediated suppression of 5-LO [61]. Moreover, NO and reactive oxygen 
species (ROS) are known to react with each other forming peroxynitrite (ONOO
-). ONOO
- 
suppressed LT synthesis in intact AM which was reversed by an ONOO
- scavenger  [60]. 
2.  Pharmacological inhibitors 
Based on the pathophysiological profile of LTs, anti-LT therapy is a reasonable pharmacological 
strategy for treatment of a variety of inflammatory diseases as well as atherosclerosis, 
osteoarthritis or cancer. Therefore, development of compounds which intervene in the 5-LO 
pathway is attempted. 
In principle there are two different ways of anti-LT therapy, namely (i) repression of LT 
formation and (ii) blocking LT action at its specific receptors. LT receptor antagonists are 
discussed in detail in [34]. 
Blocking LT formation can be achieved by suppression of substrate availability, direct inhibition 
of 5-LO and inhibition of FLAP. A simplified illustration is given in figure 6. Introduction 
  31
 
Figure 6: Pharmacological strategies of anti-LT therapy 
Experiments with cPLA2 deficient mice revealed that lack of cPLA2 leads to a complete 
repression of eicosanoid formation [306, 342]. Since glucocorticosteroids suppress expression of 
PLA2, glucocorticosteroids have been assumed to inhibit formation of all eicosanoids. This has 
been confirmed in various settings in vitro, but in urine, gained from patients treated with high 
doses of glucocorticosteroids, significant amounts of eicosanoids are still detectable [56]. 
Moreover, dexamethasone increases the expression of 5-LO and FLAP in human monocytes 
[277]. 
Direct inhibitors of 5-LO can be separated into three groups: (i) redox-active compounds, (ii) 
iron-ligand inhibitors and (iii) nonredox inhibitors. 
Phenols like nordihydroguaretic acid, caffeic acid, flavonoids, or coumarins are potent 
redox-active compounds. They act by reducing the active site iron causing an interruption of the 
catalytic cycle of the enzyme. However, the reducing properties and the poor selectivity result in 
severe side effects such as methemoglobin formation [220]. A synthetic approach led to potent 
and orally active compounds such as BW755C or AA-861. But they failed to enter the market 
due to several side effects [103]. 
Derivatives of hydroxamic acid and N-hydroxyurea form the group of iron-ligand inhibitors. 
BWA4C, a hydroxamic acid, is a potent 5-LO inhibitor with an IC50 of 40 nM in stimulated 
granulocytes. Since rapid hydrolysis of this substance leads to formation of toxic nitroxide 
radicals, the development of alternative substances was required [335]. Zileuton (Zyflo
®) is the Introduction 
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only direct 5-LO inhibitor which was licensed for the treatment of asthma, solely in the USA. It 
is a N-hydroxyurea derivate with a short oral half life of 3 h. The compound revealed an IC50 
between 0.5 to 1 µM in a variety of cell types, independent of the origin [20, 49]. Chronic 
administration of zileuton is associated with improved airway function, decreased asthma 
symptoms, and a decreased need for alternative medication in patients with mild to moderate 
asthma [86]. However, in diseases like allergic rhinitis, rheumatoid arthritis, and ulcerative 
colitis, zileuton showed no significant benefit [349]. A refinement of the potency and oral half 
life of zileuton led to the development of ABT-761. It exhibits an improved metabolic stability 
with t½=15  h and the IC50 was decreased up to 150 nM in whole blood [38]. Another new 
approach is to connect benzhydryl piperazine, the H1 pharmacophore of the antihistamines 
cetirizine, with a N-hydroxyurea moiety. First results showed an IC50 for 5-LO and H1 receptors 
of 150 nM and 420 nM, respectively, in human whole blood [196]. 
The handicap of redox-active compounds and iron-ligand inhibitors are their poor selectivity and 
low bioavailability which led to the development of nonredox-type 5-LO inhibitors. They were 
suggested to act by competing with AA for binding to 5-LO. Almost all inhibitors of this class 
contain a methoxyalkylthiazol or a methoxytetrahydropyran moiety. Improvements of lead 
structures resulted in ZD2138 or its ethyl analogue ZM230487 which exhibit IC50 of 20 – 50 nM 
in whole blood [65]. ZD2138 inhibited antigen-induced release of LTD4 and LTB4 with IC50 
values of 0.3 µM and 0.4 µM, respectively [179]. In contrast, treatment with ZD2138 did not 
prevent pulmonary inflammation or the development of AHR. Moreover, ZD2138 did not inhibit 
more chronic responses following multiple antigen exposure [339]. In asthmatic subjects the 
inhibitor did not protect against allergen-induced asthmatic responses [234]. Thus, it seems that 
treatment of acute inflammatory diseases with nonredox-type 5-LO inhibitors is succeessful, but 
inhibition of chronic inflammatory processes fails in this respect. 
Additionally, ZM 230487 or the Merck compound L-739,010, suppress cellular LT synthesis of 
ionophore stimulated granulocytes with IC50 values of about 50  nM. However, in cell 
homogenates or in preparations of purified enzyme as well as when LOOH are added to intact 
cells, up to 150-fold higher concentrations are required for similar inhibition of 5-LO activity. 
Addition of reducing agents such as GSH or DTT reversed the inhibitory potency of ZM230487 
or L-739,010 so that 5-LO inhibition was comparable with that of intact cells [359]. These data 
suggest that physiological conditions associated with oxidative stress and increased peroxide 
levels lead to impaired efficacy of nonredox-type 5-LO inhibitors like ZM230487 or L-739,010. 
Replacement of the dihydroquinolinone pharmacophore of Zeneca's ZD2138 by ionisable 
imidazolylphenyl moiety has led to the discovery of a novel series of potent and orally active Introduction 
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nonredox-type 5-LO inhibitors [214]. Structural optimization led to metabolic stability as well as 
improved bioavailability and a good toxicological profile [213]. In this study, the molecular 
pharmacology of CJ-13,610, a recently developed analogue of these compounds, was tested in 
various in vitro test systems with relevance for the in vivo pharmacology [paper IV]. 
A new approach for treating inflammatory diseases is the development of dual inhibitors of the 
5-LO/COX pathways which posses a wider spectrum than that of classical nonsteroidal 
anti-inflammatory drugs (NSAIDs) [99]. Among dual inhibitors, a novel class of non-antioxidant 
compounds has been described; the most potent and well balanced dual inhibitor is ML3000 
([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid, 
presently in clinical phase III [99, 187]. The compound inhibits 5-LO in bovine and human 
granulocytes with IC50 of 0.18 and 0.23 µM [187]. 
Hyperforin represents a substance of plant origin within the dual inhibitors. In freshly isolated 
human PMNL stimulated with Ca
2+-ionophore A23187, hyperforin inhibited 5-LO product 
formation with IC50 values of about 1-2  µM. Experiments with purified human 5-LO 
demonstrate that hyperforin is a direct 5-LO inhibitor (IC50 approximately 90 nM), acting in a 
noncompetitive fashion. In ionophore-stimulated human platelets, hyperforin suppressed COX-1 
product formation with an IC50 of 3 µM. Hyperforin could not interfere with COX-2 product 
formation and did not significantly inhibit 12- or 15-LO in platelets or leukocytes, respectively 
[8]. 
Other potent non synthetic substances which inhibit LT formation are 11-keto-beta-BA (KBA) 
and their acetyl derivative 3-O-acetyl-11-keto-beta-BA (AKBA). They are contents of the gum 
resin of Boswellia serrata. Among the BAs, AKBA induced the most pronounced inhibition of 
5-LO product formation with an IC50 of 1.5 µM [294]. Effects of BAs on the MAPK cascade, 
cellular Ca
2+ mobilisation as well as formation of ROS, release of AA, and LT biosynthesis are 
depicted in this study [paper V,VI]. 
An additional target for inhibition of LT synthesis is the development of FLAP inhibitors. The 
indole derivate MK886 potently inhibits LT formation in intact cells (IC50=2.5 nM) but shows an 
impaired efficacy in whole blood (IC50=1.1  µM) and failed to directly inhibit 5-LO [114]. 
Bay x1005, a quinoline derivate, as well as MK0591, a indole/quinolines hybrid, are also found 
to be FLAP inhibitors exhibiting potent LT synthesis-inhibitor properties [104, 210]. For 
Bay x1005 inhibits allergen-induced asthma and bronchoconstriction in asthma subjects [69]. 
But nevertheless it shows only a weak activity in whole human blood (IC50=11.6 µM) [104]. The 
impaired efficacy of FLAP inhibitors in whole blood assays is conceivable since FLAP is not 
absolutely required for cellular LT synthesis if exogenous AA is present [287, 327, 357]. Also Introduction 
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high affinity of FLAP inhibitors to plasma proteins may impair the efficacy [52]. Moreover, 
since AA triggers apoptosis [258] it is not surprising that inhibitors of FLAP, like MK886, have 
the same effect [94]. It is obvious that also other members of the MAPEG-family are potential 
targets of these compounds [184]. Since these drugs compete with AA and other unsaturated 
fatty acids (UFA)s for binding to fatty acid binding sites it should be also considered that they 
may possess several additional properties. A 5-LO inhibitor overview gives figure 7. 
 
Figure 7: 5-LO inhibitorsAims of the present studies 
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III.  Aims of the present studies 
LTs are key mediators involved in a variety of inflammatory and allergic disorders but also in 
diseases like cancer, osteoporosis and atherosclerosis. Therefore, anti-LT therapy might be 
beneficial for the treatment of such diseases [106, 305, 325, 352]. Due to the fact that 5-LO 
initializes the biosynthesis of LTs, detailed knowledge about the cellular activation of 5-LO is 
required for the development of drugs targeting this enzyme. 
Ca
2+, ATP, phosphatidylcholine, LOOH and leukocyte factors are involved in the enzymatic 
regulation in vitro [103, 272]. Recent data showed that phosphorylation of 5-LO by p38 MAP 
kinase dependent MK-2 is a novel pathway which leads to a Ca
2+-independent cellular LT 
formation [353, 355]. However, there are indications that ERK1/2 are involved in regulation of 
cellular 5-LO activity [25, 193, 380]. 
One main goal of this study was to elucidate if ERK1/2 phosphorylate 5-LO and if there is 
evidence for ERK1/2 signalling in the activation of 5-LO in intact cells. 
The classical nonredox-type 5-LO inhibitors failed in clinical trials evaluating the efficacy in 
chronic inflammatory diseases [234, 339]. Some diseases, which are associated with an increased 
level of 5-LO metabolites, revealed an inreased phosphorylation status of the cells. Inflammatory 
reactions, cancer, or atherosclerosis are some examples [127, 163]. In this respect, the second 
main goal was to investigate if the activation pathway of 5-LO determines the efficacy of 
nonredox-type 5-LO inhibitors and if the novel inhibitor CJ-13,610 exhibits advantages over 
former compounds.  
Further purposes were to address the effects of the 5-LO inhibitors boswellic acids on various 
signalling pathways important for inflammatory responses of neutrophils. 
Finally, the aim of this study was to enlighten the link between the cytoskeleton and cellular LT 
formation.Methods 
IV.  Methods 
 
Method Paper 
 
isolation of human polymorphonuclear leukocytes (PMNL)  I-VII 
5-LO activity assay  I-IV, VI, VII 
cellular cPLA2 activity ([
3H]AA release)  I, VI, VII 
subcellular fractionation, detergent lysis  IV, VII 
gel electrophoresis, Western blot  I, II, IV-VII 
immunoprecipitation I 
MAPK activation  I, III, V-VII 
in-gel kinase assay  III, IV 
in vitro protein kinase assay  I, II, III 
transient transfection of HeLa cells  I-IV 
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protein expression using E.coli  I, III, IV 
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2+ levels  V, VI, VII 
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HeLa cells (human cervix carcinoma cells)  I-IV 
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A.  Paper I: Extracellular signal-regulated kinases phosphorylate 
5-lipoxygenase and stimulate 5-lipoxygenase product formation in 
l e u k o c y t e s               
Paper II: 5-lipoxygenase activation by MAPKAP-2 and ERKs 
Background and rationale: 
Upon stimulation of intact cells, LT formation is an interplay of various enzymes including 
cPLA2, FLAP and 5-LO. Besides elevation of intracellular Ca
2+, phosphorylation of cPLA2 by 
MAP kinase as well as phosphorylation of 5-LO by MK2 at Ser271 leads to an increased AA 
release and LT formation respectively [113, 355, 360]. Based on inhibitor studies, there are 
several reports suggesting also a role for ERK1/2 in agonist induced 5-LO translocation and 
product formation in HL-60 cells [193] and leukocytes [2, 19, 25, 380]. Priming of eosinophils 
with IL-5 or GM-CSF and subsequent stimulation with fMLP leads to ERK activation 
concomitant with LTC4 formation [19]. Moreover, inhibition of MEK1/2 by U0126 prevents 
5-LO translocation in fMLP-challenged human neutrophils [25]. Finally, U0126 completely 
inhibits both PAF-induced ERK phosphorylation and LTC4 generation in PAFR cells [2]. 
Although, 5-LO contains the minimal consensus sequence Ser/Thr-Pro for phosphorylation by 
ERK1/2, so far phosphorylation by these kinases could not be proved [194]. 
The aim of this study was to identify 5-LO as a substrate for ERK1/2 and to provide the 
molecular basis for the involvement of ERK1/2 signalling in the activation of 5-LO in intact 
cells. A second aim was to point out the parallels of MK2 to ERK1/2 regarding phosphorylation 
and activation of 5-LO. 
Results: 
By  in vitro kinase assays using activated recombinant ERK2 kinase and purified 5-LO as 
substrate, a concentration dependent phosphorylation of 5-LO by ERK2 could be demonstrated. 
In contrast to myelin basic protein (MBP) 5-LO was a weak substrate for ERK2. Addition of AA 
or other UFAs up to 50 µM promoted 5-LO phosphorylation. However, saturated fatty acids had 
no effect on 5-LO phosphorylation. After substitution of Ser663 to Ala in 5-LO enzyme, ERK2 
failed to strongly phosphorylate 5-LO, independent of added UFAs. Using specific inhibitors for 
PKC (GF109203x) and for MEK1/2 (U0126), we could demonstrate the involvement of these 
enzymes in ERK1/2 activation by PMA in MM6 cells. Furthermore, ERK1/2, 
immunoprecipitated from PMA-primed or Ca
2+ ionophore stimulated MM6 cells, 
phosphorylated 5-LO or MBP in in vitro kinase assays. Results 
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Interestingly, ERKs are involved in AA release and 5-LO product formation in MM6 cells. Thus, 
inhibition of PKC or MEK1/2 suppressed PMA-induced [
3H]AA release and also 5-LO product 
formation. Also for human PMNL, an involvement of ERKs in 5-LO product formation could be 
demonstrated. Addition of increasing amounts of exogenous AA to PMNL in absence of 
extracellular Ca
2+ resulted in an increased activation of ERK1/2 correlating with an elevated 
level of 5-LO products. U0126 (3 µM) reduced residual 5-LO activity to 40% in contrast to 
5-LO activity induced by Ca
2+ or cell stress, which was not affected by U0126. Also addition of 
chemotactic fMLP to PMNL resulted in ERK1/2 dependent 5-LO product formation. 
Transient transfection of HeLa cells with wt 5-LO or Ser663Ala-5-LO and subsequent 
stimulation with increasing amounts of AA in presence of Ca
2+ ionophore led to a similar 
product formation. However, stimulation of 5-LO activity by AA alone resulted in a distinct 
reduced LT formation for mutated 5-LO in contrast to wt 5-LO, implicating a prominent role for 
ERKs in cellular 5-LO activation. Further experiments revealed a conjugated role of MK2 and 
ERKs regarding activation of cellular 5-LO product formation. Thus, preincubation of human 
PMNL with SB203580 or U0126 followed by challenging with AA in absence of extracellular 
Ca
2+ led to a markedly reduced LT formation with 60% and 40% residual activity, respectively. 
Combining both inhibitors gave an additive effect resulting in 17% residual activity. These 
results could be supported by experiments using HeLa cells transfected with wt 5-LO, 
Ser663Ala-5-LO or a 5-LO mutant (Ser271Ala/Ser663Ala-5-LO) where both phosphorylation 
sites were removed. For wt 5-LO, the ratio of AA- to AA plus ionophore-induced 5-LO product 
formation at 10-60  µM AA was 24-43%, for 5-LO-Ser663Ala 11-22%, and for the 
5-LO-Ser271/663Ala 5-14%. Thus, phosphorylation at both, Ser663 and Ser271, appears to be 
required for 5-LO product formation in intact cells at low Ca
2+ levels. 
In analogy to ERK2, 5-LO was also a weak substrate for MK2 and dose dependently 
phosphorylated by both kinases up to 30 mU of kinase. Moreover, according to phosphorylation 
by ERK2 also addition of up to 50  µM AA as a cofactor to MK2 led to an increased 
phosphorylation of 5-LO. This UFA-promoted phosphorylation correlated with a raised 5-LO 
activity in intact human PMNL. Adding increasing amounts of exogenous AA gave maximum 
5-LO kinase activity associated with maximum LT formation. Specific inhibition of kinases 
upstream of both 5-LO kinases by SB203580 (p38 MAPK) or/and U0126 (MEK1/2) pointed out 
the involvement of MK2 and ERK1/2 in 5-LO activation in intact cells. 5-LO reveals putative 
phosphorylation motifs for MK2 (aa 266-271) and ERK2 (aa 661-664) with Ser271 and Ser663 
as potential phosphorylation sites. Finally, after mutation of these residues to alanine and 
transfection of HeLa cells with wt and mutated 5-LO, cellular 5-LO activity was determined. Results 
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Nearly identical amounts of 5-LO products were accumulated when cells were treated with AA 
plus Ca
2+ ionophore, whereas clearly less LTs were produced by mutated 5-LO as compared to 
wt 5-LO when cells were stimulated with AA alone. Lastly, removing of both potential 
phosphorylation sites resulted in an even more pronounced reduction of AA-induced 5-LO 
activity. 
The author of this thesis contributes the results of studies regarding the influence of saturated and 
unsaturated fatty acids, determined by in vitro kinase assay. 
B.  Paper  III: Phosphorylation- and stimulus-dependent inhibition of 
cellular 5-lipoxygenase activity by nonredox-type inhibitors 
Background and rationale: 
The bioactive lipids have pivotal functions in pathophysiology of inflammatory diseases such as 
allergy or arthritis [303] and are involved in carcinogenesis [121, 281], metabolism of bone  
[111, 186] and atherogenesis [271, 323]. Suppression of 5-LO mediated LT formation via 
specific 5-LO inhibitors confirmed the therapeutic value of antileukotriene therapy in asthma and 
other inflammatory diseases [325]. Furthermore, based on recently discovered clinical 
implications of LTs in cancer [15, 82, 112], osteoporosis [6, 186], and vascular diseases [271, 
378], 5-LO inhibitors may also posses considerable potency in the treatment of such diseases. 
In addition to activation by Ca
2+, 5-LO can also be activated via phosphorylation by MK2 and/or 
ERKs using genotoxic (SA) or osmotic (NaCl) stress, or even AA alone as stimulus [paper I, II, 
45, 354-356, 360]. In particular, activation of 5-LO by phosphorylation is Ca
2+-independent in 
human PMNL [353]. 
The nonredox-type 5-LO inhibitors, such as ZM230487 and L-739.010, are potent, orally active 
inhibitors of LT biosynthesis in a variety of ex vivo and in vitro models which reduce acute 
inflammatory responses [219, 220, 321], but failed to suppress more chronic inflammatory 
processes [234]. It was found that nonredox-type 5-LO inhibitors require GPx for efficient 
inhibition of 5-LO activity [359]. 
The aim of this study was to reveal if the activation pathway of 5-LO contributes to the efficacy 
of nonredox-type 5-LO inhibitors. 
Results: 
In a 5-LO activity assay under standard assay conditions using Ca
2+ ionophore as stimulus, 
ZM230487 and L-739.010 were potent nonredox-type 5-LO inhibitors in isolated human PMNL 
with IC50 values of 20  nM and 10  nM, respectively. In contrast, 10- to 100-fold higher 
concentrations were required when 5-LO was activated by phosphorylation using genotoxic Results 
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(10 µM SA) or osmotic (300 mM NaCl) stress as stimulus. In an analogous manner, activation of 
5-LO by 60  µM AA alone caused a shift of the IC50 value up to 0.4  µM and 0.8  µM for 
ZM230487 and L-739.010. Also, upon treatment of PMNL with natural ligands such as PAF or 
fMLP the potency of nonredox-type 5-LO inhibitors was significantly impaired. In contrast, the 
potency of the iron ligand inhibitor BWA4C was stimulus-independent with a consistent IC50 of 
70-90 nM. 
Further experiments showed that Ca
2+-depletion impaired the efficacy of ZM230487 in 
SA-activated PMNL. Removal of extracellular Ca
2+ by adding 1 mM ETDA further reduced the 
efficacy of ZM230487 up to fivefold compared to conditions when extracellular Ca
2+ was 
present. Again, almost no difference could be shown for BWA4C in this respect. To check if 
Ca
2+ is required for potent 5-LO inhibition by nonredox-type 5-LO inhibitors, PMNL were 
exposed to SA 3 min before synchronic addition of AA and Ca
2+ ionophore. The results revealed 
that SA counteracted efficiently 5-LO inhibition by ZM230487 in ionophore-stimulated PMNL 
and that Ca
2+ was not needed for effective 5-LO inhibition. This fact could be underlined by 
using purified 5-LO enzyme. 
Although treating PMNL with Ca
2+ ionophore leads to activation of MK2, phosphorylation of 
5-LO is not responsible for an impaired potency of nonredox-type 5-LO inhibitors in this case. 
This can be explained by comparison of kinetic data. In ionophore-induced 5-LO product 
formation 80% of the maximal product amount were achieved after 1 min. However, significant 
activation of MK2 occurred first after 1  min, with a maximum after 2  min in ionophore-
challenged PMNL. Consequently, 5-LO phosphorylation events should not counteract inhibition 
of ionophore-induced 5-LO activity by nonredox inhibitors. 
Transfection of HeLa cells with wt 5-LO or non-phosphorylatable mutant 5-LO 
(Ser271Ala/Ser663Ala) showed that deletion of the phosphorylation sites increases the efficacy 
of nonredox-type 5-LO inhibitors. In HeLa cells expressing wt 5-LO, stimulation with 40 µM 
AA, ZM230487 and L-739.010 suppressed 5-LO product formation with IC50 values of 630 nM 
and 510  nM, respectively. Interestingly, for Hela cells transfected with mutant 5-LO, 6- to 
10-fold lower concentrations were needed. In contrast, the iron ligand inhibitor BWA4C showed 
no such differences. 
To verify if phosphate incorporation alone protects 5-LO towards nonredox-type inhibitors, 
ZM230487 was tested against phosphorylated and non-phosphorylated purified enzyme. 
However, there was no significant shift of the IC50 values of ZM230487 for phosphorylated 
compared to unphosphorylated enzyme in cell free assays. 
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The author of this thesis is responsible for the following studies, published in this paper: 
•  Efficacy of nonredox-type 5-LO inhibitors in human PMNL 
•  Ca
2+ depletion impairs the efficacy of nonredox-type 5-LO inhibitors in SA-activated 
PMNL 
•  SA counteracts efficient 5-LO inhibition by ZM230487 in ionophore-stimulated PMNL 
•  Ca
2+ has no influence on inhibition of purified 5-LO by ZM230487 
•  Effects of N-acetylcysteine on 5-LO inhibition by ZM230487 
•  Effects of in vitro phosphorylation of 5-LO on the susceptibility toward ZM230487 
C.  Paper IV:  Molecular  pharmacological profile of the nonredox-type 
5-lipoxygenase inhibitor CJ-13,610 
Background and rationale: 
Although a huge number of 5-LO inhibitors have been developed within the last 20 years, only 
one of the compounds could make it to the market. This is due to the fact that these inihibitors 
showed poor efficacy in vivo, only a short half life, and a number of side effects. However, with 
respect to the biological properties of LTs, further development of 5-LO inhibitors is still 
beneficial for the treatment of a variety of diseases (see above and [352]). 
5-LO contains a nonheme iron in the active site, which is essential for catalytic activity in its 
oxidized form. Reducing compounds (such as polyphenols) or iron-ligands (such as zileuton) are 
potential inhibitors of 5-LO, but despite their high potency in vitro, these compounds exhibit 
only poor bioavailability, only modest selectivity for 5-LO and thus a high potential for side 
effects [325]. 
Another approach for efficient and selective 5-LO inhibition is the development of nonredox-
type inhibitors. Promising data revealed a high potency in several ex vivo and in vitro studies of 
such compounds but they failed to inhibit more chronic inflammatory processes [234, 339]. It 
was found that the efficacy of nonredox-type inhibitors depends on the peroxide level [359] as 
well as on the activation pathway of 5-LO [paper III]. In contrast to the known inhibitors, the 
new compound CJ-13,610 exhibits an enhanced metabolic stability which results in fewer in vivo 
metabolites, as well as improved bioavailability and a better toxicological profile. 
The aim of this study was to characterize the molecular pharmacological profile of the novel 
ionizable imidazolylphenyl compound CJ-13,610. 
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Results: 
When freshly isolated human PMNL were incubated with CJ-13,610 and stimulated with Ca
2+ 
ionophore in the absence of exogenous AA, the IC50 value was 70  nM. Supplementation of 
exogenous AA impaired the efficacy of CJ-13,610 and shifted the IC50 to higher values. In detail, 
adding 2  µM AA resulted in an IC50 of about 280  nM and further increase of substrate 
concentration up to 100 µM diminished the potency of CJ-13,610. Kinetic analysis emphasizes 
competitive inhibition of 5-LO in intact human PMNL. Moreover, at low substrate availability 
CJ-13,610 completely blocked 5-LO activity whereas at high concentrations of AA, some basal 
activity still remained. 
In order to check if CJ-13,610 is a direct 5-LO inhibitor, the efficacy of this compound in broken 
cell preparations was examined. Likewise for classic nonredox-type inhibitors, also CJ-13,610 
failed in homogenates at high peroxide levels, independent of the substrate concentration. 
However, restoring peroxidase activity by inclusion of thiols, the inhibitor regained its potency. 
At low AA levels (4 µM) the IC50 value was about 280 nM. When the AA concentration was 
increased up to 40 µM, the IC50 shifted to 700 nM, indicating a competitive mode of action. This 
could also be observed in the corresponding Lineweaver-Burk plot. Regarding inhibition of 
purified recombinant 5-LO, CJ-13,610 failed again under non-reducing conditions. Again, when 
30 mU GPx-1 was added, CJ-13,610 showed an IC50 of about 5 µM at 4 µM AA. Using 40 µM 
AA as substrate, the compound failed completely to inhibit 5-LO. 
To confirm the hypothesis that the efficacy of CJ-13,610 depends on the peroxide level, 
exogenous LOOH were added to intact cells before challenging the cells with Ca
2+ ionophore 
and AA. When 3 µM 13(S)-HpODE was added to the cells, the IC50 shifted from 0.55 µM to 
3.1  µM. Further increase of LOOH to 10  µM completely abolished 5-LO inhibition by 
CJ-13,610. Interestingly, in the absence of exogenous AA, 3 µM 13(S)-HpODE reduced the 
efficacy to the same extent. 
In contrast to ZM230487 and L-739.010, the potency of CJ-13,610 was not affected by cell 
stress. Stimulating human PMNL with 10 µM SA, 300 mM NaCl, or 2.5 µM Ca
2+ ionophore led 
to similar IC50 values. 
In order to confirm that inhibition of 5-LO by CJ-13,610 is independent of the phosphorylation 
status of the enzyme, HeLa cells were transfected with wt 5-LO or mutant 5-LO where the 
phosphorylation sites were removed. Interestingly, in contrast to PMNL, low concentrations of 
CJ-13,610 led to an increased 5-LO product synthesis in HeLa cells transfected with wt 5-LO. 
The IC50 values for mutant and wt enzyme were approximately the same but were 10-fold higher 
than in human PMNL. Results 
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Finally, the effect of CJ-13,610 on 5-LO translocation was examined using a subcellular 
fractionation protocol. In resting cells, 5-LO was detected mainly in the non-nuclear fraction. 
However, challenging cells with Ca
2+ ionophore caused enrichment in the nuclear fraction which 
was not affected by increasing amounts of CJ-13,610 up to 10 µM. 
All experiments and results, published in this paper, were performed by the author of this thesis. 
D.  Paper  V:  Boswellic acids activate p42  MAPK and p38  MAPK and 
stimulate Ca
2+ mobilization 
Background and rationale: 
Boswellic acids (BAs) are pentacyclic triterpenes which have been identified as the active 
principles of Frankincense, the gum resin of Boswellia species. Boswellia serrata (BS) extracts 
have been traditionally used as folk medicine to cure inflammatory and arthritic diseases [296]. 
Moreover, BAs were pointed out to suppress the formation of LTs by targeting 5-LO [294, 297] 
and to inhibit human leukocyte elastase [295]. In addition, they have been reported to affect the 
growth and differentiation of tumour cells [115, 146, 200, 256, 364]. Activation of caspase-8 
[200] and ERK1/2 [256], or inhibition of topoisomerases [146] may contribute to these effects. 
Intriguingly, the potency of AKBA to inhibit LT formation strongly depends on the cell type and 
differs between intact cells (~12  µM) and homogenates (~50  µM) [357]. Furthermore, low 
concentrations of BS extract [293] and 3-oxo-tirucallic acid [26], isolated from BS extracts, 
enhanced 5-LO product formation. For this reason, the aim of this study was to address the 
effects of BAs on various signalling pathways regulating cellular 5-LO product synthesis in 
PMNL such as MAPK and Ca
2+. 
Results: 
After treatment of human PMNL with increasing amounts of BS  extract up to 13  µg/ml, 
activation of MAPK by extracts of B.serrata and isolated BAs was analyzed using 
phospho-specific antibodies. BS extract (0.38 to 13 µg/ml) led to a dose dependent activation of 
p38 and ERK2 and also its ingredients AKBA (30  µM) and KBA (30  µM) showed similar 
effects for both MAPKs. In contrast, the corresponding keto-free BAs β-BA and A-β-BA 
showed no activation of ERK2 and only slight activation of p38  MAPK. The pentacyclic 
triterpenes  α-amyrin and ursolic acid failed to activate MAPKs. These effects could be 
underlined also by in-gel kinase assay with MBP as substrate for ERK2. 
Concentration response experiments with AKBA revealed that p38 and ERK2 became clearly 
activated when cells were treated with 30  µM. In contrast, 100  µM KBA were required for 
substantial activation of ERK2 whereas 10 to 30 µM was sufficient for activation of p38. The Results 
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failure of β-BA and A-β-BA indicated that the 11-keto group is a structural requirement for 
activation of MAPKs. Kinetic analysis exhibited a rapid activation after 30 s with a maximum 
after 1 to 2.5 min. 
In order to check if BAs induce Ca
2+ mobilisation, isolated PMNL were loaded with the dye 
FURA-2 and subsequently the fluorescence was analyzed and [Ca
2+]i determined. In 
unstimulated cells the basal [Ca
2+]i was about 40-50 nM. After stimulation with 30 µM AKBA, 
the [Ca
2+]i raised up to ~230 nM, similar to treatment with 1 µM fMLP (~240 nM). Challenging 
cells with 30 µM KBA gave Ca
2+ concentrations up to 145 nM. Other pentacyclic triterpenes 
were virtually not effective. 
To elucidate the activation pathways upstream of MAPK, the dependency on Ca
2+ mobilisation 
was verified. Depletion of extracellular and/or intracellular Ca
2+ only partially suppressed 
AKBA-induced ERK2 activation. Finally, the involvement of PKC and phosphatidyl 
inositol 3-kinase (PI 3-K) was investigated by Western blot analysis and in-gel kinase assay. 
Inhibition of PKC by RO-31-8425 slightly reduced ERK2 and p38 activation by 30 µM AKBA, 
whereas GF109203x rather enhanced ERK2 activation. Inhibition of PI  3-K by wortmannin 
strongly decreased ERK2 and p38 activation by AKBA. 
The following experiments of this paper were performed by the author of this thesis: 
•  Activation of MAPK by extracts of B. serrata and isolated BAs 
•  Effects of PKC and PI 3-K inhibitors on MAPK activation induced by AKBA 
All results were determined by in-gel kinase assay. 
E.  Paper  VI:  Coupling of boswellic acid-induced Ca
2+ mobilisation and 
MAPK activation to lipid metabolism and peroxide formation 
in human leukocytes 
Background and rationale: 
In paper V it was shown that KBA and AKBA activate MAPKs and stimulate Ca
2+ mobilisation 
in human PMNL. In this study we attempted to connect these observed effects to functional 
responses of PMNL including formation of ROS, release of AA, and LT biosynthesis. 
Results: 
Human PMNL were loaded with DCF-DA and subsequently the oxidation of the dye was 
measured via fluorescence spectoscopy. fMLP (1 µM), Ca
2+ ionophore (2.5 µM) as well as PMA 
(100 nM) caused a rapid formation of ROS. Also, challenging cells with AKBA and KBA (each 
30 µM) led to prominent ROS formation, whereas BAs without keto-moiety, namely β-BA and 
A-β-BA, had only moderate effects. DPI, a direct inhibitor of NADPH oxidase, almost Results 
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completely blocked PMA- and also AKBA-induced ROS formation. Depletion of extra- and 
intracellular Ca
2+ had similar effects. Further inhibitor studies revealed an involvement of PI 3-K 
(using 50 nM wortmannin or 30 µM LY-294002) and ERK1/2 (3 µM U0126) in AKBA-induced 
ROS formation. This differed clearly from the activation pathway of PMA-induced ROS 
formation since only the PKC inhibitor RO-318425 had a pronounced effect. Pertussis toxin, a 
potent inhibitor of Gαi/0-proteins, attenuated BA-induced mobilisation of Ca
2+ and MAPK 
activation in PMNL. 
The action of BAs on the liberation of AA was tested and both, AKBA and KBA, considerably 
enhanced the release of [
3H]-labelled AA, whereas β-BA and A-β-BA showed only a weak 
impact. Chelation of Ca
2+ again completely abolished the effects of keto-BAs. 
Although BAs had been reported to inhibit 5-LO product formation, the later results suggested a 
feasible activation of 5-LO due to the ability of BAs to mobilize Ca
2+ and activate ERK1/2. 
Interestingly, simultaneous addition of AA and keto-BA in absence of Ca
2+ resulted in an 
increase of 5-LO products up to 3.8 fold as compared to cells stimulated with AA alone, whereas 
β-BA and A-β-BA had no effects. Concentration response analysis indicated that AKBA at 
higher concentrations (100 µM) failed to stimulate 5-LO. Surprisingly, adding MAPKs inhibitors 
did not influence AKBA-induced LT formation. Since prolonged exposure of 5-LO to Ca
2+ or 
ROS leads to inactivation of the enzyme [103], extended treatment of cells with AKBA could 
explain its inhibitiory potency. Therefore, cells were preincubated in the absence of Ca
2+ with 
AKBA and finally stimulated with Ca
2+  ionophore and AA in the presence of Ca
2+. This 
experiment showed a strongly impaired efficacy of AKBA when cells were preincubated in the 
absence of Ca
2+. 
Finally, the impact of BAs was tested towards different haematopoietic cell lines, such as 
differentiated MM6 and granulocytic HL-60 cell lines. None of the BAs had any influence 
regarding MAPKs activation, Ca
2+ mobilisation or ROS formation in MM6 cells, whereas effects 
of BAs in granulocytic HL-60 cells equated those in PMNL. 
The testings of BAs regarding their ability to elevate the liberation of AA from PMNL were 
carried out by the author of this thesis. 
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F.  Paper  VII: Inhibitors of actin polymerization upregulate arachidonic 
acid release and 5-lipoxygenase activation by upregulation of 
Ca
2+ mobilisation in polymorphonuclear leukocytes involving 
Src family kinases 
Background and rationale: 
Previous studies proposed a regulatory role of the cytoskeleton for the capacity of leukocytes to 
form LTs. Inhibition of actin polymerization by cytochalasin (Cyt) potentiates LT formation 
induced by fMLP [128, 254, 300]. Additionally, 5-LO is able to bind to actin [192] and interacts 
with CLP, an actin-binding protein [265, 266]. Consequently, there are several implications for 
an involvement of the cytoskeleton in matters of regulation of LT biosynthesis. 
The aim of this study was to enlighten the link between the cytoskeleton and cellular LT 
formation and to elucidate the signalling molecules modulating the effector enzymes 5-LO and 
cPLA2. 
Results: 
Freshly isolated PMNL were incubated in presence or absence of 3 µM latrunculin B (LB), a 
potent inhibitor of actin polymerization, with increasing amounts of TG. Determination of 
synthesized 5-LO products revealed an increasing signal starting at a concentration of 1 µM TG 
in absence of LB. Inhibition of actin polymerisation by 3 µM LB already led to a prominent 
signal using 0.01 µM TG as stimulus, and increased LT formation up to 20-fold. Dose response 
experiments showed an EC50 of 0.2  µM LB with a maximal effect at 3  µM. Furthermore, 
synchronic stimulation with LB and TG gave the strongest effect, whereas prolonged 
preincubation reduced 5-LO stimulatory effects of LB. In contrast to the TG signal, LB only 
marginally potentiated ionophore- or fMLP-induced LT formation. Finally, kinetic analysis 
showed a lag-phase of 70 sec when TG was coincubated with LB, as compared to TG alone 
(150 sec). 
In accordance with 5-LO product formation, LB multiplied also the release of AA from PMNL 
induced by TG, but not by Ca
2+ ionophore or fMLP. Again, the EC50 of LB for the AA release 
was about 0.2 µM, and pronounced effects were obtained at suboptimal concentrations of TG 
(0.01 to 1 µM). 
In order to determine if LB also promotes 5-LO translocation, PMNL were stimulated with TG 
or ionophore with or without LB. Subsequently, subcellular localisation of 5-LO was assessed. 
Whereas TG caused only weak 5-LO translocation to the nucleus, addition of LB caused a 
significant enrichment of 5-LO at the NE. In contrast, the innate prominent effect of ionophore 
was not further promoted. Results 
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Based on these results, elevation of intracellular Ca
2+ might be the reason for the observed LB 
effects. PMNL were loaded with FURA-2 and subsequently Ca
2+ mobilisation was determined 
using fluorescence spectrometry. TG caused a moderate Ca
2+ influx (from 100 to about 200 nM) 
as compared to ionophore (from 100 to about 800 nM). Intriguingly, LB alone gave a delayed 
but prominent signal up to 300 nM [Ca
2+]i. An additive effect was observed when cells were 
simultaneously stimulated with LB and TG (500 nM). Similar effects were also detected for 
ionophore and fMLP. Concentration-response studies showed an EC50 of ~0.2 µM LB regarding 
augmentation of TG-induced elevation of [Ca
2+]i. Parallel to 5-LO activity and AA release, there 
were also concentration-dependent effects of TG on [Ca
2+]i, whereas LB consequently 
potentiated Ca
2+ mobilisation on top of TG signalling. U73122, a PLC inhibitor, suppressed 
LB-induced elevation of [Ca
2+]i as well as the upregulatory effects of LB but not the TG signal 
alone. 
Activation of cPLA2 and 5-LO is also regulated by p38 MAPK and ERK1/2 [113, 360, paper I, 
II]. LB alone caused only weak but rapid MAPK activation. Also, treating cells with TG induced 
a low signal as compared to fMLP and Ca
2+ ionophore. Costimulation of PMNL with LB and TG 
did not result in an increased activation of p38 MAPK or ERK1/2. 
Inhibitor studies revealed that Src family kinases mediate the stimulatory effects of LB on Ca
2+ 
mobilisation, AA release and 5-LO activity. The specific Src kinase inhibitors PP2 and SU6656 
suppressed LB-induced and -upregulatory effects of intracellular Ca
2+ level but failed to reduce 
TG mediated signalling. The inactive analogue PP3 showed no influence. Similar results were 
shown for cPLA2-mediated AA release and 5-LO activity. Finally, inhibition of Src family 
kinases by PP2 and SU6656 also blocked the upregulatory effects of LB and 5-LO translocation 
in PMNL treated with TG. 
All experiments and results, published in this manusscript, were performed by the author of this 
thesis. Discussion 
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VI.  Discussion 
A.  Phosphorylation of 5-LO related to physiological LT formation 
Phosphorylation of proteins is a covalent modification of certain amino acid residues and a 
highly effective means of controlling the activity of specific proteins in structural, 
thermodynamic, kinetic, and regulatory manners. The 5-LO sequence contains a variety of 
phosphorylation motifs for kinases including PKA, PKC, CaMKII, MK-2/3, S6 kinase, ERK1/2, 
and Cdc2 [352]. However, residues distant to a designated motif, can contribute to a potential 
phosphorylation. The protein conformation may alter the accessibility of a possible 
phosphorylation site for a certain kinase. 
In 1996, Lepley et al. were the first who demonstrated that ionophore-activated HL-60 cells 
contain a phosphorylated and a non-phosphorylated form of 5-LO [194]. Moreover, inhibitor 
studies indicated that MAPKK-1 participates in the molecular processes governing activation 
and translocation of 5-LO from the cytosol to the nuclear membrane [193]. Furthermore, the 
specific MEK1/2 inhibitor U0126 blocked LTC4 production in IL-5 primed eosinophils [19] and 
fMLP challenged neutrophils [25, 194]. Release of AA by cPLA2 is required for biosynthesis of 
LTs. Activation of cPLA2 is mediated by phosphorylation via MAPKs [113, 199]. Inhibition of 
MAPK activity by U0126 or SB203580 suppressed AA and LTC4 release in fMLP stimulated 
eosinophils [380]. But also in presence of exogenous AA, 5-LO activity was blocked by the 
specific MEK1/2 inhibitor PD98059 [193], implicating a more direct effect of ERKs in respect to 
5-LO regulation. However, phosphorylating of 5-LO in vitro, using purified MAPK, could not be 
shown. 
We could demonstrate that 5-LO is phosphorylated by MK-2/3 and ERK1/2 [355, paper I, II]. In 
gel kinase assay identified 5-LO as a substrate for MK-2/3 and a as poor substrate for ERK1/2. 
However, addition of UFAs such as AA increased the potency for both kinases, MK-2/3 and 
ERK1/2, to phosphorylate 5-LO [paper I, II, 360]. This effect was restricted to 5-LO as substrate, 
but did not occur on phosphorylation of MBP (ERKs) or Hsp27 (MK-2/3), suggesting a 
regulatory role of AA/UFAs regarding 5-LO conformation [paper I, II, 360]. 
By site directed mutagenesis studies, Ser271 was pointed out as potential phosphorylation site on 
5-LO for MK-2/3 [360]. On the other hand, ERK1/2 failed to phosphorylate 5-LO, when Ser663 
was substituted by Ala in the 5-LO sequence. HeLa cells transfected with 5-LO  Ser663Ala 
produced only about 20% of 5-LO activity in contrast to cells transfected with wt 5-LO when 
cells were treated with 60 µM AA [paper I]. Thus, the results support a strong evidence for 
Ser663 as a putative ERK phosphorylation site in 5-LO. Discussion 
  50
We failed to demonstrate in vivo phosphorylation of 5-LO after stimulation of PMNL or 
differentiated MM6 and subsequent immunoprecipitation of 5-LO [paper I]. Experimental 
settings, rapid dephosphorylation, or inefficient 
32P-labelling of cells might be the reason. 
Furthermore, only a small amount of phosphorylated 5-LO may appear in stimulated cells, 
sufficient to induce substantial LT biosynthesis. However, stimulus-dependent differences in 
5-LO product formation of the 5-LO  Ser663Ala compared to wt  5-LO suggests that 
phosphorylation by ERKs plays a role for 5-LO activation in intact cells. 
For cPLA2 it is known that both, mobilisation of intracellular Ca
2+ and phosphorylation, lead to 
activation of the enzyme [113, 270]. Our studies regarding cellular activation of 5-LO showed a 
similar pattern. HeLa cells, expressing the 5-LO Ser663Ala mutant, revealed equal LT formation 
compared to cells expressing wt 5-LO when the enzyme was activated by Ca
2+. However, the 
5-LO Ser663Ala mutant, lacking the ERK1/2 phosphorylation site, produced significantly lower 
amounts of 5-LO metabolites when an ERK-dependent stimulus such as AA was used [paper II]. 
It was shown for AA, that it causes a pronounced ERK activation in various cell types [48, 145], 
but only a moderate Ca
2+ influx [231, 353]. 
Almost all natural ligands that induce LT formation in human neutrophils, such as fMLP, PAF, 
C5a, or AA, activate ERKs [41, 95, 120] without inducing a pronounced mobilisation of Ca
2+ 
[231, 309, 363]. In this context, inhibition of ERK activation by specific inhibitors could not 
prevent 5-LO activity induced by Ca
2+ ionophore or by cell stress (mediated by phosphorylation 
of 5-LO via MK-2), whereas AA-induced LT formation correlated with ERK activity [paper I]. 
Interestingly, autoregulatory loops for AA-induced 5-LO activity may occur in cells since 
addition of exogenous 5-H(p)ETE to neutrophils stimulated ERKs, and conversion of AA by 
5-LO was required for ERK activity [48, 50]. 
ERK and p38 MAP kinase activation are equally required for activation and maintenance of 
cPLA2 activity [137]. A similar activation pathway can be supposed also for 5-LO (see figure 8). 
Using conditions where 5-LO phosphorylation is markedly promoted, we observed a gradually 
reduced enzyme activity when one or both phosphorylation sites (Ser271 and Ser663) were 
removed [paper I, II]. Moreover, blocking 5-LO kinase activation by specific inhibitors 
(SB203580 and/or U0126), we also observed effects implying that p38 and ERK pathway act in 
conjunction to stimulate 5-LO product formation [paper I, II]. Discussion 
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Figure 8: Phosphorylation of 5-LO 
Translocation of a variety of enzymes (e.g. PKC, PI  3-K, or cPLA2) to cellular membranes 
depends on their phosphorylation status [352]. There is clear evidence that also phosphorylation 
of 5-LO contributes to translocation of the enzyme. The PKC activator PMA up-regulates 
capacities for phosphorylation and translocation of 5-LO in MM6 cells and human PMNL [356]. 
Rapid nuclear translocation was also observed after activation of p38 MAPK by SA in human 
neutrophils, independent of the intra- or extracellular Ca
2+ level [353]. Moreover, mutation of 
Ser271 reduced ionophore-induced LTB4 synthesis in parallel with reduced nuclear localization 
of 5-LO [202]. Also the ERK pathway plays an essential role in 5-LO redistribution since 
inhibition of MEK1/2 blocked translocation in HL-60 cells and neutrophils [25, 193]. 
In intact cells, concentrations of 150 - 350 nM Ca
2+ are sufficient for activating 5-LO [309]. 
Incorporation of anionic phosphate into a molecule alters the netto charge of the whole molecule 
and adds a negative charge to the protein. Therefore it might be reasonable that phosphorylated 
5-LO shows a higher affinity to Ca
2+. For this reason the necessity of Ca
2+ for activation of 5-LO 
would be impaired when the enzyme is phosphorylated. However preliminary results did not 
confirm this hypothesis (unpublished data). Discussion 
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B.  Cell stress and phosphorylation alter the efficacy of nonredox-type 5-LO 
inhibitors 
LTs participate in host defense reactions and pathophysiological conditions such as immediate 
hypersensitivity and inflammation [143, 305]. In view of these properties, inhibitors of 5-LO 
have therapeutic potential in a range of diseases including inflammatory disorders, cancer, 
osteoporosis, and atherosclerosis [325, 352]. 
In search of potential orally active and specific inhibitors, nonredox-type 5-LO inhibitors came 
in the focus of anti-LT research. In several in vitro and ex vivo systems they exhibited high 
efficacy [65, 219, 321]. However, significantly higher doses were required for in vivo studies 
[321], and they failed in respect to suppression of chronic inflammatory diseases [339]. 
The results of paper III provide strong evidence that the efficacy of the nonredox-type 5-LO 
inhibitors depends on the 5-LO activation pathway. 10- to 100-fold higher concentrations are 
required for cell stress-induced 5-LO product formation, including 5-LO kinase activity, in 
contrast to ionophore-induced LT formation, initiated by elevation of intracellular Ca
2+. 
BWA4C, an iron ligand inhibitor, revealed a potent efficacy, independent of the activation 
pathway. Studies using mutant 5-LO, lacking the phosphorylation sites, underlined the 
hypothesis that phosphorylation of 5-LO strongly impairs the potency of nonredox 5-LO 
inhibitors [paper III]. Further experiments showed that inhibition of both 5-LO kinases via 
SB203580 and U0126 and subsequent stimulation of 5-LO via SA in presence of exogenous AA 
restored the potency of the classical nonredox-type 5-LO inhibitors (unpublished data). 
In general, 5-LO can be activated by two different pathways. First, by mobilisation of 
intracellular Ca
2+ and second, by p38 MAPK- and/or ERK-dependend phosphorylation of 5-LO 
which is Ca
2+ independent [352]. p38 is activated in response to cell stress and chemotactic 
factors such as LPS and ILs [144, 180]. Activation of ERKs is observed after priming cells with 
GM-CSF, PMA, fMLP or PAF which also all lead to an increased 5-LO activity [paper I]. 
Therefore, it seems reasonable that, under physiological conditions, LT formation occurs after 
activation of 5-LO kinases associated with cell stress (heat shock, osmotic or genotoxic stress), 
with the release of inflammatory cytokines (TNFα, IL-1) or chemotactic factors (C5a, PAF, 
fMLP). As a result, phosphorylation-dependent 5-LO catalysis showed an impaired sensitivity 
towards nonredox-type inhibitors which may explain the loss of effectivity of these inhibitors in 
the treatment of chronic inflammatory diseases [234, 339]. 
More detailed investigations showed that Ca
2+ is not required for efficient 5-LO inhibition. 
Treating cells with genotoxic stress via SA 3 min before stimulation with ionophore showed also 
a loss of potency of the nonredox inihibitor ZM230487 [paper III]. Oxidative stress and Discussion 
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increased peroxide levels lead to an impaired efficacy of nonredox-type 5-LO inhibitors, too 
[359]. However, NaCl or SA did not increase the cellular peroxide level, and addition of 
reducing agents such as N-acetylcysteine (NAC) to cells stimulated by cell stress did not restore 
the potency of ZM230487 [paper III], implying a mechanism independent of the peroxide level. 
Transfection experiments support the hypothesis that in intact cells phosphorylation of 5-LO 
alters the susceptibility to nonredox-type 5-LO inhibitors. Mutation of 5-LO resulted in a 
different sensitivity towards ZM230487 or L739.010 as compared to wt 5-LO when the enzyme 
was activated via p38 MAPK/ERK-mediated pathways. In detail, the non-phosphorylatable 
mutant 5-LO (Ser271Ala/Ser663Ala) activity was significantly more suppressed by 
ZM230487/L-739.010 than the phosphorylatable wt 5-LO [paper III]. However, in vitro studies 
using purified enzyme revealed that phosphate incorporation alone is not the sole reason for this 
effect [paper III], implicating that cellular integrity or cellular components are required. In 
previous in vitro studies it was found that deletion of the phosphorylation sites did not alter the 
enzymatic activity of 5-LO  in vitro [paper I, 360]. However, deletion of phosphorylation sites 
caused significant loss of 5-LO product formation in intact HeLa cells stimulated by MAPK 
pathways [paper I, II, 360], supporting the finding that phosphorylation of 5-LO affects catalytic 
properties of the enzyme in intact cells only. Indeed, 5-LO interacts with several proteins [265, 
267] and these interactions might be affected by the phosphorylation status of 5-LO. 
Initially, for nonredox-type 5-LO inhibitors such as ZM230487 and L-739.010 a competitive 
mode of action was assumed by binding to a fatty acid substrate binding site at the active site. 
However, only under non-reducing conditions this type of inhibitors revealed such competitive 
properties [359]. Instead, under reducing conditions the compounds propably bind to a 
regulatory domain distal of the catalytic site, presumably a fatty acid hydroperoxide binding site. 
Since phosphorylation of 5-LO is promoted by UFA [paper I, II] it is reasonable that 
incorporation of phosphate in close proximity to such a regulatory fatty acid binding site enables 
the enzyme to interfere with a cellular protein as outlined before. Such protein/protein 
interactions could interefere with the affinity of ZM230487/L739.010 to the potential binding 
site by promoting the binding of LOOH to 5-LO which in turn compete with the nonredox-type 
5-LO inhibitors at this regulatory site. This model would be compatible with the evidence that 
the efficacy of BWA4C does not differ between the phosphorylated and non-phosphorylated 
5-LO. 
So far, potential nonredox-type 5-LO inhibitors were tested by functional test-systems using 
leukocytes stimulated by the unphysiological stimulus Ca
2+ ionophore [219, 321, 357]. Although 
Ca
2+ ionophore causes not only a rapid mobilisation of Ca
2+ but also activates MAP kinases Discussion 
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[paper I, III], kinetic studies revealed that Ca
2+ is the predominant mediator of 5-LO activity 
under these conditions [paper III]. 
Based on these facts, it is not astonishing that ZM230487 or L-739.010 showed high activity in 
several ex vivo and in vitro test-systems, but failed in clinical studies. Thus, the development of 
new nonredox-type 5-LO inhibitors should lead to compounds which show a high inhibition 
efficacy, independent of the 5-LO activation pathway. For this reason, the use of 
phosphorylation-based test-systems as described should be taken into account. 
C.  CJ-13,610 as novel approach for potent 5-LO inhibition 
The initial idea for the development of nonredox-type 5-LO inhibitors was to design molecules 
which compete with AA at the catalytic binding site of 5-LO [220]. In fact, their precise mode of 
action has not been elucidated so far. Under reducing conditions, ZM230487 or L-739.010 
showed an uncompetitive mode of inhibition. However, elevated peroxide levels changed the 
mode of action to a competitive manner [359]. Moreover, detailed studies revealed, that LOOH 
compete with the inhibitors at a potential regulatory binding site of 5-LO, since oxidative stress 
and increased peroxide levels lead to impaired efficacy of ZM230487 or L-739.010 [359]. Also, 
the new nonredox-type inhibitor CJ-13,610 requires a low peroxide tone for potential 5-LO 
inhibition. Again, addition of LOOH impaired the efficacy of the compound [paper IV]. 
Experimental data support that 5-LO has two fatty acid binding sites, a regulatory LOOH 
binding site and an catalytic AA binding cleft at the active site [45, 298]. In contrast to 
ZM230487, the potency of CJ-13,610 is impaired by AA also under reducing conditions, 
implying that the compound interferes not only with a regulatory site but also with the catalytic 
AA binding site. This could be shown by several experimental setups: In intact PMNL, addition 
of exogenous AA clearly impaired the potency of CJ-13,610. Also in broken cell preparations, 
supplemented with DTT, elevated levels of AA significantly decreased the efficacy of the 
compound. Finally, by using purified enzyme in the presence of GPx and GSH, CJ-13,610 
strongly suppressed 5-LO activity at 4 µM AA but failed at 40 µM AA [paper IV]. These data 
revealed a completely different inhibitory profile for ZM230487 or L-739.010 whose high 
affinity to 5-LO was not affected by AA under reducing conditions [359]. Intriguingly, LOOH is 
superior to AA in competing with CJ-13,610, since addition of 3 µM HpODE results in a shift of 
the IC50 value independent of the present amount of AA [paper IV]. For this reason it should be 
considered that CJ-13,610 may have a reduced potency in chronic inflammation which are 
associated with high LOOH levels and free AA [51, 62]. In fact, the classical nonredox-type 
5-LO inhibitors failed in the treatment of chronic inflammatory diseases [234, 339]. Discussion 
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In HeLa cells, transiently transfected with 5-LO, the IC50 of CJ-13,610 was about 10-fold higher 
than in PMNL [paper IV]. Differences in LOOH and Ca
2+ levels, expression levels of GPx or the 
absence of FLAP may be the cause of the impaired potency of CJ-13,610 in HeLa cells. 
However, cotransfection of 5-LO and FLAP had no influence regarding inhibition of LT 
formation by CJ-13,610 [paper IV]. These findings were supported by the fact that CJ-13,610 
does not inhibit the translocation of 5-LO, which may be FLAP dependent [262]. Therefore, the 
reasons for the difference in the efficacy of CJ-13,610 in HeLa cells and PMNL remain to be 
elucidated. 
In response to external stimuli, cellular LT formation occurs after redistribution of cytosolic 
5-LO to the nuclear envelope or cellular membranes [262]. This is mediated by elevation of 
intracellular Ca
2+ and/or phosphorylation of 5-LO by MK-2/3 and ERK1/2, respectively [30, 
paper I, II]. Inhibition of phosphorylation-mediated activation of 5-LO required 10- to 100-fold 
higher concentrations of ZM230487 and L-739.010 than for Ca
2+-mediated 5-LO activity 
[paper III]. In contrast, the efficacy of CJ-13,610 is independent of the 5-LO activation pathway 
in PMNL. Also, CJ-13,610 exhibits no pronounced differences in the potencies towards 
phosphorylatable wt- or non-phosphorylatable mutant 5-LO in HeLa cells [paper IV]. It is 
noteworthy that several diseases, which are associated with an increased level of 5-LO 
metabolites, display also an increased cellular phosphorylation status. Inflammatory reactions, 
cancer, or atherosclerosis are some examples [127, 163]. 
Based on the fact that the potency of CJ-13,610 does not depend on the activation pathway of 
5-LO, treatment of LT-associated diseases with CJ-13,610 might be beneficial. Although the 
therapeutic potential of CJ-13,610 could be limited under conditions of elevated peroxide levels, 
the novel compound exhibits advantages over former members of this class of inhibitors, which 
failed in clinical trials. 
D.  Boswellic acids activate proinflammatory functions in PMNL 
Frankincense extracts and BAs, biologically active pentacyclic triterpenes from frankincense, 
block LT biosynthesis and exert anti-inflammatory effects [295, 357]. However, low 
concentrations of BAs [293] and 3-oxo-tirucallic acid [26] enhance LT formation. In this study 
we could demonstrate that BAs, namely 11-keto-BAs, stimulate activation of ERK2 as well as 
p38 MAPK. Also, mobilisation of intracellular Ca
2+ by (A)KBAs was detected [paper V]. 
Consequently, BAs were able to induce the production of ROS, liberation of AA and, finally, 
induction of LT formation in PMNL and differentiated HL-60 cells [paper VI]. Notably, only 
11-keto-BAs contributed to the later effects. In detail, the presence of the 11-keto group is Discussion 
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essential for these effects since β-BAs, lacking the keto group, failed in this respect. In parallel, 
the 11-keto group is necessary for suppression of the synthesis of DNA, RNA and protein in 
HL-60 cells [314]. It is remarkable that the 11-keto group was essential for inhibition of 5-LO 
activity [298], but on the other hand necessary for induction of LT formation [paper VI]. 
Isoforms of PKC are associated with the activation of ERK1/2 as well as p38 MAPK in PMNL 
[197]. However, specific inhibitors of PKC only partially inhibited (A)KBA-induced MAPK 
activation [paper V], which was also shown for fMLP-induced MAPK activation [174]. Inhibitor 
studies revealed that PI 3-K, which is partially involved in MAPK activation [174], plays a role 
in keto-BA-induced ERK2 activity [paper V]. In addition, treating of PMNL with (A)KBA 
resulted in a prominent increase of ROS which was abolished by the specific NADPH oxidase 
inhibitor DPI [paper VI]. Activation of NADPH oxidase requires Ca
2+ and phosphorylation by 
certain kinases [79]. Pharmacological targeting of the proximal signalling pathways revealed that 
(A)KBA-induced ROS formation seemingly depends on PI 3-K and ERK2 activation as well as 
on Ca
2+ but not on p38 MAPK activation [paper VI]. Similarly, fMLP-induced activation of 
NADPH oxidase was suppressed by inhibition of ERK2 [79] and PI  3-K [81] but not by 
inhibition of p38 MAPK [79]. 
Certain signalling pathways, including Ca
2+ mobilisation and phosphorylation via MAPK, can 
lead to cPLA2 activation and AA release [113]. 11-keto-BAs, but not β-BA and A-β-BA, 
induced the release of considerable amounts of AA, with a similar efficacy as fMLP. Like 
ligands acting via GPCR, AKBA-induced AA liberation also depends on Ca
2+ and ERK2 activity 
[paper VI]. Interestingly, AA can induce apoptosis of macrophages [230] and therefore the 
apoptotic effect of AKBA, observed in granulocytic HL60 cells [146], may be explained by 
increased levels of free cellular AA. 
BAs were reported as specific, nonredox-type inhibitors of 5-LO [294]. It is obvious that also 
additional factors are involved in suppression of cellular 5-LO activity since there is a difference 
of the IC50 values in intact cells (2-5 µM) and homogenates (15-50 µM) [357, 359]. Rapid and 
prolonged levels of Ca
2+ and ROS cause suicide inactivation of 5-LO activity [103]. For this 
reason, preincubation of intact cells with (A)KBA may result in reduced 5-LO activity after 
suicide inactivation induced by Ca
2+ and/or ROS. Paradoxically we observed that (A)KBA 
stimulated LT formation in PMNL when coincubated with AA [paper VI]. Also other ingredients 
of  B. serrata extracts such as 3-oxo-tirucallic acid enhanced 5-LO product formation in 
ionophore-challenged PMNL [26]. As reported earlier, 5-LO activity depends on Ca
2+ and 
activation of MAPK [352, paper I, II]. Surprisingly, AKBA-induced 5-LO activity was neither 
sensitive to inhibition of MAPK via SB203580 or U0126 nor to depletion of Ca
2+ [paper VI]. Discussion 
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This implicates that so far unknown 5-LO stimulatory factors or pathways may be activated by 
11-keto-BAs. 
Remarkably, the effects of (A)KBAs are similar to other chemotactic factors. Stimulation of 
neutrophils with PAF or fMLP caused a rapid and transient activation of MAPK and increased 
[Ca
2+]i [95, 232, 235]. Also characteristics of the fMLP signal such as time course, partial 
dependence on Ca
2+ and PKC plus the involvement of PI 3-K, are conform with those induced 
by 11-keto-BAs [237]. Since G-proteins link the fMLP-receptor interaction to functional cellular 
responses [182], the BA-mediated signal could also be mediated by a GPCR and the 11-keto 
group might be essential for binding to this conceivable receptor. This is supported also by the 
fact that PTx suppressed AKBA induced Ca
2+ mobilisation and MAPK activation. However, 
such a receptor was not identified so far. 
E.  Inhibitors of actin polymerization, effects on LT biosynthesis 
Neutrophils provide the body´s first line of defense against bacterial infection, and are stimulated 
to move towards these sites by chemoattractans. Chemotaxis requires actin polymerisation 
followed by the formation of new filaments. Several reports were described that inhibition of 
actin polymerization potentiates the release of agonist-induced formation of AA metabolites 
[128, 254, 300], but so far the mechanisms involved were not elucidated. In this project we could 
show that inhibitiors of actin polymerization led to an elevation of [Ca
2+]i associated with an 
increase of free AA and 5-LO translocation. These events can increase LT formation [paper VII]. 
As outlined before, for LT biosynthesis several conditions have to be fulfilled including 
sufficient supply of AA by cPLA2, activation of 5-LO and association of the enzyme with the NE 
[352]. Agonists, which induce LT formation, are also able to increase [Ca
2+]i. cPLA2 requires 
about 350-400 nM Ca
2+ for activation whereas 5-LO shows a linear dependence on Ca
2+ and 
saturates at this concentration [309]. Treating PMNL with the Ca
2+ ionophore caused the release 
of about 800 nM [Ca
2+]i resulting in a prominent formation of LTs. However TG, which caused 
moderate increase of [Ca
2+]i (230 nM), led only to low amounts of 5-LO products [paper VII], 
implying that the extent of 5-LO products correlates with the concentration of [Ca
2+]i. We 
observed that LB alone, which disrupts the microfilament organisation, caused an elevation of 
cellular Ca
2+ levels [paper VII, 347]. Since TG plus LB gave additive effects regarding [Ca
2+]i 
(460 nM), it is conceivable that the TG-induced LT formation was upregulated by coaddition of 
LB [paper VII]. Although addition of LB on top of ionophore treatment resulted in additional 
Ca
2+ mobilisation, there was neither an increase in liberation of AA nor of 5-LO activity. This is Discussion 
  58
not surprising since ionophore alone generated Ca
2+ levels, which are high enough for maximal 
cPLA2 activation. 
Regulation of cPLA2 and 5-LO via phosphorylation of serine residues is another aspect which 
should be considered [paper I. paper II, 113, 355], particularly when the Ca
2+ level is low [270, 
353]. Addition of LB caused rapid ERK2 and p38 MAPK activation but was much less effective 
compared to fMLP or ionophore [paper VII]. Since LB induced a prominent Ca
2+ influx, we 
conclude that phosphorylation of cPLA2 and/or 5-LO plays a minor role in the upregulating 
effect of LB. Supplementation of exogenous AA as substrate did not lead to an increased LT 
formation by LB [paper VII], confirming the hypothesis that LB elevates 5-LO product 
formation mainly by affecting cPLA2. Even though LB promoted 5-LO translocation, activation 
of cPLA2 seems to be the key step for substantial LT formation. 
A variety of chemotactic agents, such as fMLP, PAF and C5a, not only activate the AA pathway 
but also induce actin polymerization via binding to GPCR [379]. It is of interest that cPLA2 as 
well as 5-LO bind to certain proteins which are linked to the cytoskeleton. Vimentin, a 
component of cell intermediate filaments, interacts with the C2-domain of cPLA2 [233] and also 
5-LO was shown to bind to cytoskeletal proteins including α-actinin, actin and CLP [192, 265, 
267]. The effects of actin polymerization on liberation of AA and LT formation, respectively, are 
discussed in a controversial manner. Several reports described that depolymerization of F-actin 
by CD or LB has an attenuating effect in stimulus-induced release of [Ca
2+]i and of AA release, 
in various cell types [67, 283, 292]. However, in accordance with our results, cytochalasin 
increased the [Ca
2+]i in human PMNL after stimulation with fMLP [243]. Similarly, inhibition of 
cytoskeletal rearrangement by botulinum C2 toxin amplifies ligand-evoked lipid mediator 
generation in human neutrophils [119]. Moreover, disruption of F-actin in human basophils also 
promotes events such as histamine release, LTC4 release, and the intracellular Ca
2+ signal [347]. 
In conclusion, the effect of actin polymerization on the AA pathway apparently depends on the 
cell type and the nature of the stimulus, but appears to be based on the Ca
2+ level of the cell. 
Our results implicate that the effects of LB are associated with activation of PLC isoenzymes and 
the Src family kinases. The PLC inhibitor U73122 [24] significantly suppressed the release of 
intracellular stored Ca
2+, evoked by LB [paper VII], whereas the structurally related negative 
control U73433 failed. It was reported that Src family kinases are capable of activating PLCγ1 
and -2 isoforms in response to different chemoattractans [170, 260, 268]. We could demonstrate 
that the specific Src kinase inhibitors PP2 [135, 301] and SU6656 [23, 31] selectively blocked 
the effects of LB on Ca
2+ mobilisation, AA release, 5-LO translocation, and 5-LO product 
formation. In contrast, the inactive compound PP3, used as a negative control for PP2, showed Discussion 
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no effect [paper VII]. Fgr, Hck, and Lyn are tyrosine protein kinases expressed in neutrophils 
[170]. Mice, deficient in Src family kinases Hck and Fgr, revealed defective adhesion-dependent 
neutrophil functions [201]. Additionally, there is evidence that disassembly of F-actin leads to an 
activation of Src kinases. For example, actin depolymerization, induced by LB, causes activation 
of phosphotyrosine kinases [93]. Moreover, CD induced increases in the phosphorylation levels 
of c-Src [302]. 
In conclusion, cytoskeletal dynamics and activation of Src kinases have an influence in AA 
metabolism. Our studies support the hypothesis that alteration of [Ca
2+]i via Src kinase signalling 
and accordingly liberation of AA via cPLA2 is followed by the metabolism of AA by 5-LO, 
resulting in formation of proinflammatory LTs. The F-actin cytoskeleton is a fundamental 
component of all eukaryotic cells. It provides force and stability and plays an integral role in a 
diverse array of cellular processes including migration and adhesion of PMNL to sites of 
inflammation. Chemoattractant-induced actin polymerization may be regarded as a regulatory 
process, which controls Ca
2+-dependent functions. Metabolism of AA is one example. Summary 
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VII.  Summary 
5-LO is the key enzyme in the biosynthesis of LTs and is predominantly expressed in myeloid 
cells, but was also found in dendritic cells. LTs are bioactive lipid mediators and play a 
fundamental role in a variety of inflammatory diseases such as asthma, psoriasis, arthritis or 
allergic rhinitis. Moreover, they are also involved in cancer cell proliferation, bone remodelling 
associated with osteoarthritis, and atherosclerosis. Based on these facts it is of considerable 
interest to develop drugs which target 5-LO. However, today no 5-LO inhibitor is available on 
the market. The only 5-LO inhibitor zileuton (Zyflo
®, Abbott), which was on the US market, has 
been withdrawn from the market in June 2003. In order to identify an inhibitor of 5-LO for 
clinical application, such a compound should not only exhibit powerful efficacy in in vitro assays 
but also in ex vivo and  in vivo models. For this reason the development of potential 5-LO 
inhibitors requires the knowledge about the detailed activation pathway of the 5-LO enzyme. 
In resting cells 5-LO resides in the cytosol or in the soluble compartment of the nucleus. Upon 
stimulation, 5-LO translocates to the nuclear membrane and colocalizes with cPLA2, FLAP and 
LTC4S. At the nuclear membrane AA is released by cPLA2 and presented by FLAP to 5-LO for 
LT formation. 
The nonphysiological stimulus Ca
2+  ionophore causes a rapid and prominent increase in 
intracellular Ca
2+ which results in an intensive activation of 5-LO and consequently in 
substantial LT formation. Natural ligands such as fMLP, PAF, C5a or zymosan lead to a 
moderate Ca
2+ mobilisation and thus, 5-LO activity is rather low. However, priming of 
leukocytes with cytokines, phorbol esters, LPS, or growth factors and subsequent treatment with 
natural ligands results in a more prominent increase in 5-LO product formation. In general, this 
elevated level of LTs is considered to be due to an increased liberation of AA by cPLA2 resulting 
in higher substrate availability. 
Ca
2+, ATP, PC and LOOH are factors, which are capable of modulating the in vitro activity of 
5-LO. Much less is known about the factors that dominate the regulation of 5-LO in intact cells. 
Recent data revealed that p38-dependent MK-2/3 phosphorylates 5-LO and plays a significant 
role in the Ca
2+-independent cellular activation of 5-LO. Osmotic stress, heat shock, or chemical 
stress induces 5-LO product formation in parallel with p38 MAPK activation in PMNL. 
Additionally, inhibitor studies gave evidence for the assumption that also the MEK1/2 pathway 
is involved in the in vivo activation of 5-LO. 
Indeed, using in-gel kinase- and in vitro kinase-assays, we could show, that 5-LO is a substrate 
for ERK1/2 [paper I]. Addition of polyunsaturated fatty acids such as AA or oleic acid Summary 
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potentiated the rate of ERK2-phosphorylated 5-LO [paper I] but also of MK-2-phosphorylated 
5-LO [paper II]. These effects seem to be specific for MK-2 and ERK2, since promotion of 
protein phosphorylation was restricted to 5-LO as substrate. Unfortunately, we failed to 
convincingly assess in vivo phosphorylation of 5-LO immunoprecipitated from stimulated 
32Pi-labelled PMNL, MM6 or HL-60 cells. The experimental setup or rapid dephosphorylation 
might be the reason [paper I]. Studies with specific kinase inhibitors and mutated 5-LO enzyme 
prove that both, phosphorylation by MK-2 at Ser271 and by ERK1/2 at Ser663, contribute to the 
cellular activation of 5-LO in response to natural stimuli that do not prominently alter the 
intracellular Ca
2+-level [paper  I,  II]. In contrast, using Ca
2+ ionophores,  both, 
non-phosphorylatable and phosphorylatable 5-LO showed comparable enzyme activity. 
Together, phosphorylation of 5-LO by p38 MAPK-dependent MK-2/3 and ERKs is an 
alternative activation pathway of 5-LO. Moreover, these findings provide evidence that the 
utilization of assays, in which physiological stimuli and priming agents are operative, are more 
adequate for mimicking the physiological conditions of 5-LO activation in leukocytes. 
Nonredox-type 5-LO inhibitors were originally designed to compete with AA at the catalytic site 
of 5-LO. In fact, ZM230487 and L-739.010 potently suppress LT biosynthesis in several in vitro 
and ex vivo test systems. However, they failed in clinical trials of chronic inflammatory diseases. 
In this study we could demonstrate that inhibition of 5-LO product formation by nonredox-type 
5-LO inhibitors in human PMNL depends on the activation pathway of 5-LO [paper III]. Thus, 
compared with 5-LO product formation induced by Ca
2+ ionophore, cell stress-induced 5-LO 
activity involving 5-LO kinase pathways required about 10- to 100-fold higher concentrations of 
ZM230487 and L-739.010 for comparable 5-LO inhibition. No such differences were observed 
for the iron ligand inhibitor BWA4C [paper III]. Further experiments revealed that Ca
2+ is not 
required for sufficient 5-LO inhibition and that simultaneous stimulation with Ca
2+ ionophore 
and cell stress did not restore the potent 5-LO inhibition. Moreover, studies with transiently 
transfected HeLa cells showed that the non-phosphorylatable 5-LO enzyme (5-LO 
Ser271Ala/Ser663Ala) is significantly more sensitive towards nonredox-type inhibitors than 
phosphorylatable wt 5-LO, when cells are stimulated under conditions, where 5-LO kinases are 
active [paper III]. In conclusion, our data indicate, that activation of 5-LO via phosphorylation 
strongly decreases the potency of nonredox-type 5-LO inhibitors as compared to conditions 
where 5-LO is stimulated by Ca
2+. However, incorporation of phosphate alone is not sufficient to 
protect 5-LO against these inhibitors, but requires cellular integrity. Based on these data, the 
application of new test systems should be taken into account for the development of novel 5-LO 
inhibitors which consider the activation pathway of 5-LO. Summary 
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In the course of this study we examined the molecular profile of the novel nonredox-type 5-LO 
inhibitor CJ-13,610 in various in vitro test systems. In intact human PMNL, challenged with 
Ca
2+ ionophore, CJ-13,610 potently suppressed 5-LO product formation with an IC50 = 0.07 µM. 
Supplementation of exogenous AA impaired the efficacy of CJ-13,610, implying a competitive 
mode of action [paper IV]. Previous data revealed that LOOH compete with the classical 
nonredox-type 5-LO inhibitors ZM230487 and L-739.010 at a putative regulatory site, and for 
this reason, the compounds were much less effeective at elevated peroxide levels or in broken 
cell systems. In analogy to ZM230487 and L-739.010, also CJ-13,610 failed to inhibit 5-LO in 
cell-free systems under nonreducing conditions up to 30 µM. However, inclusion of GPx activity 
restored the efficacy of CJ-13,610 (IC50=0.3 µM) [paper IV]. In contrast to former members of 
this type of inhibitors, the potency of CJ-13,610 does not depend on the cell stimulus or the 
activation pathway of 5-LO. Thus, 5-LO product formation in PMNL induced by 
phosphorylation events was equally suppressed by CJ-13,610 as compared to Ca
2+-mediated 
5-LO activation. In transfected HeLa cells, CJ-13,610 only slightly discriminated between 
phosphorylatable wt 5-LO and a mutant 5-LO that lacks phosphorylation sites [paper IV]. In 
summary, CJ-13,610 may posses considerable potential as a potent orally active nonredox-type 
5-LO inhibitor that lacks certain disadvantages of former members of this class of 5-LO 
inhibitors. However, reduced efficacy should be taken into account in the treatment of diseases 
where elevated peroxide levels occur in the cell. 
Extracts of Boswellia serrata gum resins have been traditionally used as a folk medicine to cure 
inflammatory and arthritic diseases. Furthermore, it was found that BAs, the active principles of 
these extracts, potently suppress the formation of proinflammatory LTs in intact cells by 
inhibiting 5-LO. However, significantly higher concentrations of BAs were required for equal 
inhibition of 5-LO in broken cells systems. Therefore, additional factors seem to be responsible 
for the potent inhibition of LT formation in intact cells. 
11-keto-BAs activate p38 MAPK, ERK1/2 and stimulate Ca
2+ mobilisation in human PMNL. 
Moreover, 11-keto-BAs induce the formation of ROS, release of AA, and subsequently LT 
biosynthesis [paper V, VI]. Inhibitor studies revealed that ROS formation is Ca
2+-dependent and 
is mediated by NADPH oxidase involving PI 3-K and MAPK activation [paper V, VI]. Also the 
release of AA depends on Ca
2+ and ERK1/2 [paper VI]. Studies with different haematopoietic 
cells revealed that the activation of signal cascades by BAs depends on the cell type. The 
activation pattern of leukocytes by 11-keto-BAs is quite similar to chemoattractans such as 
fMLP or PAF, however, a specific receptor for BAs, mediating these signals, has not been 
identified so far. Apparently keto-BAs at relatively high concentrations cause functional Summary 
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leukocyte responses, which are pro-inflammatory. The 5-LO activity-reducing effects in intact 
cells of BAs could be explained by pronounced elevated Ca
2+ and ROS levels which may cause a 
suicide inactivation of 5-LO. 
Finally, we investigated the effects of inhibitors of actin polymerization on 5-LO product 
formation upon stimulation with Ca
2+ mobilizing agents [paper VII]. We found that substances 
that block actin polymerization such as latrunculin B (LB) and cytochalasin D (CD) enhance the 
release of AA as well as nuclear translocation of 5-LO and LT formation in isolated human 
PMNL challenged with TG. These effects were not observed when Ca
2+ ionophore was used as 
stimulus. Investigation of the stimulatory mechanisms revealed that LB elicits Ca
2+ mobilisation 
and potentiates agonist-induced elevation of intracellular Ca
2+, regardless of the nature of the 
agonist. LB caused a rapid but only moderate activation of p38 MAPK and ERKs. Selective Src 
family kinase inhibitors such as PP2 and SU6656 blocked LB- or CD-mediated 
Ca
2+  mobilisation and suppressed the upregulatory effects on AA release and 5-LO product 
synthesis [paper VII]. Therefore, inhibitors of actin polymerization cause activation of Src 
family kinases that mediate enhancement of intracellular Ca
2+ levels, thereby facilitating the 
release of AA and LT formation in response to certain agonists. 
In conclusion, for the suitable development of novel agents directed against a certain target, 
knowledge about the cellular biology, in particular the regulation of the activity, is necessary. As 
exemplified in this study, phosphorylation of 5-LO is an aspect which influences the regulation 
of 5-LO activity and has a fundamental impact on enzyme inhibition. Further studies about the 
mode of action of inhibitors as well as the role of the cytoskeleton in regulation of 5-LO activity 
are essential for the development of new potential 5-LO inhibitor drugs. Zusammenfassung 
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VIII.  Zusammenfassung 
Leukotriene (LT) sind bioaktive Lipidmediatoren, die in einer Vielzahl von 
Entzündungskrankheiten wie z.B. Asthma, Psoriasis, Arthritis oder allergische Rhinitis involviert 
sind. Des weiteren spielen LT in der Pathogenese von Erkrankungen wie Krebs, Osteoarthritis 
oder Atherosklerose eine Rolle. Die 5-Lipoxygenase (5-LO) ist das Enzym, das für die Bildung 
von LTA4 aus Arachidonsäure (AA) verantwortlich ist. Aufgrund der physiologischen 
Eigenschaften der LT, ist die Entwicklung von potentiellen Arzneistoffen, welche die 5-LO als 
Zielstruktur besitzen, von erheblichem Interesse. Bis heute jedoch ist kein 5-LO Hemmer auf 
dem europäischen Arzneimittelmarkt erhältlich. Der Wirkstoff Zileuton (Zyflo
, Abbott) wurde 
im Juni 2003 in den USA vom Markt genommen. Für eine erfolgreiche Behandlung der bereits 
erwähnten Krankheiten muss ein designierter Wirkstoff nicht nur in in vitro Untersuchungen 
sondern auch in ex vivo und in vivo Modellen eine ausgeprägte Wirkung zeigen. Aus diesem 
Grund erfordert die erfolgreiche Entwicklung eines potentiellen 5-LO Inhibitors ein genaues 
Wissen über die Aktivierungsvorgänge des Enzyms in der Zelle. 
In Zellen befindet sich die 5-LO im Zytosol oder im löslichen Kompartement des Zellkerns. 
Nach Stimulierung wandert das Enzym zur Kernmembran und kolokalisiert mit zytosolischen 
Phospholipase A2 (cPLA2), dem 5-LO-aktivierenden-Protein (FLAP) und der LTC4-Synthase. 
An der Kernmembran wird die AA mittels der cPLA2 freigesetzt, durch das Helferprotein FLAP 
5-LO präsentiert und anschließend zu LT metabolisiert. 
Der unphysiologische Stimulus Ca
2+-Ionophor verursacht einen schnellen und deutlichen 
Anstieg des intrazellulären Ca
2+. Dies führt zur Aktivierung der 5-LO und folglich zur Bildung 
von LT. Natürliche Stimuli, wie N-Formyl-methionyl-leucyl-phenylalanin (fMLP), Plättchen 
aktivierender Faktor (PAF), C5a oder Zymosan verursachen eher einen moderaten Ca
2+ Einstrom 
und somit eine geringere 5-LO-Aktivierung. Jedoch ergibt die Vorbehandlung von Zellen mit 
Zytokinen, Phorbolestern, Lipopolysacchariden oder Wachstumsfaktoren und anschließender 
Stimulation mit natürlichen Liganden einen prominenten Anstieg der 5-LO Aktivität. Dies ist 
vorwiegend auf die erhöhte Freisetzung von AA zurückzuführen. Ca
2+, ATP, Phosphatidylcholin 
und Lipidhydroperoxide sind Faktoren, welche die in vitro Aktivität der 5-LO beeinflussen. 
Neueste Daten zeigen, dass die p38-abhängige MK-2/3 5-LO phosphorylieren kann und dies eine 
entscheidende Rolle bei der Ca
2+-unabhängigen zellulären 5-LO-Aktivierung spielt. Osmotischer 
Stress, Hitzeschock oder chemischer Stress verursachen 5-LO-Produktbildung, die mit der 
Aktivierung von p38 MAPK einhergeht. Inhibitorstudien weisen darauf hin, dass der 
MEK1/2-Signalweg ebenfalls in vivo an der 5-LO Aktivierung beteiligt ist. Zusammenfassung 
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Tatsächlich konnten wir mittels „In-gel kinase“ und „In vitro kinase“ Untersuchungen zeigen, 
dass die 5-LO ein Substrat für die Extracellular signal-regulated kinase (ERK) und MK-2/3 
darstellt. Der Zusatz von mehrfach ungesättigten Fettsäuren (UFA), wie AA oder Ölsäure, 
verstärkte den Phosphorylierungsgrad der 5-LO sowohl durch ERK1/2 [Paper  I,  II] als auch 
durch MK-2/3 [Paper II]. Diese verstärkende Wirkung von UFAs auf die Phosphorylierung der 
5-LO ist spezifisch für ERK1/2 und MK-2/3, und wurde für andere Kinasen nicht beobachtet. 
Eine  in vivo-Phosphorylierung der 5-LO, nach 5-LO Immunopräzipitation aus stimulierten 
PMNL, MM6 oder HL-60 Zellen, konnte jedoch nicht gezeigt werden. Die experimentellen 
Bedingungen oder eine zu schnelle Dephosphorylierung könnten hierfür die Ursachen sein 
[Paper I]. Ser271 (MK-2/3) und Ser663 (ERK1/2) wurden als Phosphorylierungsstellen der 5-LO 
identifiziert [Paper I, II]. Die genannten Kinasen sind demnach auch für die 5-LO Aktivierung 
durch natürliche Stimuli verantwortlich, die den zellulären Ca
2+-Spiegel kaum beeinflussen. 
Durch Austausch beider Serinreste (271/663) der 5-LO durch Alanin konnte gezeigt werden, 
dass die katalytische Aktivität des Enzyms nach Ca
2+-Stimulation nicht beeinflusst wird. Bei der 
Aktivierung durch Phosphorylierung zeigte die Doppelmutante jedoch eindeutig weniger 
Aktivität als das Wildtyp-Enzym. Wir können daraus schließen, dass Phosphorylierung der 5-LO 
durch ERK1/2 und/oder MK-2/3 einen alternativen Aktivierungsmechanismus neben Ca
2+ 
darstellt. 
Ursprünglich wurden Nonredox-5-LO-Inhibitoren als kompetetive Wirkstoffe entwickelt, die mit 
AA um die Bindung an die katalytische Domäne der 5-LO konkurrieren. Vertreter dieser 
Inhibitoren, wie ZM230487 und L-739,010, zeigen eine potente Hemmung der LT-Biosynthese 
in verschiedenen Testsystemen. Sie scheiterten jedoch in klinischen Studien. In dieser Arbeit 
konnten wir zeigen, dass die Wirksamkeit dieser Inhibitoren vom Aktivierungsweg der 5-LO 
abhängig ist [Paper  III]. Verglichen mit 5-LO Aktivität, die durch den unphysiologischen 
Stimulus Ca
2+-Ionophor induziert wird, erfordert die Hemmung Zellstress-induzierter Aktivität 
eine 10- bis 100-fach höhere Konzentrationen der Nonredox-5-LO-Inhibitoren. Für den 
Eisenliganden BWA4C konnte dies nicht gezeigt werden [Paper III]. Studien mit transfizierten 
HeLA-Zellen unterstreichen diese Ergebnisse. Die nicht-phosphorylierbare 5-LO Mutante 
(Ser271Ala/Ser663Ala) war wesentlich sensitiver als der Wildtyp, wenn das Enzym durch 5-LO 
Kinasen aktiviert wurde [Paper III]. Somit zeigen diese Ergebnisse, dass, im Gegensatz zu Ca
2+, 
die 5-LO Aktivierung mittels Phosphorylierung die Wirksamkeit der Nonredox-Inhibitoren 
deutlich verringert. Der Einbau von Phosphatresten in das Enzym ist jedoch nicht allein 
verantwortlich für diesen Wirkungsverlust. Somit sollten bei der Entwicklung neuer 5-LO Zusammenfassung 
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Inhibitoren u.a. Testbedingungen gewählt werden, in denen die 5-LO Aktivität durch 
Phosphorylierung induziert wird. 
Desweiteren wurde das pharmakologische Profil des neuen 5-LO Inhibitors CJ-13,610 mittels 
verschiedener in vitro-Testsysteme charakterisiert. In intakten PMNL, die durch Ca
2+-Ionophor 
stimuliert wurden, hemmte die Substanz die 5-LO Produktbildung mit einem IC50-Wert von 
70  nM. Wurde jedoch AA exogen hinzugefügt, verminderte sich die Wirkung und die 
erforderliche Konzentration des Inhibitors stieg an. Dies deutet auf eine kompetitive Wirkweise 
hin [Paper IV]. Die klassischen Nonredox-Inhibitoren ZM230487 und L-739,010 konkurrieren 
mit Fettsäurehydroperoxiden an einer möglichen regulatorischen Domäne des 5-LO Enzyms. 
Aus diesem Grund versagen diese Substanzen unter Bedingungen, in denen erhöhte 
Peroxidspiegel in der Zelle vorliegen. In Analogie zu ZM230487 und L-739,010 bleibt ebenfalls 
eine Hemmung der 5-LO Aktivität durch CJ-13,610 bei erhöhten Peroxidspiegeln ebenfalls aus 
[Paper  IV]. Die Senkung des Peroxidspiegels durch Erneuerung der 
Glutathionperoxidaseaktivität stellt die Wirkung von CJ-13,610 in zellfreien Systemen 
(IC50=0,3µM) wieder her. Im Gegensatz zu den bekannten Nonredox-Inhibitoren hängt die 
Wirkung von CJ-13,610 nicht vom Aktivierungsweg der 5-LO ab. Die LT-Biosynthese wird 
gleich stark unterdrückt, unabhängig davon, ob das Enzym durch Ca
2+ oder durch 
Phosphorylierung aktiviert wird. Auch in transfizierten HeLa-Zellen zeigt sich kein Unterschied 
in der Hemmwirkung zwischen wt  5-LO oder der mutierten 5-LO, bei der die 
Phosphorylierungsstellen fehlen [Paper  IV]. Aus diesem Grund besitzt CJ-13,610 ein 
beachtliches Potential als wirksamer 5-LO Inhibitor, dem einige der bekannten Nachteile der 
älteren Substanzen fehlen. Eine verminderte Wirkung ist jedoch unter Bedingungen zu erwarten, 
bei denen ein erhöhter Peroxidspiegel vorliegt. 
Extrakte aus dem Harz des Weihrauchs (Boswellia serrata) werden in der traditionellen 
Volksmedizin bei der Behandlung von Entzündungskrankheiten eingesetzt. In 
polymorphkernigen Leukozyten (PMNL) hemmen Boswelliasäuren (BA), die aktiven 
Inhaltsstoffe des Weihrauchharzes, die Biosynthese der LT. In Zellhomogenaten jedoch sind für 
die gleiche Wirkung wesentlich höhere Konzentrationen erforderlich, was auf eine zusätzliche 
Wirkweise der BAs schließen lässt. 
11-keto-BAs induzieren die Aktivierung von p38  MAPK, ERK1/2 und stimulieren die 
Ca
2+-Mobilisierung in PMNL. Zusätzlich verursachen BAs die Bildung von reaktiven 
Sauerstoffspezies (ROS), die Freisetzung von AA und die damit verbundene Bildung von LT 
[Paper  V,  VI]. Untersuchungen mit spezifischen Inhibitoren zeigten, dass diese induzierte 
ROS-Bildung Ca
2+-abhängig ist. Zudem wird die ROS-Bildung durch die NADPH-Oxidase Zusammenfassung 
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vermittelt, wobei eine Aktivierung von PI 3-K und MAPK mit einbezogen ist [Paper V, VI]. Die 
BA-induzierte AA-Freisetzung wird ebenfalls über den Ca
2+-Spiegel und die Aktivierung von 
ERK1/2 reguliert [Paper VI]. Untersuchungen mit verschiedenen hämatopoetischen Zellen haben 
ergeben, dass die Aktivierung von Signalkaskaden sehr stark vom Zelltyp abhängig ist. 
Interessanterweise zeigt die Aktivierung von Leukozyten durch 11-keto-BAs ein ähnliches Bild 
wie bei der Aktivierung durch fMLP oder PAF. Allerdings konnte bis jetzt kein spezifischer 
Rezeptor, der diese Signale vermittelt, identifiziert werden. Dagegen kann die reduzierende 
Wirkung von BAs bezüglich der 5-LO Aktivität durch erhöhte Ca
2+-Spiegel bzw. ROS-Spiegel 
erklärt werden, die dann zu einer Inaktivierung der 5-LO führen. 
Schließlich wurde im Rahmen dieser Arbeit die Wirkung von Inhibitoren der Aktin-
polymerisation auf die 5-LO Produktbildung untersucht. Inhibitoren wie Cytochalasin D (CD) 
oder Latrunculin B (LB), verstärken sowohl die AA-Freisetzung, die Translokation der 5-LO als 
auch die LT Bildung in isolierten PMNL, die mit Thapsigargin (TG) stimuliert wurden. Diese 
Wirkung konnte nicht beobachtet werden, wenn die Zellen mit Ca
2+-Ionophor behandelt wurden 
[Paper  VII]. Nähere Untersuchungen ergaben, dass LB selbst einen Anstieg des [Ca
2+]i 
verursacht und einen, durch Agonisten verursachten, Ca
2+-Einstrom verstärkt. LB führt zu einer 
raschen, aber eher moderaten Aktivierung von p38 MAPK und ERKs. Selektive Inhibitoren von 
Kinasen der Src-Familie, wie PP2 und SU6656, blockieren den LB- oder CD-vermittelten 
Ca
2+-Anstieg und unterdrücken die hochregulierende Wirkung auf die AA-Freisetzung und 
LT-Bildung [Paper VII]. Somit führen Inhibitoren der Aktinpolymerisation zu einer Aktivierung 
von Src-Kinasen. Diese wiederum verstärken den Stimulus-induzierten Anstieg des 
intrazellulären Ca
2+ und dadurch die Freisetzung von AA und die Bildung von LT. 
Grundsätzlich ist es also von fundamentaler Bedeutung bei der Entwicklung von neuen 
Arzneistoffen die zellulären Zusammenhänge, insbesondere die Regulierung der Aktivität von 
Enzymen, zu kennen. Wie in dieser Arbeit gezeigt, hat die Phosphorylierung der 5-LO einen 
starken Einfluss auf die Regulation der 5-LO Aktivität und eine elementare Wirkung auf die 
Hemmung des Enzyms durch verschiedene Wirkstoffe. 
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ABSTRACT 
 
5-Lipoxygenase (5-LO) is the key enzyme in the biosynthesis of proinflammatory leukotrienes. 
Here, we demonstrate that extracellular signal-regulated kinases (ERKs) can phosphorylate 5-LO 
in vitro. Efficient phosphorylation required the presence of unsaturated fatty acids and was 
abolished when Ser-663 was mutated to alanine. In intact HeLa cells stimulated with arachidonic 
acid (AA), impaired 5-LO product formation was evident in cells expressing the S663A-5-LO 
mutant compared with cells expressing wild-type 5-LO. For Mono Mac 6 cells, priming with 
phorbol myristate acetate (PMA) before stimulation with ionophore was required for ERK1/2 
activation and efficient 5-LO phosphorylation, in parallel with substantial AA release and 5-LO 
product formation. Inhibition of PKC by GF109203x or MEK1/2 by U0126 (or PD98059) 
abolished the 5-LO up-regulation effects of PMA. In contrast, these inhibitors failed to suppress 
5-LO product formation induced by stimuli such as AA plus ionophore, which apparently do not 
involve the ERK1/2 pathway. Based on inhibitor studies, ERKs are also involved in AA-
stimulated 5-LO product formation in PMNL, whereas a role for ERKs is not apparent in 5-LO 
activation induced by ionophore or cell stress. Finally, the data suggest that ERKs and p38 
MAPK-regulated MAPKAPKs can act in conjunction to stimulate 5-LO by phosphorylation. 
 
Key words: arachidonic acid • leukotriene • p38 MAP kinase 
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elease of arachidonic acid (AA) and activation of 5-lipoxygenase (5-LO) in response to a 
variety of external stimuli initiates the biosynthesis of proinflammatory leukotrienes 
(LTs), a family of lipid mediators with pivotal roles in asthma and inflammatory disorders 
(1). Activated 5-LO catalyzes the formation of 5-hydroperoxyeicosatetraenoic acid from AA and 
the subsequent dehydration to LTA4, an unstable epoxide, which is further converted to LTB4, 
C4, D4 and E4 (2).   
 Attention has been focused on the activation of cellular 5-LO, which involves enzyme 
translocation from a soluble locus to the nuclear envelope, where it colocalizes with cytosolic 
phospholipase A2 (cPLA2) and 5-lipoxygenase-activating protein (for review, see ref 3). 
Activation of 5-LO can be induced by various soluble and particulate stimuli such as N-formyl-
methionyl-leucyl-phenylalanine (fMLP), platelet-activating factor (PAF), cytokines, immune 
complexes, and microbes and by ionophores or thapsigargin, which raise the intracellular Ca
2+ 
levels (for review, see ref 4). Ca
2+ activates 5-LO in vitro and in vivo (see ref 5 and references 
therein), and it was recently found that the putative N-terminal C2-like domain of 5-LO binds 
Ca
2+ and is important for translocation to the nucleus and association with membranes (6￿8).  
 
Phosphorylation appears to activate 5-LO in various leukocytes depending on the stimulus (9￿
14). p38 mitogen-activated protein kinase (MAPK)-regulated MAPK-activated protein kinases 
(MAPKAPKs, MKs) have been identified as 5-LO kinases that phosphorylate 5-LO at Ser-271 in 
vitro, which is promoted by unsaturated fatty acids (UFAs) (10, 11). Of interest, stimulation of 
polymorphonuclear leukocytes (PMNL) by cell stress induces Ca
2+-independent 5-LO product 
formation involving p38 MAPK (13). 
 
Extracellular signal-regulated kinases (ERK)1/2 are typically activated by growth-related stimuli 
through the Raf-1/MEK1/2 protein kinase cascade. Investigation of substrate specificity using 
synthetic peptides revealed that the Pro-Xaa-Ser/Thr-Pro motif represents the optimal primary 
sequence for ERK1/2 phosphorylation (15, 16). However, whereas many protein substrates such 
as cPLA2, epidermal growth factor receptor, myelin basic protein (MBP), and ELK-1 conform to 
this motif (for review, see ref 17), the minimal consensus sequence for ERK1/2 is Ser/Thr-Pro. 
Thus, in addition to primary sequence requirements, recognition of substrates may depend on 
their structure.  
 
Based on inhibitor studies, previous reports suggested an involvement of ERK1/2 in agonist-
induced 5-LO product formation and translocation in granulocytes or differentiated HL60 cells 
(9, 18￿23). Although 5-LO contains a putative ERK phosphorylation motif, ERKs could not be 
demonstrated to phosphorylate 5-LO in vitro (24). In this study, we show that ERKs 
phosphorylate 5-LO in vitro and that this phosphorylation was strongly stimulated by UFAs. We 
provide evidence for the involvement of ERK1/2 signaling and 5-LO phosphorylation in the 
activation of 5-LO in intact cells. 
 
MATERIALS AND METHODS 
 
Human transforming growth factor beta1 (TGFβ1) was purified from outdated platelets as 
previously described (25). Calcitriol (1,25-dihydroxyvitamin D3) was from Biomol (Plymouth 
Meeting, PA). Human recombinant 5-LO was expressed in Escherichia coli (26) and purified as 
described previously (5). Anti-5-LO antiserum (AK7, 1551) was affinity purified on a 5-LO 
column. Materials and sources: RPMI 1640, GIBCO BRL (Life Technologies, Rockville, MD); 
fetal calf serum and bovine insulin, Sigma (Deisenhofen, Germany); [γ-
32P]ATP (110 
TBq/mmol), Amersham; activated (rat, recombinant) ERK2 isoform and 5(S)-HPETE, Biomol; 
activated GST-MK2, Upstate Biotechnology (Lake Placid, NY); arachidonic acid, arachidic acid, 
linoleic acid, linolenic acid, palmitic acid, oleic acid, Ca-ionophore A23187, fMLP, MBP and PMA, Sigma; PD 98059 and U0126, Alexis (Gr￿nberg, Germany); SB203580 and GF109203x, 
Calbiochem (Bad Soden, Germany); high-performance liquid chromatography (HPLC) solvents, 
Merck (Darmstadt, Germany). 
 
Cells and transient transfections 
 
MM6 cells were cultured and differentiated with TGFβ1 and calcitriol as previously described 
(27). Cells were harvested by centrifugation (200g, 10 min, room temperature) and washed once 
in phosphate-buffered saline (PBS) pH 7.4. Human PMNL were freshly isolated from leukocyte 
concentrates obtained from healthy donors at St Markus Hospital as previously described (13). 
HeLa cells were maintained and transiently transfected using the Ca
2+ phosphate method as 
previously described (11). 
 
Site-directed mutagenesis, expression, and purification of 5-LO proteins 
 
The codons for Ser-271 and Ser-663 in the plasmid pT3-5LO were mutated using the 
QuikChange kit from Stratagene (La Jolla, CA) as previously described (7). The mutated DNA 
was confirmed using the DYEnamic ET Terminator Cycle Sequencing kit (Amersham 
Pharmacia Biotech), followed by analysis on a Applied Biosystem PRISM 377 sequencer 
(carried out by KISeq, Core Facilities at Karolinska Institutet). E. coli MV1190 was transformed 
with mutated or wild-type (wt) DNA; recombinant 5-LO proteins were expressed at 27￿C and 
purified as previously described (7). The mutated plasmids pcDNA3.1-5LO-S663A and 
pcDNA3.1-5LO-S271A-S663A were prepared from pcDNA3.1-5LO (28) in the same manner. 
 
Western blotting 
 
For determination of phosphorylated ERK1/2, MM6 cells (3 × 10
6) or PMNL (5 × 10
6) were 
resuspended in 100 ￿l PBS containing 1 mg/ml glucose and 1 mM CaCl2 (PGC buffer) and 
stimulated at 37￿C. Incubations were stopped by addition of the same volume of 2× sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer (SDS-b; 
20 mM Tris/HCl, pH 8, 2 mM EDTA, 5% SDS [w/v]), 10% β-mercaptoethanol) and heated at 
95
oC for 6 min. Total cell lysates corresponding to 0.5 × 10
6 cells in 20 ￿l were mixed with 4 ￿l 
of glycerol/0.1% bromphenolblue (1:1, vol/vol) and analyzed by SDS-PAGE using a Mini 
Protean system (Bio-Rad, Munich, Germany) on a 10% gel. After electroblot to nitrocellulose 
membrane (Hybond C, Amersham), blocking with 5% nonfat dry milk in 50 mM Tris-HCl, pH 
7.4, and 100 mM NaCl (TBS), membranes were washed and incubated with phospho-specific 
ERK1/2 (Thr202/Tyr204) antibodies (AB) (New England Biolabs, Frankfurt, Germany) 
overnight at 4￿C. Immunoreactive proteins were visualized using alkaline phosphatase 
conjugated IgGs as previously described (26). 
 
Immunoprecipitation 
 
For preparation of immunoprecipitates (IPs), MM6 cells (1 × 10
7) were resuspended in 1 ml PGC 
buffer and stimulated. After 2 min at 37￿C, cells were lysed by addition of 1 ml ice-cold lysis 
buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.5 % NP-40, 50 mM NaF, 2 mM Na3VO4, 25 mM ￿-glycerophosphate, 1 mM sodium pyrophosphate, 10 mM 
4-nitrophenyl phosphate, 1 mM PMSF, 10 ￿g/ml leupeptin, and 60 ￿g/ml soybean trypsin 
inhibitor). After sonification (1 × 5 sec), supernatants were obtained by centrifugation of the 
lysates (16,000g, 10 min, 4
oC), precleared by incubation with 20 ￿l of Protein A/G PLUS-
Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) and incubated with 2 ￿l of phospho-
ERK1/2 (Thr202/Tyr204) AB overnight at 4
oC. The immune complexes were precipitated (3 h at 
4￿C) with 20 ￿l of A/G Plus-Agarose and washed twice with lysis buffer and twice with kinase 
buffer and immediately used for protein kinase assays.  
 
Protein kinase assays 
 
Phosphorylation of 5-LO and MBP in vitro was performed as described previously (10). In brief, 
purified recombinant 5-LO or MBP (40 pmol each) were preincubated in the absence or presence 
of fatty acids with the activated kinases (MK2, ERK2) or the ERK1/2-IPs from MM6 cells in 
presence of ATP (100 ￿M) and [γ-
32P]ATP (100 nCi/￿l) for 30 min at 30
oC. The reaction was 
terminated by addition of the same volume of SDS-b, and samples (20 ￿l) were separated by 
SDS-PAGE. Proteins were first visualized by Coomassie staining to ensure correct loading of 
protein. Phosphorylated proteins were analyzed using a Phosphorimager Fuji FLA 3000. 
 
Determination of 5-lipoxygenase product formation 
 
PMNL (5 × 10
6), HeLa (2 × 10
6), or MM6 cells (3 × 10
6)  in 1 ml PGC buffer were preincubated 
for 30 min at 37￿C in the presence or absence of the indicated inhibitors. Then, cells were 
stimulated with the indicated agents. After 10 min at 37￿C, the reaction was stopped with 1 ml 
methanol and 30 ￿l 1 N HCl, and 500 ￿l PBS were added. Formed 5-LO products were extracted 
and analyzed by HPLC as previously described (29). 5-LO product formation is expressed as ng 
5-LO products per 10
6 cells, which includes the all-trans isomers of LTB4, LTB4, 5(S)-hydroxy-
6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE), and 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-HPETE) for MM6 and HeLa cells.  For PMNL, the 5(S),12(S)-
dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid [5(S),12(S)-DiHETE] is also included in the 
calculation. 5-HETE and 5-HPETE coelute as one major peak; integration of this peak represents 
both eicosanoids. Cysteinyl LTs (LTC4, D4, and E4) were not detected, and oxidation products of 
LTB4 were not determined. 
 
Determination of [
3H]arachidonic acid release from phospholipids 
 
MM6 cells were resuspended at 2 × 10
6/ml in RPMI 1640 medium containing 4.8 nM [
3H]AA 
(corresponding to 0.25 ￿Ci/ml, specific activity 200 Ci/mmol) and incubated for 90 min at 37
oC. 
Thereafter, cells were centrifuged and washed to remove unincorporated [
3H]AA. Labeled cells 
(5 × 10
6) were resuspended in 1 ml PGC buffer containing 2 mg/ml fatty acid free albumin. The 
samples were preincubated at 37
oC with or without additives before the addition of ionophore 
A23187 (5 ￿M). After 10 min, the reaction was stopped with 1 ml methanol and 30 ￿l 1 N HCl, 
and 500 ￿l PBS were added and [
3H]AA was extracted and analyzed by HPLC as described 
previously (12).  
RESULTS 
 
5-LO is efficiently phosphorylated by ERK2 in vitro in the presence of unsaturated fatty 
acids, role of Ser-663 
 
Because several reports have proposed a role for ERK1/2 in activation of the 5-LO pathway (9, 
19￿24), we addressed whether ERKs are actually capable of phosphorylating 5-LO. In vitro 
kinase assays were conducted using purified recombinant 5-LO as substrate and purified 
activated ERK2 as kinase; activated GST-MK2 was used as a positive control (see refs 10 and 
11). 
 
As shown in Figure 1A, 5-LO was dose-dependently phosphorylated by active ERK2 and MK2 
in vitro. The 5-LO phosphorylation rates of ERK2 appeared somewhat lower than those obtained 
by MK2, and compared to MBP (which is an excellent in vitro substrate for ERKs [30]), 5-LO 
was less efficiently phosphorylated by ERK2. Thus, about 20- to 30-fold higher amounts of 
kinase were required for similar phosphate incorporation into 5-LO vs. MBP (40 pmol each).  
 
Recently, we found that UFAs promote 5-LO phosphorylation by MK2, but not by the 5-LO 
kinases PKA or CaMKII (11). AA increased 5-LO phosphorylation by ERK2 in a dose-
dependent fashion up to 25-fold (at 50 ￿M AA, Fig. 1B). Opposite effects of AA were observed 
when MBP was used as substrate. Thus, AA dose-dependently decreased ERK2 activity toward 
MBP, and at 50 ￿M AA, phosphorylation of MBP was almost completely abolished. In addition 
to AA, the UFAs oleic acid and linoleic acid increased ERK2 activity toward 5-LO. In contrast, 
the saturated arachidic acid and palmitic acid as well as 5-HETE, the hydroxylated metabolite of 
AA, failed to enhance 5-LO phosphorylation rates (Fig. 1C).  
 
The minimal consensus sequence for ERK1/2 is Ser/Thr-Pro, and such a motif is present in 5-LO 
(YLSP at residues 661-664). In order to identify phosphorylation sites, Ser-663 in 5-LO was 
mutated to alanine (S663A-5-LO) and subjected to phosphorylation by ERK2. As shown in 
Figure 1D, in the absence of UFAs, wt-5-LO as well as the S663A-5-LO mutant were only 
marginally phosphorylated by ERK2. However, a striking difference between wt- and S663A-5-
LO was apparent when the kinase reaction was performed in presence of AA. Whereas AA 
increased the phosphorylation of wt-5-LO, AA (or oleate, data not shown) led to only a marginal 
increase in the phosphorylation rate (about twofold) for the S663A mutant, indicating that 
enhanced phosphate incorporation due to UFAs requires the Ser-663 residue in 5-LO.  
 
ERK activation correlates to 5-LO activation in MM6 cells 
 
For MM6 cells, priming with PMA before stimulation with ionophore was found to be required 
for prominent AA-release and 5-LO product formation (12), and we attempted to correlate ERK 
activity to 5-LO activation. In accordance with the effect on 5-LO product synthesis, treatment of 
MM6 cells with ionophore alone failed to activate ERK1/2, but priming with PMA for 10 min 
with or without subsequent ionophore treatment resulted in a clear activation of ERK1/2, 
preferentially ERK2 (Fig. 2A, lower band). Inhibition of the upstream kinases protein kinase C (PKC) by GF109203x (IC50 ≈ 0.1 ￿M) or MEK1/2 by U0126 (IC50 ≈ 0.3 ￿M)  (or PD98059, IC50 
≈ 3 ￿M, data not shown), dose-dependently reduced ERK1/2 activation by PMA.  
 
Next, we determined the ability of endogenous ERK1/2, immunoprecipitated from MM6 cells, to 
phosphorylate 5-LO in vitro. MBP was used as control, and 50 ￿M AA was included when 5-LO 
phosphorylation was assayed. ERK1/2 derived from MM6 cells  that had been primed with PMA 
before stimulation with ionophore markedly phosphorylated 5-LO (and MBP), and pretreatment 
of the cells with U0126 (3 ￿M) prevented the effect of PMA (Fig. 2B). Stimulation of MM6 cells 
with ionophore alone gave no significant change in immunoprecipitated ERK1/2 activity, 
compared with untreated control cells. When kinase activity toward 5-LO was determined in 
absence of exogenous AA, only faint bands of phosphorylated 5-LO were detected (data not 
shown).  
 
ERKs are involved in PMA-up-regulated 5-LO product formation in MM6 cells  
 
We determined the contribution of ERK1/2 in PMA-up-regulated AA release and 5-LO product 
formation in MM6 cells using specific inhibitors. Priming with PMA enhanced ionophore-
induced [
3H] AA release up to sixfold, and inhibition of PKC by GF109203x (0.3 ￿M) or 
ERK1/2 activity by U0126 (1 ￿M) or PD98059 (10 ￿M) suppressed the liberation of AA (Fig. 
3A).  
 
In accordance with previous results (12), priming with PMA increased ionophore-stimulated 5-
LO product formation in MM6 cells up to sevenfold in the absence of exogenous substrate, but 
also in the presence of exogenous AA, a significant (P < 0.01) increase (twofold) in 5-LO 
product formation was found (Fig. 3 B, C). No 5-LO products were detected when cells were 
stimulated with PMA alone (data not shown). The up-regulation effects of PMA were efficiently 
blocked by GF109203x (IC50 ≈ 0.2 ￿M) as well as by U0126 (IC50  ≈ 0.3 ￿M) or PD98059 (IC50  
≈ 5 ￿M, data not shown) at concentrations that correlated with the suppression of PMA-induced 
ERK1/2 activation (compare Fig. 2A). However, neither GF109203x nor U0126 (or PD98059, 
not shown) blocked 5-LO product formation induced by ionophore plus AA in nonprimed cells, 
indicating that the inhibitors basically reduced PMA-up-regulated 5-LO activity. In broken cell 
preparations, the IC50 values for 5-LO catalytic activity were determined at >10 ￿M  for 
GF109203x, >10 ￿M for U0126 and >100 ￿M for PD98059 (data not shown). Thus, direct 
effects of these kinase inhibitors on 5-LO catalytic activity, at the concentrations that abolished 
PMA-priming, are negligible. 
 
ERKs are involved in AA-induced 5-LO product formation in PMNL 
 
AA can activate ERKs in PMNL, predominantly ERK2, involving G protein-coupled receptors 
(31), and it was demonstrated that AA induces 5-LO product formation in PMNL (11, 32￿34). In 
Ca
2+-free medium, a dose-dependent induction of 5-LO product formation by AA was observed 
that was accompanied with the phosphorylation of ERK2 (Fig. 4A). The 5-LO product pattern is 
shown in a HPLC chromatogram obtained from PMNL stimulated with 40 ￿M AA (Fig. 4B). 
U0126 and PD98059 were used to investigate the involvement of ERKs in 5-LO product 
formation. Exogenous AA was added to all incubations to exclude reduced 5-LO product synthesis due to alterations in substrate supply, by possible inhibition of cPLA2 (35). PMNL 
were treated with AA (60 ￿M) alone, with AA (10 ￿M) plus 2.5 ￿M ionophore (leading to 
prominent Ca
2+ influx), or with AA (40 ￿M) plus 0.3 M NaCl (which activates 5-LO 
independent of Ca
2+ involving p38 MAPK pathways (13). As shown in Fig. 4C (left panel), AA-
induced 5-LO product formation was partially reduced by U0126 (0.3￿3 ￿M) to about 50￿60% 
at inhibitor concentrations that prevented ERK2 activation (Fig. 4C, right panel). In contrast, 5-
LO product formation induced by AA plus ionophore or by AA plus NaCl (conditions that 
apparently activate 5-LO independent of ERK1/2) was hardly affected by U0126. Similar results 
were obtained with PD98059 (data not shown). 
 
Furthermore, in PMNL (depleted from adenosine to augment 5-LO product synthesis from 
endogenous substrate (36)), 5-LO product synthesis induced by the physiological agonist fMLP 
(no exogenous AA) correlated to ERK1/2 activation and was completely reduced by 3 ￿M 
U0126 (Fig. 4D). When exogenous AA (5 ￿M) was included, only partial (∼41%) reduction of 
fMLP-induced 5-LO product formation was detected (Fig. 4E), suggesting that alterations in 
endogenous AA supply contribute to impaired 5-LO product synthesis. Combination of U0126 
with the p38 MAPK inhibitor SB203580 (10 ￿M), gave no further 5-LO inhibition (data not 
shown). Together, suppression of 5-LO product formation by ERK activation inhibitors 
depended on the stimulus and on the signal transduction pathway utilized to activate 5-LO. 
 
Role of putative phosphorylation sites in 5-LO for product formation 
 
To investigate the impact of 5-LO phosphorylation for enzyme activation in intact cells, we 
transiently transformed HeLa cells with plasmids encoding wt-5-LO or S663A-5-LO, and 5-LO 
product formation was determined. As shown in Fig. 5, HeLa cells expressing wt- or S663A-5-
LO gave similar prominent product formation after stimulation with both ionophore (10 ￿M) and 
AA (0￿60 ￿M), whereas 5-LO product formation for the S663A mutant was significantly lower 
compared with wt-5-LO, when cells were treated with AA (10￿60 ￿M) alone. Thus, for S663A-
5-LO, the amount of the formed products after incubation with AA (40 or 60 ￿M) was only 18 or 
22% of the products obtained after incubation with AA plus ionophore the corresponding ratio 
for wt-5-LO was 41 or 43% (Fig. 5).  
 
ERKs act in conjunction with MK2 to activate 5-LO 
 
AA-induced 5-LO product formation in PMNL was also partially suppressed (by 40%) by the 
p38 MAPK inhibitor SB203580 (10 ￿M). Intriguingly, combining U0126 (3 ￿M) with 
SB203580 (10 ￿M) caused 5-LO suppression by 83% (Fig. 6A), suggesting that both ERKs and 
p38 MAPK pathways are involved in AA-induced 5-LO product formation. Again, formation of 
5-LO products induced by Ca
2+-dependent pathways, using AA plus ionophore, was hardly 
suppressed by combinations of the kinase inhibitors. 
 
Recently, we also found reduced 5-LO product formation in HeLa cells transformed with 
S271A-5-LO vs. wt-5-LO after stimulation with AA (11). To investigate whether both Ser-271 
and Ser-663 could be of importance for AA-induced 5-LO activity in intact cells, we transfected 
HeLa cells with plasmids encoding S271A-S663A-5-LO and determined 5-LO product generation. The expression levels of the S271A-S663A mutant were only 30￿40% compared 
with the wt-5-LO (insert Fig. 6B), which correlate with the reduced formation of 5-LO products 
in broken cell preparations (data not shown). In relation to the protein expression levels, S271A-
S663A-5-LO gave comparable 5-LO product formation after incubation with AA plus ionophore 
as found for wt-5-LO. However, for wt-5-LO the ratio of AA- to AA plus ionophore-induced 5-
LO product synthesis at 10￿60 ￿M AA was 24￿43%, for S663A-5-LO 11￿22%, and for the 
S271A-S663A-5-LO 5￿14% (Fig. 6B). Thus, at low Ca
2+ levels, phosphorylation at both Ser-663 
and Ser-271 appears to be required for 5-LO product formation in intact cells. 
 
DISCUSSION 
 
Based on inhibitor studies, the ERK signaling pathway has been implicated in the activation of 5-
LO, but the precise mechanisms involved have not been elucidated yet. For example, PD98059 
blocked 5-LO activity and translocation in ionophore-stimulated HL-60 cells (9, 18) and U0126 
suppressed LT synthesis in untreated or IL-5 primed eosinophils as well as in neutrophils 
challenged by fMLP (19, 20, 23). Also in PAF-stimulated RBL-2H3 cells, LTC4 generation (but 
not CCL2 production) was blocked by U0126 (22). Note that cPLA2, which provides AA as 
substrate for 5-LO, is regulated by ERKs (35, 37). Thus, it is not clear from some of these studies 
(19, 20, 22, 23) whether reduced 5-LO activity by ERK inhibitors is due to impaired AA 
availability. However, also in the presence of exogenous AA, PD98059 blocked 5-LO activity in 
HL-60 cells (9), suggesting a more direct role of ERK in regulating 5-LO. 
 
Although in previous studies 5-LO phosphorylation by ERKs could not be detected (24), we 
found that ERK2 and ERK1/2 immunoprecipitated from MM6 cells phosphorylate human 
recombinant 5-LO in vitro. These opposite findings could be related to different assay conditons, 
for example, purity, integrity, and the amount of 5-LO used or kinase buffer composition. Also, 
compared with the excellent in vitro substrate MBP (30), 5-LO is a rather poor substrate for 
ERK2, and ERK2 activity toward 5-LO was not readily detectable in in-gel kinase assays 
(compare ref 10 and 11). However, UFAs (but not saturated fatty acids or 5-HETE) markedly 
enhanced 5-LO phosphorylation by ERK2, and endogenous ERKs derived from MM6 cells 
required AA for efficient phosphorylation of 5-LO. Previously, we found that UFAs also 
promote 5-LO phosphorylation at Ser-271 by MK2, but not by PKA or CaMKII (11), and 
phosphorylation of other MK2 substrates (e.g., heat shock protein 27) was not enhanced. Thus, 
the ability of UFAs to promote protein phosphorylation seems to be specific for 5-LO as 
substrate and is restricted to particular 5-LO kinases. The underlying mechanisms are unclear, 
presumably UFAs lead to exposure of the serine residues or favor substrate recognition and 
access of the kinases (compare ref 11). Because mutation of Ser-663 to alanine abolished 
substantial phosphorylation in presence of AA, it appears that Ser-663 is an ERK 
phosphorylation site in 5-LO.  
 
It was shown that in response to ionophore, which activates ERKs and p38 MAPK pathways in 
leukocytes (38), 5-LO phosphorylation occurred in intact HL-60 cells (24), although only a very 
small amount of the total 5-LO protein was phosphorylated. We failed to convincingly assess in 
vivo phosphorylation after 5-LO immunoprecipitation from stimulated PMNL, MM6 or HL-60 
cells preincubated with 
32Pi. This might be attributable to inefficient 
32P-labelling of 5-LO due to experimental settings or dephosphorylation during timely long experimental procedures. 
However, it is also conceivable that (in contrast to cPLA2) only a small fraction of the cellular 5-
LO is subject to phosphorylation. This small activated pool of 5-LO in turn may activate the bulk 
of enzyme via 5-LO derived lipid hydroperoxides that convert the active site iron from the 
ferrous to the ferric state, a process that is essential for initializing the 5-LO catalytic redox cycle 
(39, 40). Along these lines, it was implied also by others that on stimulation of neutrophils by 
AA, only a small amount of 5-LO is initially activated by Ca
2+-independent mechanisms before 
activation of the bulk of 5-LO (34). The stimulus-dependent difference in 5-LO product 
synthesis of the S663A 5-LO mutant compared to wt-5-LO in HeLa cells suggests that 5-LO 
phosphorylation by ERKs indeed plays a role for 5-LO activation in intact cells.  
 
Recent studies have proposed that 5-LO in intact PMNL can be activated by at least two different 
pathways: either by elevation of intracellular Ca
2+ (using ionophore as stimulus), or by a cell 
stress-induced, p38 MAPK-regulated pathway which is Ca
2+-independent (13). For cPLA2, 
which is substrate for ERKs, p38 MAPK and p38 MAPK-regulated kinases (41, 42), stimuli 
leading to activation of MAPKs (PMA) and cPLA2 phosphorylation caused AA release also at 
basal Ca
2+ levels (43), whereas Ca
2+-mobilizing agents (ionophore) stimulated AA release when 
phosphorylation of cPLA2 was blocked (35). Our studies confirm the hypothesis of Ca
2+- and/or 
phosphorylation-mediated 5-LO enzyme activation. Thus, 5-LO product formation in HeLa cells 
expressing wt- or S663A-5-LO was quantitatively the same when cells had been stimulated with 
AA plus ionophore, where Ca
2+ is the predominant 5-LO activator and phosphorylation might be 
of minor importance. However, the S663A-5-LO mutant, lacking the ERK1/2 phosphorylation 
site, produced significantly lower amounts of 5-LO metabolites when an ERK-dependent 
stimulus such as AA was used. It was shown that AA causes pronounced ERK activation in 
various cell types (31, 44, 45) but leads to only moderate Ca
2+ fluxes (13, 32, 33). 
 
Notably, most of the natural ligands that stimulate LT synthesis in PMNL (e.g., fMLP, PAF, 
C5a, or AA) activate ERKs (31, 46￿48) but lead to rather moderate elevations of intracellular 
Ca
2+ compared with the nonphysiological stimulus ionophore (32, 33, 49, 50). In this respect, 
ERK activation inhibitors failed to suppress 5-LO product synthesis induced by ionophore or by 
ERK-independent phosphorylation pathways (via p38 MAPK using cell stress as stimulus), 
whereas AA-induced 5-LO product synthesis significantly correlated with ERK activity (Fig. 4). 
For 5-LO activation induced by fMLP (that causes Ca
2+ mobilization in PMNL [50]), both Ca
2+ 
and phosphorylation events may contribute (13), explaining less pronounced 5-LO inhibition by 
U0126 (Fig. 4E). Intriguingly, exogenous addition of 5-HPETE or 5-HETE to neutrophils 
stimulated ERKs, involving G protein-linked receptors, and conversion of AA by 5-LO was 
required for ERK activity (31, 51), implying autoregulatory loops for AA-induced 5-LO 
activation via ERKs.  
 
Also in MM6 cells induction and up-regulation of 5-LO product formation significantly 
coincided with ERK activity, confirming a direct role of ERKs in 5-LO activation. Thus, 
ionophore alone failed to activate ERK1/2 in MM6 cells for unknown reasons, and 5-LO product 
synthesis from endogenous AA was low. Preincubation with PMA induced ERK activity and 
also 5-LO product synthesis, which was highly sensitive to specific ERK activation inhibitors at 
concentrations that were similar to those required to prevent ERK activation. This reduced 5-LO product synthesis in PMA-primed cells might be due to impaired AA availability. However, 
PMA-up-regulated 5-LO product formation was abolished by GF109203x, U0126 and PD98059 
also in presence of exogenous AA, implying a direct stimulatory effect of ERKs on 5-LO and 
possible alterations in the supply of endogenous AA should be negligible. Apparently in MM6 
cells, both phosphorylation processes and elevated Ca
2+ levels are of importance for substantial 
5-LO product synthesis.  
 
Finally, our data suggest that enzyme phosphorylation by ERK2 and MK2 at multiple sites can 
act in conjunction to activate 5-LO (Fig. 7). In PMNL, AA and fMLP also activate p38 MAPK 
leading to activation of the 5-LO kinase MK2 (11, 36, 45). Thus enzyme phosphorylation by 
ERK2 and MK2 at multiple sites might be necessary for AA-induced 5-LO activation, supported 
by the synergistic effects of U0126 and SB203580 (Fig. 6A). Moreover, for HeLa cells the ratio 
of AA to AA/ionophore-induced 5-LO product formation of S271A-S663A-5-LO, lacking the 
phosphorylation sites for MK2 and for ERKs, was significantly lower when compared with 5-LO 
mutants lacking only one phosphorylation site (S271A-5-LO or S663A-5-LO) (compare ref 11). 
Synergistic actions of MAPK pathways (depending on the stimulus) were also observed for the 
activation of cPLA2 (35, 52).  
 
In conclusion, our data show that ERKs, particularly in the presence of UFAs, are capable of 
phosphorylating 5-LO, which may contribute to 5-LO product synthesis. Importantly, ERKs can 
act in conjunction with p38 MAPK-regulated MKs to activate 5-LO in intact cells, where UFAs 
such as AA, might play a central role in the convergence of MAPK signaling cascades, leading 
to phosphorylation and activation of 5-LO. These findings might provide the molecular basis of 
5-LO activation in leukocytes in response to particular agonists and priming agents and might 
provide new strategies for pharmacological intervention with LT biosynthesis during 
inflammatory diseases. 
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 Fig. 1 
 
 
 
Figure 1. Extracellular signal-regulated kinase (ERK)2 phosphorylates 5-lipoxygenase (5-LO) in vitro: effects of 
unsaturated fatty acids. A) Phosphorylation of 5-LO (left panel) and myelin basic protein (right panel). Phosphorylation 
of the proteins (40 pmol each) was determined by in vitro kinase assay as described in Materials and Methods. Arrows 
indicate the positions of the corresponding proteins. One mU of each kinase (MK2 and ERK2) incorporates 1 pmol of 
phosphate into a standard substrate peptide. Because the standard substrates are different for the different kinases, the unit 
amounts are not strictly comparable. B) Arachidonic acid (AA) promotes 5-LO phosphorylation by ERK2. C) Effects of 
fatty acids on 5-LO phosphorylation by ERK2. D) Ser-663 is required for AA-induced increase in 5-LO phosphorylation 
by ERK2. The proteins (40 pmol each) were incubated with 10 mU active ERK2 in the absence or presence of the fatty 
acids, and phosphorylation was determined by in vitro kinase assays. Equal amounts of 5-LO and S663A-5-LO protein 
were determined by Coomassie staining. Results are representative of three separate experiments. 
 Fig. 2 
 
                          
 
Figure 2. Activation of ERKs in MM6 cells. A) ERK1/2 activation by phorbol myristate acetate (PMA) involves 
protein kinase C and MEK1/2. MM6 cells (3 ×  10
6) in 100 µl phosphate-buffered saline pH 7.4 containing 1 mg/ml 
glucose and 1 mM Ca
2+ (PGC buffer) were preincubated with U0126 or GF109203x for 20 min at 37°C and then primed 
with or without 100 nM PMA for 10 min before addition of 5 µM ionophore as indicated. After 2.5 min, incubations were 
terminated by addition of the same volume of SDS-b, and ERK1/2 activation was determined by Western blot using 
specific antibodies (AB) that detect the dually phosphorylated forms of ERK1/2. B) Phosphorylation of 5-LO and myelin 
basic protein by ERKs immunoprecipitated from MM6 cells. MM6 cells (1 ×  10
7 in 1 ml PGC buffer) were preincubated 
with 3 µM U0126 for 20 min at 37°C and then primed with or without 100 nM PMA for 10 min before addition of 5 µM 
ionophore as indicated. After 2 min, cells were lysed, and phosphorylated ERK1/2 were immunoprecipitated as described 
in Material and Methods. Phosphorylation of 5-LO (in the presence of 50 µM arachidonic acid [AA]) and MBP (no AA) 
by aliquots of phospho-ERK1/2-IPs was determined by in vitro kinase assay. Results are representative of three separate 
experiments. 
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Figure 3. Involvement of ERKs in arachidonic acid release and 5-LO product formation in MM6 cells.   
(A) Inhibition of PKC or MEK1/2 suppresses PMA-induced [
3H]AA release. MM6 cells (2 ×  10
6/ml in RPMI 1640 
medium) were prelabeled with 0.25 µCi/ml [
3H]AA for 90 min at 37°C. After unincorporated [
3H]AA was removed, cells 
(5 ×  10
6 in 1 ml phosphate-buffered saline pH 7.4 containing 1 mg/ml glucose, 1 mM Ca
2+, and 2 mg/ml fatty acid free 
albumin) were preincubated with the indicated inhibitors for 20 min at 37°C, primed in absence or presence of PMA for 
10 min at 37°C before addition of 5 µM ionophore. After 10 min, free [
3H]AA was determined by high-performance 
liquid chromatography (HPLC). Results are given as mean + SE, n = 3. B, C) Inhibition of PKC or MEK1/2 suppresses 
PMA-induced 5-LO product formation. MM6 cells (3 ×  10
6) in 1 ml PGC buffer were preincubated with the inhibitors 
(GF109203x (B) or U0126 (C)) for 20 min at 37°C and then primed with or without 100 nM PMA for 10 min at 37°C 
before addition of 5 µM ionophore with or without 40 µM of exogenous AA as indicated. After another 10 min, 5-LO 
product formation was determined by HPLC. Results are given as mean + SE, n = 4–5. Student t test, *P < 0.05 and  
**P < 0.01. 
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Figure 4. Involvement of ERKs in 5-LO product formation in polymorphonuclear leukocytes (PMNLs). 
A) AA-induced 5-LO product formation and activation of ERK2. To determine the activation of ERKs, 5 × 10
6 PMNL 
were resuspended in 100 ￿l phosphate-buffered saline (PBS) containing 1 mM EDTA and stimulated with the indicated 
concentration of AA at 37￿C. After 2 min, incubations were terminated and phosphorylation of ERK2 was determined 
after sodium dodecyl sulfate-polyacrylamide gel electrophoresis by Western blot (WB). To determine 5-LO product 
formation, 5 × 10
6 PMNL were resuspended in 1 ml PBS containing 1 mM EDTA. 5-LO products were determined 10 
min after stimulation by high-performance liquid chromatography (HPLC). Results are given as mean +SE, n = 3￿4.  
B) Typical HPLC chromatogram of 5-LO products extracted from PMNL that were stimulated with 40 ￿M AA for 5 min 
at 37￿C. 1: prostaglandin B2; 2, 3: trans-isomers of LTB4; and 4: LTB4; all recorded at 280 nm. 5: 12-HETE recorded at 
235 nm; 6: 5-HETE recorded at 235 nm. C) Effects of U0126 on 5-LO product formation. For stimulation with 60 ￿M 
AA, 5 × 10
6 PMNL were resuspended in 1 ml PBS containing 1 mM EDTA. Alternatively, for stimulation with 2.5 ￿M 
ionophore plus 10 ￿M AA or with 300 mM NaCl plus 40 ￿M AA, cells were resuspended in phosphate-buffered saline, 
pH 7.4, containing 1 mg/ml glucose and 1 mM Ca
2+ (PGC buffer). Before stimulation, cells were preincubated with 
U0126 for 30 min at 37￿C. Ten minutes after addition of stimuli, 5-LO product formation was determined by HPLC. 
Results are given as mean +SE, n = 3￿4. Student t test: **P < 0.01. The control values (100%) in absence of inhibitors 
were 57.1 ± 7.7, 53.7 ± 9.8, and 100.7 ± 2.2 ng/10
6 cells stimulated with 60 ￿M AA, NaCl plus AA, and ionophore plus 
AA, respectively. To determine the activation of ERKs (right panel), PMNL (5 × 10
6 in 100 ￿l PBS containing 1 mM 
EDTA buffer) were preincubated with U0126 for 30 min at 37￿C before addition of 60 ￿M AA. After 2 min, incubations 
were terminated and phosphorylated ERK2 was determined by WB. D) Activation of ERKs and 5-LO by N-formyl-
methionyl-leucyl-phenylalanine (fMLP). PMNL (5 × 10
6/ ml PGC buffer) were preincubated with 3 ￿M U0126 for 25 
min at 37￿C. Then, adenosine deaminase (5 U/ml) was added 5 min before stimulation with 1 ￿M fMLP. Incubations 
were terminated after 2 min to determine phosphorylated ERK2 by WB. To determine 5-LO product formation, 
incubations were terminated after 10 min. Results are given as mean +SE, n = 3. Student t test: **P < 0.01. E) Effects of 
U0126 on fMLP-induced 5-LO product formation in presence of exogenous AA. PMNL were treated as previously 
described, except that 5 ￿M AA was added with fMLP, and 5-LO product formation was determined. Results are given as 
mean +SE, n = 4. Student t test: **P < 0.01. Fig. 5 
 
 
 
Figure 5. 5-LO product formation in transformed HeLa cells. 5-LO product formation of wt and S663A-5-LO. HeLa 
cells were transiently transformed with plasmid DNA (10 µg) encoding wt-5-LO or S663A-5-LO. Cells (2 ×  10
6) were 
resuspended in 1 ml PGC buffer and stimulated with the indicated concentrations of AA in the absence or presence of 10 
µM ionophore for 10 min at 37°C. 5-LO product formation was determined by HPLC. Results are given as mean +SE, n = 
3. For one set of HeLa samples (total cell lysates corresponding to 0.1 ×  10
6 cells), the expression of 5-LO proteins was 
analyzed by WB using anti-5-LO antiserum (AK7, 1551) (insert). Fig. 6 
 
                                          
 
Figure 6. ERKs and p38 MAPK-regulated MK2 act in conjunction to stimulate 5-LO product formation. 
(A) Effects of U0126 and SB203580 on 5-LO product formation in PMNL. PMNL (5 ×  10
6/ml) were preincubated with 
U0126 (3 µM) and SB203580 (10 µM) as indicated for 30 min at 37°C. For stimulation with 60 µM AA, cells were 
resuspended in 1 ml PBS containing 1 mM EDTA. For stimulation with 2.5 µM ionophore plus 10 µM AA, cells were 
resuspended in PGC buffer. Ten minutes after addition of stimuli, 5-LO product formation was determined by HPLC. 
Results are given as mean +SE, n = 4–5. Student t test: *P < 0.05 and ** P< 0.01. One hundred percent of 5-LO product 
formation is defined as the amounts of 5-LO products formed in absence of inhibitors. B) Ratio of 5-LO product 
formation in transformed HeLa cells stimulated with AA and with AA plus ionophore. HeLa cells (2 ×  10
6), transiently 
transformed with plasmid DNA (10 µg) encoding wt-5-LO, S663A-5-LO, or S271A-S663A-5-LO, were resuspended in 1 
ml PGC buffer and stimulated with the indicated concentrations of AA in absence or presence of 10 µM ionophore. After 
10 min at 37°C, 5-LO product formation was determined. Results are presented (the mean +SE, n = 3) as the quotient of 
AA-induced to AA plus ionophore-induced 5-LO product formation. Student t test: *P < 0.05 and **P < 0.01. The 
expression of 5-LO proteins was analyzed by WB (insert). Fig. 7 
 
                           
 
Figure 7. Schematic illustration of cellular 5-LO activation and AA metabolism. Extracellular stimuli lead to 
elevation of intracellular Ca
2+ and activate MAPK pathways (1). These events stimulate translocation and activation of 
cPLA2 that in turn releases AA from phospholipids at the nuclear membrane (2). Free AA may activate 5-LO 
phosphorylation by ERKs and MK2 (3). On activation, 5-LO translocates to the nuclear membrane and colocalizes with 
FLAP (4). Free AA is transferred via FLAP to 5-LO for conversion to leukotrienes (5). Depending on the stimulus and the 
cell type, phosphorylation and/or Ca
2+ may be required for activation of 5-LO. 5-LIPOXYGENASE ACTIVATION BY MAPKAPK-2 and ERKs  1
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5-Lipoxygenase (5-LO) is the key enzyme in the biosynthesis of 
proinflammatory leukotrienes from arachidonic acid (AA) (1). Ca
2+, 
phosphatidylcholine, ATP, and hydroperoxides stimulate the enzymatic 
activity of 5-LO in vitro (1). However, the mechanisms involved in the   
agonist-induced 5-LO activation in intact cells are less clear. Stimuli that 
cause an elevation of the intracellular Ca
2+ levels activate 5-LO. Ca
2+ binds 
5-LO in vitro at the enzyme´s C2 domain (2) which is a prerequisite for 
association with membranes (3).  
On the other hand, phosphorylation has a significant impact on cellular 5-
LO activity (4-6). p38 MAPK-regulated MK-2 and –3 phosphorylate 5-LO 
in vitro, that is potently promoted by unsaturated fatty acids (e.g. AA), and a 
strong correlation between such phosphorylation events and 5-LO activity in 
intact cells was found (4, 5, 7). Intriguingly, activation of 5-LO in 
polymorphonuclear leukocytes (PMNL) by cell stress, involving p38 MAPK 
and MKs, is Ca
2+-independent (7).  
5-LO was dose-dependently phosphorylated by active ERK2 in vitro 
(Fig. 1A). In analogy to MK2, 5-LO was only a poor substrate for ERK2 and 
AA increased 5-LO phosphorylation by ERK2 in a dose-dependent fashion 
up to 25-fold (Fig. 1B). Also oleic acid and linoleic acid increased ERK2 
activity towards 5-LO, whereas saturated fatty acids failed to enhance 5-LO 
phosphorylation rates. Therefore, upon cell stimulation, efficient 
phosphorylation may occur only when free AA is provided. 5-LIPOXYGENASE ACTIVATION BY MAPKAPK-2 and ERKs  2
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Figure 1: 5-LO is phosphorylated by MK-2 and ERK2; effects of AA. Protein 
phosphorylation was determined by in vitro kinase assay. (A) Purified recombinant 5-LO (3 
µg) was incubated with the indicated amounts of kinases for 30 min at 30°C. (B) 5-LO was 
incubated with 10 mU kinase together with the indicated amounts of AA. Proteins were 
separated by SDS-PAGE and phosphorylated 5-LO (arrow) was detected by autoradiography 
of the dried gel. 
Addition of exogenous AA to PMNL caused a dose-dependent induction 
of 5-LO activity that was accompanied by activation (phosphorylation) of 
ERK2 and p38 MAPK (Fig. 2A). This AA-induced 5-LO activity was 
partially reduced by U0126, an ERK pathway inhibitor, but also by the p38 
MAPK inhibitor SB203580. Combination of both inhibitors gave additive 
effects, indicating that ERK and p38 MAPK pathways act in conjunction to 
stimulate 5-LO. Importantly, 5-LO activity induced by AA plus Ca
2+-
ionophore (leading to high levels of intracellular Ca
2+ that directly activates 
5-LO) was hardly affected by U0126 and SB203580 (not shown).  
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Figure 2: Activation of p38 MAPK and ERKs correlates with 5-LO activity. Human isolated 
PMNL were incubated with the indicated amounts of AA at 37°C (A) or preincubated with 
SB203580 (10 µM) and/or U0126 (3 µM) and then stimulated with 60µM AA (B). 5-LO 
products were analyzed by HPLC 10 min after addition of AA. ERK and p38 MAPK 
activation was determined 2.5 min after addition of AA by Western blotting using phospho-
specific antibodies against the kinases. 
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The 5-LO sequence reveals putative phosphorylation motifs for MK-2 
(LERQLS; 266-271) as well as for ERK2 (YLSP; 661-664), with Ser271 and 
Ser663 as potential phosphorylation sites. Mutation of these residues to 
alanine leads to 5-LO mutant proteins that were no longer substrates for the 
respective kinases. HeLa cells were transfected with wt or the 5-LO mutants 
and cellular 5-LO activity was determined. Almost identical amounts of 5-
LO products were formed from wt and mutated 5-LO enzymes, when cells 
had been treated with AA plus ionophore, whereas significantly less 5-LO 
products as compared to wt-5-LO were formed, when cells had been 
challenged with AA alone (Fig. 3). Finally, deletion of both phosphorylation 
sites resulted in a even more pronounced reduction of AA-induced 5-LO 
activity. Together it appears that phosphorylation of 5-LO at Ser271 and 
Ser663 is of importance for 5-LO activation at low Ca
2+ levels. In this 
scenario AA may play a pivotal regulatory role on several levels in as much 
as it (1) serves as substrate for 5-LO, (2) activates 5-LO kinases, and (3) may 
promote the phosphorylation of 5-LO by ERKs and MKs. 
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Figure 3: Effects of deletion of 5-LO phosphorylation sites. HeLa cells were transiently 
transfected with wt-5-LO, S271A-5-LO (A), or S663A-5-LO (B), stimulated with 40 µM AA 
with or without 10 µM ionophore A23187 and after 10 min at 37°C, 5-LO products were 
analyzed by HPLC. 
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Phosphorylation- and stimulus-dependent inhibition of 
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ABSTRACT 
Nonredox-type 5-lipoxygenase (5-LO) inhibitors such as ZM230487 or L-739.010 potently 
suppress leukotriene biosynthesis at low cellular peroxide tone. Here, we show that inhibition of 
5-LO product formation by nonredox-type 5-LO inhibitors in human isolated polymorphonuclear 
leukocytes (PMNL) depends on the activation pathway of 5-LO. Thus, compared with 5-LO 
product synthesis induced by the Ca
2+-mobilizing agent ionophore A23187, cell stress-induced 
5-LO product formation involving 5-LO kinase pathways required ~10- to 100-fold higher 
concentrations of ZM230487 or L-739.010 for comparable 5-LO inhibition. No such differences 
were observed for the iron ligand-type 5-LO inhibitor BWA4C or the novel-type 5-LO inhibitors 
hyperforin and 3-O-acetyl-11-keto-boswellic acid. Experiments using purified 5-LO revealed 
that Ca
2+ is no prerequisite for potent enzyme inhibition by ZM230487, and exposure of PMNL 
to the combination of ionophore and cell stress did not restore potent 5-LO suppression. 
Intriguingly, a significant difference in the potency of nonredox-type inhibitors (but not of 
BWA4C) was determined between wild-type 5-LO and the mutant S271A/S663A-5-LO (lacking 
phosphorylation sites for ERK1/2 and MAPKAPK-2) in HeLa cells. Collectively, our data 
suggest that compared with Ca
2+-mediated 5-LO product formation, enzyme activation involving 
5-LO phosphorylation events specifically and strongly alters the susceptibility of 5-LO toward 
nonredox-type inhibitors in intact cells. 
Key words: leukotriene •  polymorphonuclear leukocytes •  inflammation •  MAPK • calcium 
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-Lipoxygenase (5-LO), the key enzyme in the biosynthesis of leukotrienes (LTs), 
metabolizes liberated arachidonic acid (AA) to 5-hydroperoxyeicosatetraenoic acid (5-
HpETE) and subsequently to LTA4, which is further converted to LTB4 or LTC4, 
depending on the enzymes present (1). These bioactive lipids have pivotal functions in the 
pathophysiology of inflammation and allergy (2) but also regulate carcinogenesis and survival of 
various cell types and tissues (3￿6) as well as the metabolism of bone (7, 8). Recently, 5-LO was 
identified as a major gene contributing to atherosclerosis susceptibility in mice (9). 
Enzymatic activity of 5-LO in vitro can be modulated by Ca
2+, ATP, phosphatidylcholine, and 
lipid hydroperoxides (for review, see refs. 10 and 11). In vivo, a rise of intracellular Ca
2+ can 
activate cellular 5-LO, leading to 5-LO redistribution and colocalization with 5-LO-activating 
 protein (FLAP) and cytosolic phospholipase A2 (cPLA2) at the nuclear membrane (12). Such an 
activation of 5-LO can be induced by ligation of specific receptors for naturally occurring 
soluble and particulate stimuli such as N-formyl-methionyl-leucyl-phenylalanine (fMLP), 
platelet-activating factor (PAF), cytokines, immune complexes, and microbes, but also by Ca
2+-
mobilizing agents such as ionophores, as well as by urate or phosphate crystals (13￿18). Besides 
Ca
2+, 5-LO can also be activated via phosphorylation by p38 mitogen-activated protein kinase 
(MAPK)-regulated MAPK-activated protein kinases (MAPKAPKs, MKs) and/or extracellular 
signal-regulated kinases (ERKs) (19￿24). Particularly in isolated human polymorphonuclear 
leukocytes (PMNL), 5-LO product formation was induced by cell stress in a p38 MAPK-
dependent manner, which occurred without elevation of intracellular Ca
2+ levels (22). 
LTB4 is one of the most potent chemoattractants and activators of leukocytes and has been 
shown to be involved in inflammatory processes (2). The cysteinyl-LTs C4, D4, and E4 cause 
bronchoconstriction and mucus secretion and induce plasma exudation, thus it is generally 
accepted that cys-LTs play an important role in asthma (for review, see ref 25). 5-LO inhibitors 
revealed therapeutic value in asthma and some benefit in other inflammatory diseases (11). 
Based on the recently discovered effects of 5-LO metabolites to promote proliferation and 
survival of malignant cells, bone resorption and atherosclerosis, 5-LO inhibitors, may also 
possess potential for prevention and therapy of cancer (4, 26, 27), osteoporosis (28), and vascular 
diseases (9). 
The nonredox-type 5-LO inhibitors, such as ZM230487, are highly potent, orally active 
inhibitors of LT biosynthesis in several ex vivo and in vitro models, capable of significantly 
reducing acute inflammatory responses (29, 30). However, they failed to inhibit more chronic 
inflammatory processes (31, 32), and it was found that elevated peroxide levels decrease the 
potency of ZM230487 (33). Here, we show that the potencies of the nonredox-type 5-LO 
inhibitors ZM230487 and L-739.010 depend on the cell stimulus and the 5-LO activation 
pathway, respectively. Our data suggest that phosphorylation events specifically alter the 
susceptibility of 5-LO toward nonredox-type inhibitors in intact cells. 
MATERIALS AND METHODS 
ZM230487 was a gift from Dr. R. M. McMillan (Zeneca Pharmaceuticals, Macclesfield, UK). 
BWA4C was a generous gift from Dr. L. G. Garland (Wellcome Research Laboratories, 
Beckenham, UK). Hyperforin was kindly provided by Dr. S. S. Chatterjee. We obtained these 
materials from the stated sources: Dulbecco￿s modified Eagle￿s medium (DMEM)  (GibcoBRL, 
Life Technologies, Rockville, MD); fetal calf serum (FCS), bovine insulin, Ca
2+-ionophore 
A23187, arachidonic acid, and bovine glutathione peroxidase-1 (G6137) (Sigma, Deisenhofen, 
Germany); activated (rat, recombinant) ERK2 isoform (Biomol, Plymouth Meeting, PA); 
activated GST-MK2 (Upstate Biotechnology, Lake Placid, NY); BAPTA/AM (Calbiochem, Bad 
Soden, Germany); 2’,7’-dichlorofluorescein diacetate (DCF-DA) (Molecular Probes, Eugene, 
OR); [γ-
32P]ATP (110 TBq/mmol) (Amersham Pharmacia Biotech, Buckinghamshire, UK); 3-O-
acetyl-11-keto-boswellic acid (AKBA) (ChromaDex, Laguna Hills, CA); high-performance 
liquid chromatography (HPLC) solvents (Merck, Darmstadt, Germany); and oligonucleotides 
(Cyber Gene, Huddinge, Sweden). 
 Cells and transient transfections 
Human PMNL were freshly isolated from leukocyte concentrates obtained at St Markus Hospital 
(Frankfurt, Germany). In brief, venous blood was taken from healthy adult donors and subjected 
to centrifugation at 4000g for 20 min at 20￿C for preparation of leukocyte concentrates. PMNL 
were immediately isolated by dextran sedimentation, centrifugation on Nycoprep cushions (PAA 
Laboratories, Linz, Austria), and hypotonic lysis of erythrocytes as described previously. PMNL 
(5￿10
6 cells/ml; purity >96￿97%) were finally resuspended in phosphate-buffered saline (PBS), 
pH 7.4, plus 1 mg/ml glucose (PG buffer) or alternatively in PBS plus 1 mg/ml glucose and 1 
mM CaCl2 (PGC buffer) as indicated. 
HeLa cells were maintained in DMEM, supplemented with 10% FCS, 100 ￿g/ml streptomycin, 
and 100 U/ml penicillin at 37￿C in a 5% CO2 incubator. Plasmid DNA (pcDNA3.1￿5LO, 1 
￿g/ml) was transiently transfected into HeLa cells, using the calcium phosphate method (34), 
cultured for 48 h, and assayed for 5-LO product formation. 
Site-directed mutagenesis 
The codons for Ser-271 and Ser-663 in the plasmid pcDNA3.1￿5LO were mutated using the 
QuikChange kit from Stratagene (Amsterdam, The Netherlands) as previously described (35). 
The mutated DNA was confirmed using the DYEnamic ET Terminator Cycle Sequencing kit 
(Amersham Pharmacia Biotech), followed by analysis on an Applied Biosystem (Foster City, 
CA) PRISM 377 sequencer (performed by KISeq, Core Facilities at Karolinska Institutet). 
Determination of 5-lipoxygenase product formation in intact cells 
For assays of intact cells in the presence of Ca
2+, 5￿10
6 freshly isolated PMNL or 1￿10
6 HeLa 
cells were resuspended in 1 ml PGC buffer. When 5-LO product formation was determined in 
the absence of Ca
2+, PMNL were finally resuspended in 1 ml PG buffer, and 1 mM EDTA or 1 
mM EDTA plus 30 ￿M BAPTA/AM were added. After preincubation with the indicated 
compounds at 37￿C, 5-LO product formation was started by addition of the indicated stimuli 
plus exogenous AA as indicated. After 10 min at 37￿C, the reaction was stopped with 1 ml of 
methanol and 30 ￿l of 1 N HCl, and 200 ng prostaglandin B1 and 500 ￿l of PBS were added. 
Formed 5-LO metabolites were extracted and analyzed by HPLC as previously described (36). 5-
LO product formation is expressed as nanograms of 5-LO products per 10
6 cells, which includes 
LTB4 and its all-trans isomers 5(S),12(S)-di-hydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid 
[5(S),12(S)-DiHETE] and 5(S)-hydro(pero)xy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-
H(p)ETE). 5-HETE and 5-HpETE coelute as one major peak; integration of this peak represents 
both eicosanoids. Cysteinyl LTs (LTC4, D4, and E4) were not detected, and oxidation products of 
LTB4 were not determined. 
Expression and purification of 5-LO from Escherichia coli  
Expression of 5-LO was performed in E. coli JM 109 cells, transfected with pT3￿5LO, and 
purification of 5-LO was performed as described previously (37). In brief, cells were lysed by 
incubation in 50 mM triethanolamine/HCl, pH 8.0, 5 mM EDTA, soybean trypsin inhibitor (60 
￿g/ml), 1 mM phenylmethysulphonyl fluoride, and lysozyme (500 ￿g/ml); homogenized by 
sonication (3￿15 s); and centrifuged at 19,000g for 15 min. Proteins, including 5-LO, were 
 precipitated with 50% saturated ammonium sulfate during stirring on ice for 40 min. The 
precipitate was collected by centrifugation at 16,000g for 25 min, and the pellet was resuspended 
in 20 ml PBS containing 1 mM EDTA and 1 mM PMSF. After centrifugation at 100,000g for 70 
min at 4￿C, the supernatant was applied to an ATP-agarose column (Sigma A2767), and the 
column was eluted as described previously (38). Purified 5-LO was immediately used for in vitro 
phosphorylation and for in vitro activity assay. 
In vitro phosphorylation of 5-LO 
Purified recombinant 5-LO (10 ￿g) was incubated with 50 ￿M oleic acid in the presence of 100 
mU activated MK2 and/or 100 mU activated ERK2 in kinase buffer (25 mM HEPES, pH 7.5, 25 
mM MgCl2, 25 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4, and 100 ￿M ATP). Final 
volume was 100 ￿l, and incubation time was 30 min at 30￿C. Then, 5-LO was immediately used 
for 5-LO activity assay. 
Activity assay of purified 5-LO 
Purified 5-LO (0.5 ￿g in 5 ￿l) was added to 1 ml 5-LO reaction mix (PBS, pH 7.4, 1 mM EDTA, 
1 mM ATP, and 20 ￿g/ml phosphatidylcholine) containing the test compounds. After 5￿10 min 
at 4￿C, 1 mM glutathione (GSH) and 20 mU bovine glutathione peroxidase-1 (GPx-1) were 
added, the samples were prewarmed at 37￿C for 30 s, and the reaction was started by the 
addition of 40 ￿M AA with or without 2 mM CaCl2. After incubation at 37￿C for 10 min, the 
reaction was stopped with 1 ml of methanol, and formed 5-LO metabolites were extracted and 
analyzed by HPLC as described previously. 
In-gel kinase assay 
PMNL (5￿10
7 in 1 ml PGC buffer) were stimulated with 2.5 ￿M ionophore for the indicated 
periods at 37￿C. Incubations were stopped by addition of the same volume of 2￿ sodium dodecyl 
sulfate-polyacrylamide gel electrophoesis (SDS-PAGE) sample loading buffer (SDS-b) and 
heated for 6 min at 95￿C. Total cell lysates corresponding to 0.5￿10
6 PMNL were loaded on 
10% SDS-PAGE gels. A Mini Protean system (Bio-Rad, Hercules, CA) was used, and separation 
gels contained 0.2 mg/ml purified recombinant human 5-LO. After electrophoresis, 5-LO 
phosphorylation by activated kinases was analyzed by in-gel kinase assay as described 
previously (20). 
Determination of cellular peroxide formation 
Measurement of peroxides was conducted using the peroxide-sensitive fluorescence dye DCF-
DA. Freshly isolated PMNL (5￿10
6 in 1 ml PGC buffer) were preincubated with DCF-DA (1 
￿g/ml) for 2 min at 37￿C in a thermally controlled fluorimeter cuvette in a spectrofluorometer 
(Aminco-Bowman series 2) with continuous stirring. The fluorescence emission at 530 nm was 
measured after excitation at 480 nm. The mean (–SE) fluorescence data measured 5 min after 
stimulus addition are expressed as fold increase over unstimulated cells (n=4) (see Table 1). 
 RESULTS 
Inhibition of 5-LO product formation in PMNL by nonredox-type 5-LO inhibitors is 
stimulus-dependent 
Standard test systems for screening and evaluation of 5-LO inhibitors are generally based on 
leukocytes challenged by the nonphysiological stimulus ionophore A23187. We have tested 
different types of potent 5-LO inhibitors for suppression of 5-LO product formation in human 
isolated PMNL, stimulated with either 2.5 ￿M ionophore A23187 (leading to prominent cellular 
Ca
2+ influx) or by cell stress, using sodium arsenite (SA) or hyperosmotic NaCl (300 mM) that 
activates 5-LO in a p38 MAPK/MK-dependent manner. All incubations were performed in the 
presence of 1 mM Ca
2+, and 40 ￿M AA was added as exogenous substrate. Furthermore, cells 
were stimulated with 60 ￿M exogenous AA alone after chelation of extracellular Ca
2+ by EDTA, 
conditions that also activate 5-LO by MAPK-dependent pathways (23, 24, 39). 
A striking difference in 5-LO inhibition by the nonredox-type 5-LO inhibitors (ZM230487 and 
L-739.010) was observed for PMNL stimulated with ionophore compared with cells activated by 
cell stress. ZM230487 (Fig. 1A) and L-739.010 (Fig. 1B) potently suppressed 5-LO product 
formation in ionophore-stimulated PMNL (IC50=20 nM and 10 nM, respectively). However, 10- 
to 100-fold higher concentrations of inhibitors were required for similar 5-LO inhibition when 
product formation was induced by cell stress (SA, hyperosmotic NaCl). Similarly, stimulation of 
PMNL with 60 ￿M AA alone caused a significant shift of the IC50 of ZM230487 and L-739.010 
to higher values (0.4 and 0.8 ￿M, respectively). Interestingly, also for PMNL stimulated by the 
natural ligands fMLP or PAF (in the presence of 40 ￿M AA, respectively), which activate 5-LO 
by Ca
2+ and by phosphorylation events (22, 23), the IC50 values of ZM230487 (≈110 and 180 
nM, respectively) were also significantly higher as compared with ionophore-stimulated PMNL 
(data not shown). 
In contrast, BWA4C, an iron ligand-type 5-LO inhibitor, showed no such differences (Fig. 1C), 
and the IC50 values (≈70￿90 nM) were comparable in cells stimulated with either ionophore or 
cell stress (or 60 ￿M AA alone). Also the potent 5-LO inhibitor hyperforin, acting in a 
noncompetitive fashion (40), as well as the novel-type 5-LO inhibitor AKBA (41) suppressed 5-
LO product synthesis in ionophore- and cell stress-stimulated PMNL with equal potencies (data 
not shown). 
The role of Ca
2+ on 5-LO inhibition by nonredox-type inhibitors 
We addressed the role of Ca
2+ regarding the sensitivity of 5-LO toward nonredox-type inhibitors. 
Extracellular Ca
2+ was removed by 1 mM EDTA, and depletion of extra- and intracellular Ca
2+ 
was achieved by chelation with 1 mM EDTA plus 30 ￿M BAPTA/AM. 5-LO product formation 
was almost not detectable in Ca
2+-depleted PMNL, which had been stimulated with ionophore 
plus AA (3.7–1.7 ng/10
6 cells), whereas prominent product formation was obtained from PMNL 
exposed to SA plus AA (31.1–5.8 ng/10
6 cells; compare  with ref 22). As shown in Figure 2A, 
removal of Ca
2+ further impaired the efficacy of ZM230487 (and L-739.010, data not shown) in 
SA-stimulated PMNL about fivefold, compared with cells receiving Ca
2+. Also, inhibition of 5-
LO product formation induced by 300 mM NaCl required slightly higher inhibitor concentrations 
in the absence of Ca
2+ (data not shown). No such clear differences were seen for BWA4C (Fig. 
 2B). Thus, the presence or absence of Ca
2+ hardly affected the efficacy of the 5-LO iron ligand-
type inhibitor. 
To check whether elevated concentrations of Ca
2+, generated by cell stimulation with ionophore, 
are sufficient for potent inhibition of 5-LO by the nonredox inhibitors, 5-LO inhibition was 
determined in PMNL stimulated with SA added 3 min before ionophore to ensure high 
intracellular Ca
2+ concentrations. As shown in Figure 3, the IC50 value of ZM230487 in such 
incubations was 200 nM, consistent with the IC50 value obtained from cells that received only 
SA. Thus, elevated Ca
2+ is apparently not the reason for the high efficacy of ZM230487 when 
PMNL are stimulated with ionophore. 
The effects of Ca
2+ on 5-LO inhibition in vitro were investigated using purified human 
recombinant 5-LO. For efficient inhibition of 5-LO, low hydroperoxide levels are important (33), 
accordingly, GSH (1 mM) and GPx (20 mU) were included in the assay. ZM230487 was 
equipotent in the presence and in absence of Ca
2+ (Fig. 4), with IC50 values of 60 and 65 nM, 
respectively, which are in the range of those obtained for intact PMNL stimulated with 
ionophore. 
Kinetic analysis of 5-LO product formation and 5-LO kinase activation 
As reported previously, the kinetics of p38 MAPK/5-LO kinase activation correlates to 5-LO 
product formation in PMNL stimulated with SA (compare with ref 22). Notably, exposure of 
PMNL to ionophore also results in the activation of 5-LO kinases (20, 42), which could activate 
5-LO by phosphorylation, similar to SA. However, when the kinetics of 5-LO product formation 
and 5-LO kinase activation were determined in PMNL stimulated with ionophore, a significant 
discrepancy was apparent. 5-LO product formation was half-maximal after 30 s, and after 1 min, 
~80% of maximal 5-LO product formation was achieved (Fig. 5, upper panel). However, 
significant activation of 5-LO kinases (bands at 40 [MK3], 47, and 55 kD [MK2]) occurred first 
after 1 min, and maximal kinase activity was detected after ~2 min (Fig. 5, lower panel). Thus, 
most of the 5-LO products have been formed within a period in which 5-LO kinases were not 
markedly active and 5-LO was not phosphorylated, supporting previous findings that in 
ionophore-stimulated PMNL, 5-LO kinase activity does not primarily contribute to 5-LO 
activation (22￿24, 43). Consequently, 5-LO phosphorylation events should not counteract 
inhibition of ionophore-induced 5-LO activity by nonredox inhibitors. 
The role of peroxides on 5-LO inhibition by nonredox-type inhibitors under cell stress 
conditions 
An increased peroxide tone was found to impair the efficacy of ZM230487 in ionophore-
stimulated PMNL approximately six- to eightfold (33). Therefore, it appeared possible that cell 
stress could impair the efficacy of ZM230487 by increasing the cellular peroxide level. Thus, we 
determined the cellular formation of peroxides in PMNL by using the peroxide-sensitive 
fluoresence dye DCF-DA. Stimulation of PMNL with 10 ￿M SA or with 0.3 M NaCl could not 
significantly enhance the release of peroxides compared with unstimulated PMNL, whereas 
ionophore or phorbol-12-myristate-13-acetate (PMA) (positive controls) strongly augmented the 
peroxide generation (Table 1). Moreover, pretreatment of PMNL for 20 min with 5 mM n-
acetylcysteine (NAC) before cell stress in order to scavenge peroxides caused no change in 5-LO 
 inhibition (Table 2). Thus, an elevated peroxide tone is apparently not the reason for impaired 
efficacy of nonredox 5-LO inhibitors in cell stress-treated PMNL. 
Deletion of putative 5-LO phosphorylation sites increases the efficacy of nonredox-type 
inhibitors 
Previously, we showed that Ser-271 and Ser-663 are phosphorylation sites in 5-LO for MKs and 
ERKs, respectively, and mutation of these residues reduces the capacity of the mutated 5-LO 
enzymes for 5-LO product formation in HeLa cells stimulated with exogenous AA (23, 24). 
Here, we found significant differences between wild-type (wt) and S271A/S663A-5-LO 
regarding the susceptibility toward nonredox-type inhibitors but not toward the iron ligand-type 
5-LO inhibitor BWA4C. After stimulation with 40 ￿M AA, ZM230487 (Fig. 6A) and L-739.010 
(Fig. 6B) suppressed 5-LO product formation with IC50 values of 630 nM and 510 nM, 
respectively, in HeLa cells expressing wt-5-LO (where 5-LO enzyme phosphorylation may 
occur). Mutation of Ser-271 and Ser-663 to alanine, resulted in a protein that gave low product 
formation upon AA stimulation (compare with ref 23). Interestingly, ~6- to 10-fold lower 
concentrations of ZM230487 and L-739.010 were required for inhibition of this 
nonphosphorylatable 5-LO mutant, with IC50 values of 70 nM for ZM230487 and 90 nM for L-
739.010. However, for BWA4C, the IC50 values were practically the same for both wt-5-LO and 
the mutated enzyme (IC50=45 and 50 nM, respectively) (Fig. 6C). 
Effect of in vitro phosphorylation of 5-LO on the sensitivity toward ZM230487 
We examined the susceptibility of purified phosphorylated and nonphosphorylated 5-LO toward 
ZM230487 in vitro. Human recombinant 5-LO was purified and phosphorylated by MK2 and/or 
ERK2 in the presence of 50 ￿M oleic acid (which promotes 5-LO phosphorylation). Then, 5-LO 
product formation was determined in the presence of 1 mM GSH and 20 mU GPx (in order to 
remove hydroperoxides from the incubation mixture). 
In agreement with previous findings (23, 24), enzyme phosphorylation by MK2 or ERK2 (or 
both) did not significantly alter the enzymatic activity of 5-LO in vitro (data not shown). As 
depicted in Figure 7, there was also no significant shift of the IC50 value of ZM230487 for 
phosphorylated 5-LO compared with unphosphorylated enzyme. Therefore, phosphate 
incorporation alone does not protect crude 5-LO catalytic activity against ZM230487 in cell-free 
systems, suggesting that the intact cellular environment or putative cellular constituents might be 
operative. 
DISCUSSION 
Here, we provide evidence that the efficacy of nonredox-type 5-LO inhibitors in isolated human 
PMNL depends on the 5-LO activation pathway. Thus, ~10- to 100-fold higher concentrations of 
ZM230487 or L-739.010 are required for cell stress-induced 5-LO product formation involving 
5-LO kinase pathways, compared with 5-LO product synthesis induced by ionophore, leading to 
a prominent cellular Ca
2+ influx. In contrast, no such discrepancies were observed for the iron 
ligand 5-LO inhibitor BWA4C or the novel-type 5-LO inhibitors hyperforin and AKBA. Studies 
using a mutated 5-LO protein lacking potential phosphorylation sites for 5-LO kinases indicate 
that enzyme phosphorylation might impair the efficacy of nonredox-type inhibitors (but not of 
BWA4C) in intact cells. Our data suggest that compared with Ca
2+-mediated 5-LO activation, 
 cell stress specifically alters the susceptibility of 5-LO in intact cells toward nonredox-type 
inhibitors, putatively involving enzyme phosphorylation events. 
The search for potent orally active and specific 5-LO inhibitors led to the development of 
nonredox-type 5-LO inhibitors such as ZD2138 and its ethyl analog ZM230487, which possess 
high efficacy in several in vitro and ex vivo systems (29, 30, 44). However, significantly higher 
doses were required for the same effects in functional in vivo assays, and ZD2138 failed to 
strongly suppress LT formation at sites of chronic inflammation (see ref 33 and references 
therein). Moreover, 5-LO inhibition by nonredox-type inhibitors was strikingly different in 
(ionophore-stimulated) intact cells compared with purifed 5-LO or crude enzyme in cell 
homogenates (30, 33, 45). Detailed studies showed that ZM230487 and L-739.010 require GPx 
activity for efficient 5-LO inhibition (33). No such redox-dependent effects were observed with 
other types of 5-LO inhibitors (BWA4C or AKBA). 
Activation of cellular 5-LO may occur by at least two different pathways (which may act in 
conjunction): either by elevation of intracellular Ca
2+ (10) or by Ca
2+-independent pathways 
involving ERK- and/or p38 MAPK-mediated 5-LO phosphorylation (20￿24). p38 MAPK is 
activated particularly in response to cell stress as well as after cell exposure to chemotactic 
factors, lipopolysaccharide or inflammatory cytokines, and is considered a pivotal signaling 
kinase in inflammation (46, 47). Also, AA activates p38 MAPK as well as ERKs in PMNL, and 
many priming agents (PMA, GM-CSF) and natural ligands (fMLP, PAF) that enhance or induce 
LT synthesis stimulate the activation of ERKs (see ref 23 and references therein). Thus, 
activation of 5-LO by these kinases might be of relevance for LT synthesis in vivo under 
inflammatory conditions, associated with cell stress (oxidative and osmotic stress, heat shock) or 
with the release of inflammatory cytokines (TNFα, IL-1) or chemotactic factors (fMLP, PAF, or 
C5a). Consequently, such phosphorylation-dependent 5-LO catalysis may be less susceptible 
toward nonredox-type inhibitors, which might explain the reported loss of efficacy of ZM230487 
in chronic inflammatory diseases (see  ref 33 and references therein). 
5-LO product formation induced by the nonphysiological ionophore is mediated by the massive 
influx of Ca
2+ that rapidly activates the enzyme. It appeared possible that elevated Ca
2+ is 
required to give 5-LO a conformation that will lead to the efficient noncompetitive inhibition by 
nonredox-type inhibitors. However, elevation of intracellular Ca
2+ by coaddition of ionophore 
could not improve the efficacy of ZM230487 in SA-treated PMNL (Fig. 3). Moreover, under 
reducing conditions, purified 5-LO showed the same sensitivity toward ZM230487 in vitro in the 
presence or absence of 1 mM Ca
2+ (Fig. 4), suggesting that solely the presence of Ca
2+ cannot 
confer 5-LO highly susceptible to ZM230487. 
Similar as cell stress, treatment of PMNL with ionophore leads to a strong activation of MKs 
which can phosphorylate 5-LO (20). However, ionophore-induced MK activation succeeds the 
rapid Ca
2+-mediated 5-LO product formation, indicating that phosphorylation events are not 
primarily determinants for ionophore-induced 5-LO activation, compare also (20, 22). Thus, 
under these conditions the nonredox-type inhibitors interfere with Ca
2+-stimulated catalysis of 
non-phosphorylated 5-LO. On the other hand, when 5-LO kinases were activated 3 min before 
addition of ionophore, the effect of ZM230487 was reduced (Fig. 3), implying that SA-induced 
phosphorylation events may impair the susceptibility of 5-LO against ZM230487. For fMLP- or 
PAF-induced 5-LO catalysis, both Ca
2+ and phosphorylation seem to contribute (22, 23), and 
 indeed we found reduced efficacy of the nonredox inhibitors under these conditions, similarly as 
for cell stress-induced 5-LO activation. 
Hydroperoxides have been shown to impair the potency of ZM230487 (33). Therefore, elevation 
of the cellular redox tone could be a simple explanation for the impaired efficacy of nonredox-
type inhibitors in PMNL subjected to cell stress. However, exposure of PMNL to SA or 
hyperosmotic NaCl caused no significant generation of peroxides (Table 1), and preincubation of 
PMNL with NAC, a reducing agent that quenches peroxides, did not restore the high potency of 
ZM230487 (Table 2). In this respect, it was found that hyperosmotic NaCl even suppresses the 
agonist-induced release of superoxide from PMNL (48). Therefore, other mechanisms, in 
addition to elevated hydroperoxide tone observed in our previous study (33), may mediate low 
efficacy of nonredox 5-LO inhibitors under cell stress conditions. It is possible that increased 
peroxide tone leads to 5-LO kinase activation (compare with ref 21), thus impairing the effect of 
ZM230487. 
Our transfection experiments with wt-5-LO and the mutated S271A/S663A-5-LO further support 
the hypothesis that in the intact cell, incorporation of phosphate into 5-LO impairs the efficacy of 
nonredox-type inhibitors. Thus, in HeLa cells, the nonphosphorylatable S271A/S663A-5-LO 
mutant was much more sensitive toward the nonredox-type inhibitors as compared with the 
phosphorylatable wt-5-LO. However, in vitro studies using purified enzyme in a cell-free system 
demonstrate that solely phosphate incorporation into 5-LO by MK2 and/or ERK is not sufficient 
to alter the sensitivity of 5-LO toward ZM230487 (Fig. 7). Therefore, the cellular integrity or 
cellular components are needed to mediate effects on 5-LO related to phosphorylation. Along 
these lines, we found in previous studies that in vitro, product formation of phosphorylated and 
unphosphorylated 5-LO was quantitatively the same (23, 24), and there was also no difference in 
the specific catalytic activity between the crude wt and mutated enzymes in which 
phosphorylation sites (S271, S663) have been deleted. Thus, in vitro, phosphorylation does not 
affect enzymatic properties of 5-LO. However, deletion of phosphorylation sites caused 
significant loss of 5-LO product formation in intact HeLa cells stimulated with AA (23, 24), 
supporting the finding that phosphorylation of 5-LO affects catalytic properties of 5-LO in the 
intact cell only. It appears that cellular conditions or components are operative and might act in 
conjunction with the phosphorylated form of 5-LO to stimulate product formation. Indeed, 5-LO 
interacts with several cellular proteins (49, 50), and such interactions might be affected by the 
phosphorylation status of 5-LO. Consequently, it is not surprising that phosphorylation events 
alter 5-LO inhibition by ZM230487 and L-739.010 also solely in intact cells, but not in vitro. 
The precise mode of action of ZM230487 and L-739.010 is unclear. Initially, it was suggested 
that these compounds act in a competitive manner by binding at a fatty acid substrate binding 
pocket distal to the active site of the enzyme. However, in cell-free systems under reducing 
conditions or in intact cells, ZM230487 acts a noncompetitive inhibitor (33). Thus, ZM230487 
may bind to a regulatory domain, probably at a fatty acid (hydroperoxide) binding site, and this 
interference is seemingly essential for the potent (noncompetitive) 5-LO inhibition. 
Phosphorylation of 5-LO by MK2 and by ERK is promoted by unsaturated fatty acids, such as 
AA (23, 24). It is conceivable that phosphate incorporation in close proximity to such a 
regulatory fatty acid (hydroperoxide) binding site allows the enzyme to interfere with a cellular 
protein as outlined previously. Such protein/protein interactions could hamper the interference of 
ZM230487 (and L-739.010) with 5-LO by facilitating the binding or formation of activating 
fatty acid hydroperoxides, which in turn compete with nonredox-type inhibitors at this regulatory 
 site. Such a model would also be compatible with the fact that BWA4C, presumably interacting 
at a distant binding site, does not discriminate between inhibition of wt-5-LO and of 
S271A/S663A-5-LO (Fig. 6) and that its efficacy in PMNL is equal for 5-LO activated by 
phosphorylation using cell stress as the stimulus as for Ca
2+-activated 5-LO using ionophore as 
the agonist (Fig. 1). 
Collectively, our data provide evidence that 5-LO phosphorylation leads to reduced efficacy of 
nonredox-type 5-LO inhibitors in intact cells. These findings could be of relevance for the 
development of 5-LO inhibitors, in particular for the establishment of alternative test systems 
suitable for the screening of LT synthesis inhibitors. An increased 5-LO phosphorylation status, 
associated with inflammation, malignant cell proliferation, increased bone resorption, and 
macrophage activation at atherosclerotic sites, should be taken into account for pharmacological 
targeting of the 5-LO pathway in order to control inflammatory and allergic reactions, cancer, 
osteoporosis, and vascular diseases. 
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 Table 1 
 
Generation of peroxides in PMNL  
 
Stimulus DCF-DA  fluorescence 
(fold increase over 
untreated cells) 
SA (10 µM) 
NaCl (0.3 M) 
Ionophore (2.5 µM) 
PMA (100 nM) 
  1.2 ± 0.1 
  1.1 ± 0.3 
  7.3 ± 0.4 
12.1 ± 1.4 
 
 
 
            Table 2 
 
Effects of N-acetylcysteine (NAC) on 5-LO inhibition by ZM230487  
 
 IC50 value 
(ZM230487) 
(µM) 
Stimulus –NAC  +NAC 
SA (10 µM)  0.35   0.38  
NaCl (0.3 M)  0.6   0.7  
 
 
 
 
            Fig. 1 
 
              
Figure 1. Efficacy of nonredox-type 5-LO inhibitors in PMNL is stimulus-dependent. Freshly isolated PMNL 
(5×10
6 in 1 ml PGC buffer) were preincubated with ZM230487 (A), L-739.010 (B), or BWA4C (C) at the indicated 
concentrations for 15 min at 37°C. SA (10 µM) and NaCl (300 mM) were added 3 min before addition of 40 µM AA; 
ionophore A23187 (2.5 µM) was added together with 40 µM AA. Alternatively, PMNL resuspended in PG buffer 
containing 1 mM EDTA were stimulated with 60 µM AA alone. After 10 min at 37°C, 5-LO products were determined by 
HPLC. Results are given as mean ±SE, n=3–4. The control values (100%) in the absence of inhibitors were 107.2 ± 6.5, 
37.6 ± 5.6, 48.8 ± 7.6, and 48.2 ± 9.8 ng/10
6 cells, stimulated with ionophore, SA, and NaCl (each in the presence of 40 
µM AA) and 60 µM AA alone, respectively. Fig. 2 
 
             
Figure 2. Ca
2+ depletion impairs the efficacy of nonredox-type 5-LO inhibitors in SA-activated PMNL. CaCl2  
(1 mM), EDTA (1 mM), and BAPTA/AM (30 µM) were added to 5×10
6 freshly isolated PMNL in PG buffer as indicated, 
and ZM230487 (A) or BWA4C (B) were added at the indicated concentrations. After 15 min at 37°C,  SA (10 µM) was 
added 3 min before addition of 40 µM AA. Ionophore A23187 (2.5 µM) was added together with AA. After another 10 
min, 5-LO products were determined. Results are given as mean ±SE, n=3. The control values (100%) in the absence of 
inhibitors for cells stimulated with SA were 37.6 ± 5.6, 40.2 ± 2.1, and 31.1 ± 5.8 ng/10
6 cells in the presence of Ca
2+, 
EDTA, and EDTA plus BAPTA/AM, respectively. Fig. 3 
 
                                    
Figure 3. SA counteracts efficient 5-LO inhibition by ZM230487 in ionophore-stimulated PMNL. Freshly isolated 
PMNL (5×10
6 in 1 ml PGC buffer) were preincubated with ZM230487 at the indicated concentrations for 15 min at 37°C. 
Cells were exposed to SA (10 µM) 3 min before addition of 40 µM AA as indicated; 2.5 µM ionophore A23187 was 
added together with AA. After 10 min at 37°C, 5-LO products were determined by HPLC. Results are given as mean ±SE, 
n=3–4. Fig. 4 
 
                          
Figure 4. Ca
2+ has no influence on inhibition of purified 5-LO by ZM230487. Human recombinant 5-LO was 
expressed in Escherichia coli and purified as described in Materials and Methods. Purified 5-LO was added to a 5-LO 
reaction mix containing the indicated amounts of inhibitor. After 5–10 min at 4°C, 1 mM GSH plus 20 mU GPx were 
added, the samples were prewarmed at 37°C for 30 sec, and the 5-LO reaction was started by addition of 40 µM AA in the 
absence or presence of CaCl2 (2 mM). After 10 min at 37°C, 5-LO product formation was determined by HPLC as 
described. Results are given as mean ±SE, n=3. Fig. 5 
 
 
Figure 5. Kinetics of 5-LO product formation and 5-LO kinase activation. Freshly isolated PMNL (5×10
7 in 10 ml 
PGC buffer) were stimulated with 2.5 µM ionophore plus 40 µM AA. After the indicated times at 37°C, aliquots of these 
incubations were terminated by addition of the same volume of ice-cold methanol or SDS-b to stop 5-LO product 
formation or 5-LO kinase activation, respectively. 5-LO products were determined by HPLC. Values are given as mean 
±SE, n=3. 5-LO kinase activation was determined by in-gel kinase assay, using 0.2 mg/ml 5-LO as substrate as described. 
Arrows indicate the positions of MK2 and MK3. Fig. 6 
 
 
Figure 6. Effects of 5-LO inhibitors on 5-LO product formation in HeLa cells transformed with wt-5-LO or 
S271A/S663A-5-LO. HeLa cells were transiently transformed with plasmids pcDNA3.1-5LO or pcDNA3.1-5LO-
S271A/S663A (1 µg/ml growth medium). Cells (1×10
6) were resuspended in 1 ml PGC buffer, and ZM230487 (A), L- 
 739.010 (B), or BWA4C (C) were added at the indicated concentrations. After 15 min at 37°C, cells were stimulated 
with 40 µM AA for another 10 min. 5-LO product formation was determined by HPLC. Results are given as mean ±SE, n=4. Fig. 7 
 
        
Figure 7. Effects of in vitro phosphorylation of 5-LO on the susceptibility toward ZM230487. Human recombinant 
5-LO was expressed in Escherichia coli, purified, and phosphorylated by MK2 and ERK in vitro as described in Materials 
and Methods. Phosphorylated or nonphosphorylated 5-LO (0.5 µg) were added to a 5-LO reaction mix containing the 
indicated amounts of ZM230487. After 3 min at 4°C, 1 mM GSH plus 20 mU GPx were added, the samples were 
prewarmed at 37°C for 30 sec, and the 5-LO reaction was started by addition of 2 mM CaCl2 and 40 µM AA. After 10 
min at 37°C, 5-LO product formation was determined by HPLC as described. Results are given as mean ±SE, n=3. Fig. 8 
 
             
Figure 8. Mechanisms of 5-LO activation and effects on pharmacological inhibition. On cell stimulation, 5-LO can 
be activated by elevation of Ca
2+ or via phosphorylation by members of the MAPK family, depending on the stimulus. 
Nonredox-type inhibitors, such as ZM230487, potently suppress Ca
2+-activated 5-LO (IC50 ≈ 20 nM), whereas 5-LO 
activated by phosphorylation requires much higher inhibitor concentrations (IC50 ≈ 800 nM). Apparently, an unknown 
cellular component is operative to impair the susceptibility of phosphorylated 5-LO against ZM230487. Molecular pharmacological profile of the nonredox-type
5-lipoxygenase inhibitor CJ-13,610
1LutzFischer,
1Dieter Steinhilber & *
,1Oliver Werz
1Institute of Pharmaceutical Chemistry, University of Frankfurt, Marie-Curie-Str. 9, Frankfurt D-60439, Germany
1 5-Lipoxygenase (5-LO) is a crucial enzyme in the synthesis of the bioactive leukotrienes (LTs) from
arachidonic acid (AA), and inhibitors of 5-LO are thought to prevent the untowarded
pathophysiological effects of LTs.
2 In this study, we present the molecular pharmacological profile of the novel nonredox-type 5-LO
inhibitor CJ-13,610that was evaluated in various in vitro assays.
3 In intact human polymorphonuclear leukocytes (PMNL), challenged with the Ca
2þ-ionophore
A23187, CJ-13,610potently suppressed 5-LO product formation with an IC 50¼0.07mM. Supple-
mentation of exogenous AA impaired the efficacy of CJ-13,610, implying a competitive mode of
action.
4 In analogy to ZM230487 and L-739.010, two closely related nonredox-type 5-LO inhibitors, CJ-
13,610up to 30 mM failed to inhibit 5-LO in cell-free assay systems under nonreducing conditions, but
inclusion of peroxidase activity restored the efficacy of CJ-13,610(IC 50¼0.3mM).
5 In contrast to ZM230487 and L-739.010, the potency of CJ-13,610 does not depend on the cell
stimulus or the activation pathway of 5-LO. Thus, 5-LO product formation in PMNL induced by
phosphorylation events was equally suppressed by CJ-13,610as compared to Ca
2þ-mediated 5-LO
activation. In transfected HeLa cells, CJ-13,610only slightly discriminated between phosphorylatable
wild-type 5-LO and a 5-LO mutant that lacks phosphorylation sites.
6 In summary, CJ-13,610may possess considerable potential as a potent orally active nonredox-type
5-LO inhibitor that lacks certain disadvantages of former representatives of this class of 5-LO
inhibitors.
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Introduction
Upon stimulation, certain inflammatory cell types, mainly
granulocytes and monocytes/macrophages, possess the ability
to release leukotrienes (LTs) and related lipid metabolites such
as 5(S)-hydro(pero)xyeicosatetraenoic acid (5-H(P)ETE).
These bioactive lipids are generated by the initial conversion
of arachidonic acid (AA) to 5-HPETE and LTA4 via the
enzyme 5-lipoxygenase (5-LO). The subsequent conversion of
LTA4 by LTA4 hydrolase gives LTB4, whereas metabolism
by LTC4 synthase leads to the cysteinyl-LTs C4,D 4, and E4
(Samuelsson et al., 1987; Funk, 2001). LTB4 is a potent
chemotactic and chemokinetic mediator that activates granu-
locytes (Claesson & Dahlen, 1999) and augments phagocytosis
of macrophages (Mancuso et al., 1998). The cysteinyl-LTs
cause smooth muscle contraction, mucus secretion, plasma
extravasation, vasoconstriction, and recruitment of eosino-
phils (Funk, 2001). Aside of these functions, more recent
studies suggest a role of 5-LO products also in carcinogenesis
and cell survival (Romano & Claria, 2003), in the metabolism
of bone (Chen et al., 1994; Garcia et al., 1996), and finally in
atherosclerotic processes (Mehrabian & Allayee, 2003; Dwyer
et al., 2004). Accordingly, anti-LT therapy is beneficial in
the treatment of asthma and other inflammatory diseases
(Steinhilber, 1999), but may have potential also in the treatment
of pancreatic and prostate cancer (Ghosh & Myers, 1998; Ding
et al., 1999; Romano & Claria, 2003), osteoporosis (Alanko
et al., 1998), and atherosclerosis (Mehrabian & Allayee, 2003;
Dwyer et al., 2004).
5-LO contains a nonheme iron in the active site. In the resting
state of the enzyme the iron is in the ferrous (Fe
2þ)f o r m ,
whereas the ferric (Fe
3þ) form is necessary to enter the catalytic
cycle (for a review see Ra ˚ dmark, 2002). Accordingly, reducing
compounds and iron-ligand inhibitors (such as zileuton, which
is approved for the therapy of asthma in the U.S.) are direct 5-
LO inhibitors acting at the active site iron. Despite their high
potency in vitro, these compounds exhibit only poor bioavail-
ability and only modest selectivity for 5-LO (Steinhilber, 1999).
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www.nature.com/bjpIn search of potent and selective 5-LO inhibitors, nonredox-
type 5-LO inhibitors such as ZD2138 and its ethyl analogue
ZM230487 were identified as highly potent, orally active
inhibitors of LT biosynthesis that specifically and enantio-
selectively interact with 5-LO. Although these compounds
significantly reduced a number of acute inflammatory re-
sponses (McMillan & Walker, 1992; Smith et al., 1995), they
failed to inhibit more chronic inflammatory processes (Nasser
et al., 1994; Turner et al., 1996). It was found that an elevated
peroxide tone decreases the potency of ZM230487 that may
limit the therapeutic value under chronic inflammatory
conditions, connected to increased peroxide levels (Werz
et al., 1998). Moreover, the potency of ZM230487 depends
on the 5-LO activation pathway (Fischer et al., 2003). Thus,
the sensitivity of 5-LO for ZM230487 in polymorphonuclear
leukocytes (PMNL) was about 10- to 100-fold lower for 5-LO
activated by phosphorylation as compared to Ca
2þ-mediated
enzyme activation. Finally, due to poor aqueous solubility and
moderate oral absorption, the compounds exhibit unsatisfac-
tory bioavailability.
Recently, novel ionizable imidazolylphenyl analogues of
ZD2138 with improved solubility and better oral absorption
were developed, with an in vitro activity comparable to that of
ZD2138 (Mano et al., 2003). Structural modification led to
improved pharmacokinetic and toxicological characteristics,
exemplified by CJ-13,454, a practical lead for orally active
nonredox-type 5-LO inhibitors (Mano et al., 2004). In this
study, we evaluated the molecular pharmacology of CJ-13,610,
a recently developed analogue of these imidazolylphenyl
compounds, using various in vitro test systems with relevance
for the in vivo pharmacology.
Methods
Materials
CJ-13,610was provided by Glaxo Smith Kline (Stevenage,
U.K.). The materials and sources were: Dulbecco’s modified
Eagle’s medium (DMEM), GibcoBRL, Life Technologies
(Rockville, MD, U.S.A.); fetal calf serum, bovine insulin,
Ca
2þ-ionophore A23187, arachidonic acid, dithiothreitol
(DTT), glutathione peroxidase (GPx), sodium arsenite (SA),
Sigma (Deisenhofen, Germany); HPLC solvents, Merck
(Darmstadt, Germany); 13(S)-hydroperoxy-9Z,11E-octadeca-
dienoic acid (13(S)-HPODE), Cayman; oligonucleotides,
Cyber Gene (Huddinge, Sweden).
Cell culture, plasmids, and transient transfections
Human PMNL were freshly isolated from leukocyte concen-
trates obtained at St Markus Hospital (Frankfurt, Germany).
In brief, venous blood was taken from healthy adult donors
and subjected to centrifugation at 4000 g for 20min at 201C
for preparation of leukocyte concentrates. PMNL were
promptly isolated by dextran sedimentation, centrifugation
on Nycoprep cushions (PAA Laboratories, Linz, Austria), and
hypotonic lysis of erythrocytes as described previously (Werz
et al., 2002a). PMNL (7.5 10
6 cellsml
 1; purity 496–97%)
were finally resuspended in phosphate-buffered saline pH 7.4
(PBS) plus 1mgml
 1 glucose (PG buffer), or alternatively in
PBS plus 1mgml
 1 glucose and 1mM CaCl2 (PGC buffer) as
indicated.
HeLa cells were maintained in DMEM, supplemented with
10% fetal calf serum and 100mgml
 1 streptomycin and
100Uml
 1 penicillin at 371C in a 5% CO2 incubator. Plasmid
DNA (pcDNA3.1-5LO (Provost et al., 2001) or pcDNA3.1-
5LO-S271A-S663A (Werz et al., 2002b), 10mg each) was
transiently transfected into HeLa cells using the calcium
phosphate method, cultured for 48h, and assayed for 5-LO
product formation as described elsewhere (Fischer et al., 2003).
Expression and purification of 5-LO from Escherichia
coli
Expression of 5-LO was performed in E. coli JM 109 cells,
transfected with pT3-5LO, and purification of 5-LO was
performed as described previously (Fischer et al., 2003). In
brief, cells were lysed by incubation in 50m M triethanolamine/
HCl pH 8.0, 5mM EDTA, soybean trypsin inhibitor
(60mgml
 1), 1mM phenylmethylsulfonyl fluoride (PMSF),
and lysozyme (500mgml
 1), homogenized by sonication
(3 15s) and centrifuged at 19,000 g for 15min. Proteins
including 5-LO were precipitated with 50% saturated ammo-
nium sulfate during stirring on ice for 60min. The precipitate
was collected by centrifugation at 16,000 g for 25min and
the pellet was resuspended in 20ml PBS containing 1m M
EDTA and 1mM PMSF. After centrifugation at 100,000 g
for 70min at 41C, the 100,000 g supernatant was applied to
an ATP-agarose column (Sigma A2767), and the column was
eluted as described previously (Brungs et al., 1995). Partially
purified 5-LO was immediately used for in vitro activity assays.
Determination of 5-LO product formation in intact cells
For assays of intact cells, 7.5 10
6. freshly isolated PMNL or
2 10
6 HeLa cells were finally resuspended in 1ml PGC
buffer. After preincubation with the indicated compounds at
371C, 5-LO product formation was started by the addition of
the indicated stimuli plus exogenous AA as indicated. After
10min at 371C, the reaction was stopped with 1ml of methanol
and 30mlo f1 N HCl, 200ng prostaglandin B1, and 500mlo f
PBS were added. Formed 5-LO metabolites were extracted and
analyzed by HPLC as described (Werz & Steinhilber, 1996).
5-LO product formation is expressed as ng of 5-LO products
per 10
6 cells that includes LTB4 and its all-trans isomers,
5(S),12(S)-di-hydroxy-6,10-trans-8,14-cis-eicosatetraenoic
acid (5(S),12(S)-DiHETE), and 5(S)-hydro(pero)xy-6-trans-
8,11,14-cis-eicosatetraenoic acid (5-H(p)ETE). Cysteinyl LTs
(LTC4,D 4, and E4) were not detected and oxidation products
of LTB4 were not determined.
Determination of 5-LO product formation in cell-free
systems
For the determination of 5-LO activity in cell homogenates,
7.5 10
6 freshly isolated PMNL were resuspended in PBS
containing 1mM EDTA, sonicated (3 10s) at 41C, and 1mM
ATP was added. For determination of the activity of
recombinant isolated 5-LO, partially purified 5-LO (0.5mgi n
5ml) was added to 1ml of a 5-LO reaction mix (PBS, pH 7.4,
1mM EDTA, 25mgml
 1 phosphatidylcholine, 1mM ATP, and
20mgml
 1 g-globulin). Samples of either cell homogenates or
862 L. Fischer et al Pharmacological profile of CJ-13,610
British Journal of Pharmacology vol 142 (5)partially purified 5-LO were supplemented with DTT (1mM),
GSH (1mM), GPx-1 (30mU), and CJ-13,610 as indicated.
After 5–10min at 41C, samples were prewarmed for 30s at
371C and 2mM CaCl2 and AA at the indicated concentrations
were added to start 5-LO product formation. The reaction was
stopped after 10min at 371C by the addition of 1ml ice-cold
methanol and the formed metabolites were analyzed by HPLC
as described for intact cells.
Subcellular localization of 5-LO
Subcellular localization of 5-LO was investigated as described
previously (Werz et al., 2002a). In brief, freshly isolated
PMNL (3 10
7) in 1ml PGC buffer were incubated at 371C
for 10min with the indicated stimuli and chilled on ice.
Nuclear and non-nuclear fractions were obtained after cell
lysis by 0.1% NP-40. Aliquots of these fractions were analyzed
for 5-LO protein by SDS–PAGE and immunoblotting using
anti-5-LO antiserum (AK7, 1551; affinity purified on a 5-LO
column). Proteins were visualized by alkaline phosphatase-
conjugated IgGs (Sigma) using nitroblue tetrazolium and 5-
bromo-4-chloro-3-indolylphosphate (Sigma) as substrates.
Statistics
The program ‘GraphPad PRISM 3.0’ was used for statistical
comparisons. Statistical evaluation of the data was performed
using Student’s t-test for unpaired observations. A P-value of
o0.05 was considered significant.
Results
CJ-13,610 suppresses 5-LO product formation in intact
human PMNL
Replacement of the dihydroquinolinone by an imidazolyl-
phenyl of ZM230487 as well as replacement of the ethoxy group
of the tetrahydro[2H]pyran by a carboxamide moiety led to a
novel series of nonredox-type 5-LO inhibitors (Mano et al.,
2003; 2004), exemplified by CJ-13,610 (Figure 1). Freshly
isolated human PMNL were preincubated with CJ-13,610and
stimulated with 2.5mM ionophore A23187 in the absence or
presence of exogenous AA. As can be seen in Figure 2a, CJ-
13,610dose dependently suppressed 5-LO product formation
in ionophore A23187-stimulated PMNL in the absence of
exogenous AA with an IC50 of about 70n M. Supplementation
of AA impaired the efficacy of CJ-13,610and shifted the IC 50
to higher values. Thus, at 2mM of exogenously added AA, the
IC50 was determined as 280n M and further increase of the
substrate concentration (10or 10 0 mM) caused further impaired
efficacy of CJ-13,610(IC 50 at 100mM AA was approx. 900nM).
As can be seen from the Lineweaver–Burke plot in Figure 2b,
kinetic analysis confirm competitive inhibition of 5-LO by
CJ-13,610in intact PMNL. Moreover, at low AA concentrations,
CJ-13,610completely blocked 5-LO product synthesis,
whereas at 100mM AA, some basal 5-LO activity, even at
100mM CJ-13,610, still remained. Together, these data
indicated that CJ-13,610is a potent inhibitor of 5-LO product
formation in intact cells, apparently acting in a competitive
manner.
Inhibition of 5-LO in cell-free systems by CJ-13,610
requires GPx activity
In a previous study, we found that ZM230487 and L739.010
exhibit only low efficacy in cell-free assay systems, but
replenishment of peroxidase activity by the addition of GPx-
1 plus GSH to purified 5-LO enzyme or by supplementation of
thiols (DTT or GSH) to cell homogenates leads to potent 5-LO
inhibition (Werz et al., 1997; 1998). CJ-13,610was assayed for
5-LO inhibition in whole homogenates of human PMNL. As
can be see from Figure 3a, CJ-13,610(up to 30 mM) failed to
suppress 5-LO under standard assay conditions, regardless
of the AA concentration. However, replenishment of GPx
activity by the addition of 1mM DTT renders CJ-13,610a
potent 5-LO inhibitor. Thus, at 4, 10, and 40mM AA, similar
IC50 values (approx. 280, 320, and 700nM, respectively) were
determined as compared to intact PMNL. Again, as observed
in intact cells, elevation of the AA concentration impairs the
potency of CJ-13,610in homogenates, and kinetic analysis
(Figure 3b) indicate competitive properties of CJ-13,610.
Next, human recombinant 5-LO was expressed in E. coli,
partially purified, and CJ-13,610was tested for enzyme
inhibition under reducing (presence of GPx and GSH) and
nonreducing conditions. In the absence of GPx, 5-LO activity
was not significantly inhibited by CJ-13,610up to 30 mM
(Figure 4). However, inclusion of 30mU GPx-1 and 1m M
GSH caused 5-LO enzyme inhibition with an IC50¼5mM,
when the AA concentration was adjusted to 4mM. In contrast,
at 40mM AA, addition of GPx-1 and GSH could not confer
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Figure 1 Chemical structures of nonredox-type 5-LO inhibitors. In
comparison to ZD2138 or ZM230487, for CJ-13,610 the dihydro-
quinolinone pharmacophore was replaced by a imidazolylphenyl
moiety, the alkoxy group by a carboxamide group, and the methyl
ether was replaced by a sulfide group.
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these experimental settings, AA impairs the potency of CJ-
13,610under reducing conditions in cell-free assay systems.
Exogenous lipid hydroperoxides (LOOH) reduce the
efficacy of CJ-13,610 in intact cells
In intact cells, the level of peroxides is controlled by GPx
isoenzymes (Ursini et al., 1995). Elevation of the cellular
peroxide tone, for example, by exogenous addition of 13(S)-
HPODE or diamide, reduced the potency of ZM230487 and
L-739.010 (Werz et al., 1998). As shown in Figure 5a, the potency
of CJ-13,610in intact PMNL, stimulated with ionophore
A23187 and AA, was considerably impaired when cells had
been pretreated with 13(S)-HPODE. This is visualized by a
shift of the IC50 value of CJ-13,610for untreated cells
(0.55mM) to an about six-fold higher value (3.1mM) in cells
exposed to 3mM 13(S)-HPODE. When the concentration of
13(S)-HPODE was further increased to 10mM, 5-LO inhibition
by CJ-13,610(up to 10 mM) was completely abolished.
Interestingly, in the absence of exogenous AA, 3mM 13(S)-
HPODE led to the same reduced efficacy of CJ-13,610in
PMNL stimulated with ionophore A23187 (IC50¼2.8mM,
Figure 5b). This suggests that LOOH are superior to AA in
competing with CJ-13,610and that AA may have no (or at
least only modest) additional competitive effects on top of
LOOH.
Efficacy of CJ-13,610 in intact cells is stimulus
independent
Recently, we could show that the efficacy of ZM230487 and L-
739.010 is stimulus dependent and that phosphorylation events
5
-
L
O
 
p
r
o
d
u
c
t
 
f
o
r
m
a
t
i
o
n
[
p
e
r
c
e
n
t
a
g
e
 
o
f
 
c
o
n
t
r
o
l
]
0
20
40
60
80
100
A23187 
A23187 + 2 µM AA
A23187 + 10 µM AA
A23187 + 100 µM AA
w/o 0.03 0.1 0.3 1 3 10 30 100
CJ-13,610 [µM]
1/[AA]
0.0 0.1 0.2 0.3 0.4 0.5
1
/
V
0.00
0.05
0.10
0.15
0.20
0.25
0.30
w/o
+ 1 µM CJ-13,610 
a
b
Figure 2 CJ-13,610suppresses 5-LO product formation in intact
human PMNL. (a) Freshly isolated PMNL (7.5 10
6 in 1ml PGC
buffer) were preincubated with CJ-13,610at the indicated concen-
trations for 15min at 371C. Cells were stimulated with ionophore
A23187 (2.5mM) with or without AA at the indicated concentra-
tions. After 10min at 371C, 5-LO products were extracted and
determined by HPLC as described in the Methods section. Results
are given as mean7 s.e., n¼4. (b) Kinetic analysis of 5-LO product
inhibition by 1mM CJ-13,610is given as Lineweaver–Burke plot. The
AA concentrations were 2, 5, 10, and 30mM.
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Figure 3 Inhibition of 5-LO by CJ-13,610in whole-cell homo-
genates of human PMNL. (a) Whole homogenates of human PMNL
were prepared as described, preincubated with the indicated
concentrations of CJ-13,610in the presence or absence of 1m M
DTT for 5–10min on ice. Samples were prewarmed at 371C for 30s,
then AA (4, 10, or 40mM) and 2mM CaCl2 were added. After
another 10min at 371C, 5-LO activity was determined as described
in the Methods section. Results are given as mean7 s.e., n¼3–4. (b)
Kinetic analysis of 5-LO product inhibition by 1mM CJ-13,610is
given as Lineweaver–Burke plot. The AA concentrations were 1, 2,
4, 10, and 20mM.
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inhibitors (Fischer et al., 2003). As shown in Figure 6, the
potency of CJ-13,610in PMNL stimulated with 10 mM SA or
300mM NaCl, which activate 5-LO by phosphorylation events
in a Ca
2þ-independent manner, is comparable to that obtained
in cells challenged by ionophore A23187. Cell stress alone
(in contrast to ionophore) is not capable of providing
sufficient amounts of free AA as 5-LO substrate in intact
cells. Therefore, 20mM AA was included in all experiments
in order to ensure equal substrate availability. The results
demonstrate that the efficacy of CJ-13,610is independent of
the stimulus used to evoke 5-LO activation and product
synthesis, suggesting that 5-LO phosphorylation events have
no major impact on the interference of the compound with the
enzyme.
CJ-13,610 does not inhibit translocation of 5-LO
to the nuclear membrane
Activation of 5-LO in the cell is accompanied by a rapid
translocation of the enzyme to the nuclear membrane, which
may stimulate 5-LO product synthesis (Peters-Golden &
Brock, 2001). We tested if CJ-13,610 could interfere with the
5-LO translocation process. 5-LO protein was assessed in the
nuclear and non-nuclear fraction after subcellular fractiona-
tion of PMNL. As shown in Figure 7, in resting PMNL, 5-LO
was exclusively in the non-nuclear fraction, whereas the
addition of A23187 caused enrichment of 5-LO in the nuclear
fraction and a concomitant loss in the non-nuclear fraction.
Preincubation of PMNL with CJ-13,610did not suppress this
A23187-induced 5-LO translocation.
Effects of CJ-13,610 on 5-LO product synthesis
in transfected HeLa cells
In order to confirm the hypothesis that 5-LO inhibition by CJ-
13,610does not depend on the 5-LO phosphorylation status,
HeLa cells were transiently transfected with phosphorylatable
wild-type 5-LO (WT-5-LO) or with nonphosphorylatable
mutant S271A/S663A-5-LO (lacking the phosphorylation sites
for MKs and extracellular signal-regulated kinase (ERKs),
respectively), preincubated with CJ-13,610, stimulated with
20mM AA (5-LO activation conditions that are based on
enzyme phosphorylation) and 5-LO product formation was
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mix containing the indicated amounts of CJ-13,610, 1mM GSH, and
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determined by HPLC. Results are given as mean7 s.e., n¼3.
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Figure 5 Elevation of the cellular peroxide tone impairs the
potency of CJ-13,610in intact PMNL. Freshly isolated PMNL
(7.5 10
6 in 1ml PGC buffer) were preincubated with CJ-13,610at
the indicated concentrations at 371C. After 15min, 13(S)-HPODE
was added as indicated and cells were subsequently stimulated with
(a) 2.5mM ionophore A23187 plus 10mM AA or with (b) 2.5mM
ionophore A23187 alone. After 10min at 371C, 5-LO products
were extracted and determined by HPLC. Results are given as
mean7 s.e., n¼3.
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significant differences in HeLa cells with respect to 5-LO
inhibition by CJ-13,610(Figure 8). Thus, at low concentra-
tions (1 and 3mM), CJ-13,610significantly increased (up to
1.4-fold) product synthesis of WT-5-LO, and the IC50 value of
CJ-13,610was about 10 -fold higher in HeLa (approx. 7 mM)a s
compared to PMNL. Phosphorylation-mediated 5-LO product
formation (of WT-5-LO) required about two-fold higher
inhibitor concentrations for efficient inhibition as compared
to 5-LO product formation by S271A/S663A-5-LO. Notably,
the nonphosphorylatable enzyme did not exhibit increased
5-LO product synthesis at low inhibitor concentrations.
Discussion
In the present study, we have evaluated the molecular
pharmacology of the novel nonredox-type 5-LO inhibitor
CJ-13,610using various in vitro test systems, relevant for the
in vivo pharmacology. In analogy to ZM230487 or L-739.010,
two structurally related nonredox-type 5-LO inhibitors, CJ-
13,610potently suppressed 5-LO product formation in intact
cells as well as in cell-free assay systems under reducing
conditions, whereas an elevated peroxide tone strongly
impaired the efficacy of CJ-13,610. However, in contrast to
ZM230487 and L-739.010, CJ-13,610 shows competitive
kinetics with respect to AA also under reducing conditions,
and the efficacy of CJ-13,610is cell stimulus independent and
less affected by the phosphorylation status of 5-LO. Therefore,
the pharmacological profile of CJ-13,610is in part distinct
from that of other nonredox 5-LO inhibitors and may possess
therapeutic potential as an orally active 5-LO inhibitor,
lacking certain disadvantages of former representatives of this
inhibitor class. Recently, the efficacy, safety, and tolerability
of 6 weeks treatment by oral dosing with CJ-13,610in adults
with chronic obstructive pulmonary disease was evaluated in
a phase II multicenter, randomized, double-blind placebo-
controlled parallel group study.
Nonredox-type 5-LO inhibitors have been initially designed
as active site-directed inhibitors devoid of redox and iron
ligand properties that compete with AA at a (hypothetical)
substrate binding cleft of 5-LO (McMillan & Walker, 1992).
In fact, biochemical characterization of ZM230487 and L-
739.010 revealed evidence for competitive kinetics with low
affinity under nonreducing conditions, whereas efficient 5-LO
inhibition under reducing conditions showed noncompetitive
kinetics (Werz et al., 1998). It was found that LOOH or an
elevated peroxide tone strongly counteract the high affinity
of nonredox 5-LO inhibitors and efficient inhibition of 5-LO
product formation required low LOOH levels (Werz et al.,
1998). Nevertheless, the precise mode of action and the
binding site(s) of nonredox 5-LO inhibitors have not been
elucidated yet.
In order to initialize 5-LO catalysis, LOOH are important
for the conversion of the active site iron from the ferrous to the
ferric state (Rouzer & Samuelsson, 1986; Hammarberg et al.,
2001). However, no discrete locale where LOOH bind to 5-LO
has been identified. In cell-free systems, CJ-13,610up to the
highest concentration (30mM) tested was unable to suppress
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Figure 6 Cell stress does not affect the efficacy of CJ-13,610in
intact cells. Freshly isolated PMNL (7.5 10
6 in 1ml PGC buffer)
were preincubated with CJ-13,610at the indicated concentrations
for 15min at 371C. SA (10mM) and NaCl (300mM) were added
3min prior to the addition of 20mM AA, ionophore A23187 (2.5mM)
was added together with 20mM AA. After 10min at 371C, 5-LO
products were extracted and determined by HPLC. Results are given
as mean7 s.e., n¼3.
Figure 7 Effects of CJ-13,610on nuclear 5-LO translocation in
intact PMNL. Freshly isolated PMNL (3 10
7 in 1ml PGC buffer)
were preincubated with CJ-13,610at the indicated concentrations
for 15min at 371C. Then, 2.5mM A23187 was added to the samples
and incubated for another 5min at 371C. 5-LO was detected in
nuclear and non-nuclear fractions by immunoblotting after sub-
cellular fractionation. Similar results were obtained in two
additional independent experiments.
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Figure 8 Effects of CJ-13,610on 5-LO product formation in HeLa
cells transformed with WT-5-LO and S271A/S663A-5-LO. HeLa
cells were transiently transformed with plasmids pcDNA3.1-5LO or
pcDNA3.1-5LO-S271A-S663A (10mg). Cells (2 10
6) were resus-
pended in 1ml PGC buffer and CJ-13,610was added at the
indicated concentrations. After 15min at 371C, cells were stimulated
with 20mM AA for another 10min. 5-LO products were extracted
and determined by HPLC. Results are given as mean7 s.e., n¼4.
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of GPx activity. Moreover, in intact PMNL, elevation of the
cellular peroxide tone by exogenous addition of 13(S)-HPODE
abolished the inhibitory effects of CJ-13,610. Thus, in analogy
to ZM230487 or L-739.010 (Werz et al., 1998), also CJ-13,610
requires a low peroxide tone for efficient 5-LO inhibition. Such
a pattern is unique for nonredox-type inhibitors since the
potencies of iron-ligand 5-LO inhibitors (BWA4C) or 5-
lipoxygenase-activating protein (FLAP) inhibitors (MK886)
are not affected by the peroxide tone (Werz et al., 1998).
Apparently, both CJ-13,160as well as ZM230 487 and L-
739.010 compete with activating LOOH at a putative
regulatory LOOH-binding site with high affinity, thereby
preventing 5-LO catalysis.
Experimental data indicate that 5-LO has two distinct fatty
acid-binding sites, one regulatory that may bind LOOH and
one at the catalytic site where transformation of AA takes
place (Sailer et al., 1998; Burkert et al., 2003). In contrast to
ZM230487, the potency of CJ-13,610 under reducing condi-
tions is impaired by AA, suggesting that CJ-13,610may not
only potently interfere with the regulatory LOOH- but also
with the arachidonate(substrate)-binding cleft at the active site.
Interference of CJ-13,610at such a substrate-binding cleft
could be visualized in this study by different experimental
settings: First, in intact PMNL, elevated AA concentrations
clearly impaired the efficacy of CJ-13,610; second, under cell-
free assay conditions elevated AA concentrations significantly
decreased inhibition of crude 5-LO in homogenates supple-
mented with DTT; and third, inhibition of partially purified
5-LO in the presence of GPx and GSH was apparent at 4mM
AA, but not at 40mM AA. This pattern is in sharp contrast to
ZM230487 and L-739.010, whose high affinities under redu-
cing conditions were not altered by variation of the AA
concentration, although competitive kinetics with low affinities
were evident under nonreducing conditions (Werz et al., 1997;
1998). Of interest, LOOH are superior to AA in competing
with CJ-13,610, and AA may have no additional competitive
effects on top of LOOH. Thus, the reduction in the efficacy of
CJ-13,610by 3 mM 13(S)-HPODE was quantitatively almost
the same in PMNL stimulated in the absence or in the presence
of AA. Together, these findings imply that under certain (more
chronic) inflammatory situations, which are associated with
elevated cellular levels of LOOH and free AA, a possibly
reduced efficacy of CJ-13,610should be taken into account. In
this regard, it was shown that ZD2138 failed to protect against
allergen-induced asthmatic responses in asthmatic subjects
(Nasser et al., 1994), and did not prevent pulmonary
inflammation or the development of airway hyper-responsive-
ness (Turner et al., 1996).
It should be noted that the effects of CJ-13,610determined
in HeLa cells differed from that obtained with PMNL. For
example, in HeLa cells, CJ-13,610significantly increased 5-LO
product synthesis at low (o3mM) concentrations, a phenom-
enon that cannot be readily explained. Compared to PMNL,
the IC50 value was about 10-fold higher in HeLa cells at same
substrate concentrations (20mM AA). The reason for this
difference is also not clear. Presumably, the machinery
necessary for 5-LO product formation and the existence of
regulating cofactors (e.g. FLAP, LOOH and Ca
2þ levels, GPx
activity) are different in HeLa cells. For example, it is
conceivable that CJ-13,610could interfere with the fatty
acid-binding FLAP, necessary for efficient 5-LO product
synthesis in intact cells. However, in experiments with HeLa
cells (not expressing FLAP (own unpublished observations)),
transiently transfected with FLAP, CJ-13,610was equipotent
as compared to MOCK-transfected cells (not shown). There-
fore, FLAP should not affect the potency of CJ-13,610,
supported by the finding that CJ-13,610did also not interfere
with 5-LO translocation to the nucleus in PMNL, which may
be FLAP dependent (Peters-Golden & Brock, 2001). Never-
theless, the potency of CJ-13,610may depend on the cellular
environment, that is, the presence of certain 5-LO regulatory
mechanisms or cofactors, which remain to be identified.
Activation of cellular 5-LO in response to external stimuli
involves 5-LO translocation from a soluble locale to the
nuclear membrane where the enzyme colocalizes with FLAP
(Peters-Golden & Brock, 2001), and is mediated by elevation
of the intracellular Ca
2þ levels and/or phosphorylation of 5-
LO by mitogen-activated protein kinase-activated protein
kinase (MAPKAP) kinases at Ser-271 and by ERKs 1/2 at
Ser-663 (Werz et al., 2000; 2002a,b). It was shown that the
activation of 5-LO by stimuli that induce phosphorylation of
5-LO is Ca
2þ-independent in certain cell types (Werz et al.,
2002a; Burkert et al., 2003). The efficacies of the nonredox-
type 5-LO inhibitors ZM230487 and L-739.010 depend on the
stimulus and activation pathway utilized to induce 5-LO
product synthesis (Fischer et al., 2003). Whereas Ca
2þ-
mediated 5-LO activation in PMNL is efficiently suppressed
by ZM230487 and L-739.010, 10- to 100-fold higher inhibitor
concentrations are required to suppress 5-LO product syn-
thesis induced by phosphorylation (Fischer et al., 2003). In
contrast, the efficacy of CJ-13,610in intact PMNL is not
reduced when 5-LO is activated by phosphorylation events.
Also, CJ-13,610exhibited no pronounced difference in the
potencies towards phosphorylatable wt- or nonphosphoryla-
table mutated S217A/S663A-5-LO in HeLa cells. Notably,
several diseases related or connected to elevated levels of 5-LO
products such as inflammatory reactions, allergic asthma,
various types of cancer, and atherosclerosis are associated with
an increased phosphorylation status of the cell (Hajjar &
Pomerantz, 1992; Johnson & Lapadat, 2002), which determine
the susceptibility of 5-LO towards nonredox inhibitors. Owing
to the fact that the efficacy of CJ-13,610does not depend on
the 5-LO phosphorylation status, targeting of 5-LO by such a
drug could indeed be beneficial for the therapy of these
diseases. Although the therapeutic potential of CJ-13,610
may be somewhat limited by reduced efficacy due to an
elevated peroxide tone, the compound obviously possesses
advantages over former representatives of this class of 5-LO
inhibitors that could not attain regular approval due to poor
clinical benefits.
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Here we show that extracts of Boswellia serrata
gum resins and its constituents, the boswellic acids
(BAs), activate the mitogen-activated protein kinases
(MAPK) p42
MAPK and p38 in isolated human polymor-
phonuclear leukocytes (PMNL). MAPK activation was
rapid and transient with maximal activation after
1–2.5 min of exposure and occurred in a dose-
dependent manner. The keto-BAs (11-keto-b-BA and
3-O-acetyl-11-b-keto-BA) gave substantial kinase acti-
vation at 30 mM, whereas other BAs lacking the 11-keto
group were less effective. Moreover, 11-keto-BAs in-
duced rapid and prominent mobilization of free Ca
21
in PMNL. Inhibitor studies revealed that phosphati-
dylinositol 3-kinase (PI 3-K) is involved in BA-induced
MAPK activation, whereas a minor role was apparent
for protein kinase C. MAPK activation by 3-O-acetyl-
11-b-keto-BA was partially inhibited when Ca
21 was
removed by chelation. Our results suggest that 11-
keto-BAs might function as potent activators of PMNL
by stimulation of MAPK and mobilization of intracel-
lular Ca
21. © 2002 Elsevier Science
Key Words: boswellic acids; polymorphonuclear leu-
kocyte; p38 MAPK; p44/42
MAPK;C a
21; phosphatidylino-
sitol 3-kinase; protein kinase C.
Boswellic acids (BAs) are pentacyclic triterpenes
that have been identiﬁed as the active principles of
Frankincense, the gum resin of Boswellia species. BA
derivatives inhibit human leukocyte elastase in vitro
(1) and suppress the biosynthesis of proinﬂammatory
leukotrienes by direct inhibition of leukocyte 5-lipoxy-
genase (2), which could explain the anti-inﬂammatory
properties of Frankincense stated in several experi-
mental animal models and clinical trials, for review see
(3). In addition, BAs inhibit topoisomerases in myeloid
cells and have been shown to induce differentiation
and apoptosis in leukemia cell lines (4–6) as well as
apoptosis in malignant glioma cells (7). However, little
is known about the effects of BAs on biochemical and
cellular signaling pathways in leukocytes.
Transduction of extracellular signals leading to a
diverse array of cellular responses includes the activa-
tion of speciﬁc kinases. The mammalian mitogen-
activated protein kinase (MAPK) superfamily consists
of at least four distinct groups, organized in signaling
modules (MEKK/MEK/MAPK) that transmit extracel-
lular signals by sequential phosphorylation and acti-
vation of the components of a respective cascade: the
extracellular signal-regulated kinases 1 and 2
(ERK1/2, also termed p44/42
MAPK), the p38 MAPKs, the
c-Jun NH2 terminal kinases (JNKs), and the Big
MAPK 1 (also termed ERK5) (8, 9). Although structur-
ally related, these kinases can act on different molec-
ular substrates (transcription factors, protein kinases)
and their actions may lead to distinct and sometimes
opposite biological functions (10). Whereas p44/42
MAPK
are mainly activated in response to mitogenic stimuli,
such as growth factors and G-protein-coupled receptor
agonists, p38 MAPK, JNKs and ERK5 are activated in
response to various forms of cell stress or cytokines (8,
11). The p44/42
MAPK pathway may play a pivotal role in
cell growth, differentiation and cellular transforma-
tion, but also can regulate cellular events, such as
secretion and cell motility (10). In neutrophils, the
p44/42
MAPK pathway has been proposed to play a cer-
tain role in neutrophil functions, in response to appro-
priate external stimuli (12–14). p38 MAPK activation
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acid; AKBA, 3-O-acetyl-11-keto-b-boswellic acid; KBA, 11-keto-b-
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leucyl-phenylalanine; JNK, c-jun NH2-terminal kinase; MAPK,
mitogen-activated protein kinase; MBP, myelin basic protein; MEK,
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ing buffer; WB, Western blotting.
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All rights reserved.results in the production of TNFa and IL-1 and has
been implicated in granulocyte apoptosis, adhesion,
degranulation, chemotaxis and oxidative burst [re-
viewed in (15)]. In this study we addressed the effects
of BAs on various signaling pathways important for
cellular responses of neutrophils, particularly the acti-
vation of MAPK pathways and the mobilization of
Ca
21.
MATERIALS AND METHODS
Materials. Ethanolic extracts of B. serrata were obtained from En-
gelhard Arzneimittel GmbH (Niederdorfelden, Germany); A-b-BA,
b-BA, AKBA, and KBA were purchased from ChromaDex (Laguna
Hills, CA). a-Amyrin and ursolic acid were from Extrasynthe `se (Genay,
France). Activated (rat, recombinant) p42
MAPK isoform was from Biomol;
[g-
32P]ATP (110 TBq/mmol) was purchased from Amersham–
Pharmacia Biotech (Freiburg, Germany). Materials and reagents: Ny-
coprep, PAA Laboratories (Linz, Austria); Ca
21-ionophore A23187,
N-formyl-methionyl-leucyl-phenylalanine (fMLP), and myelin basic
protein (MBP) were from Sigma (Deisenhofen, Germany). BAPTA/AM
and Fura-2/AM were from Calbiochem (Bad Soden, Germany). RO-31-
8425 was from Alexis, Switzerland, and GF109203x and wortmannin,
from Biotrend (Colonia, Germany).
Cells. Human PMNL were freshly isolated from leukocyte con-
centrates obtained at St. Markus Hospital (Frankfurt, Germany). In
brief, venous blood was taken from healthy adult donors and sub-
jected to centrifugation for preparation of leukocyte concentrates.
PMNL were immediately isolated by dextran sedimentation, centrif-
ugation on Nycoprep cushions (PAA Laboratories, Linz, Austria),
and hypotonic lysis of erythrocytes as described previously (16).
PMNL (5 3 10
6 cells/ml; purity . 96–97%) were ﬁnally resuspended
in PBS plus 1 mg/ml glucose (PG buffer), or alternatively in PBS plus
1 mg/ml glucose and 1 mM CaCl2 (PGC buffer) as indicated.
Measurement of intracellular Ca
21 levels. Freshly isolated PMNL
(1 3 10
7 in 1 ml PGC buffer) were incubated with 2 mM Fura-2/AM
for 30 min at 37°C. Cells were washed, resuspended in 1 ml PGC
buffer and transferred into a thermally controlled (37°C) ﬂuorometer
cuvette in a spectroﬂuorometer (Aminco–Bowman Series 2) with
continuous stirring. The ﬂuorescence emission at 510 nm was mea-
sured after excitation at 340 and 380 nm, respectively. Intracellular
Ca
21 levels were calculated according to the method of Grynkiewicz
et al. (17). Fmax (maximal ﬂuorescence) was obtained by lysing the
cells with 1% Triton-X 100 and Fmin by chelating Ca
21 with 10 mM
EDTA.
MAPK activation. Freshly isolated PMNL (5 3 10
6) were resus-
pended in PGC buffer or in PG buffer containing 1 mM EDTA and/or
30 mM BAPTA/AM, ﬁnal volume was 100 ml. After addition of the
indicated stimuli, samples were incubated at 37°C and the reaction
was stopped by addition of 100 ml of ice-cold 23 SDS–PAGE sample
loading buffer [SDS-b: 20 mM Tris/HCl, pH 8, 2 mM EDTA, 5% SDS
(w/v), 10% b-mercaptoethanol], vortexed, and heated for 6 min at
95°C. Twenty microliters of total cell lysates was analyzed for acti-
vated MAPK by SDS–PAGE and Western blotting (WB) or by in-gel
kinase assay.
SDS–PAGE and Western blotting. Total cell lysates (20 ml) were
mixed with 4 ml of glycerol/0.1% bromophenol blue (1:1, v/v) and
analyzed by SDS–PAGE on a 10% gel. After electroblot to nitrocel-
lulose membrane (Amersham–Pharmacia), blocking with 5% nonfat
dry milk for1ha tR T ,membranes were washed and incubated with
primary antibody for overnight at 4°C. Phospho-speciﬁc antibodies
(AB) recognizing p44/42
MAPK (Thr202/Tyr204), p38 MAPK (Thr180/
Tyr182), and JNK (Thr183/Tyr185) were obtained from New En-
gland Biolabs, Inc., and used as 1:2000 dilution. The membranes
were washed and incubated with 1:1000 dilution of alkaline phos-
phatase conjugated IgGs (Sigma) for2ha tR T .After washing,
proteins were visualized with nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolylphosphate (Sigma) in detection buffer (100 mM Tris/
HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl2).
In-gel kinase assay. Total cell lysates of PMNL corresponding to
0.5 3 10
6 cells were analyzed for p42
MAPK activity by in-gel kinase
assay using MBP (0.5 mg/ml) as substrate as described (18). Phos-
phorylated proteins were visualized using a Fuji Phosphorimager
FLA-3000.
RESULTS
Boswellic Acids Activate p38 MAPK and p42
MAPK
in Human Isolated PMNL
Ethanolic extracts of B. serrata resin as well as the
four major pentacyclic triterpenic acids present,
namely b-boswellic acid (b-BA), 3-O-acetyl-b-boswellic
acid (A-b-BA), 11-keto-b-boswellic acid (KBA), and
3-O-acetyl-11-keto-b-boswellic acid (AKBA) (Fig. 1),
were assayed for activation of MAPK in freshly isolated
PMNL from human peripheral blood. Ca
21-ionophore
A23187 was utilized as positive control (18). After stim-
ulation, cells were lysed and total cell lysates were
subjected to WB using phospho-speciﬁc AB against
p44/42
MAPK, p38 MAPK, and JNKs. In addition, MAPK
activities of total cell lysates were assessed by in-gel
kinase assay using MBP as substrate.
As can be seen from Fig. 2A, exposure of PMNL to
crude extracts of B. serrata (0.38 to 13 mg/ml) for 3 min
led to a dose-dependent activation of p42
MAPK and p38
MAPK, whereas p44
MAPK and JNKs (not shown) seemed
not to be activated. Similarly, KBA and AKBA (30 mM
each, corresponding to '3.8 mg/ml B. serrata extracts)
caused activation of p42
MAPK and p38 MAPK 1.5 min
after addition, whereas b-BA and A-b-BA (30 mM for
1.5 min, each) did not activate p42
MAPK and caused only
slight activation of p38 MAPK (Fig. 2B). AKBA also
slightly activated p44
MAPK and was more efﬁcient in
FIG. 1. Structures of boswellic acids and derivatives.
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MAPK activation than KBA. However, KBA was
virtually equally effective as AKBA in activation of
p38 MAPK. The pentacyclic triterpenes a-amyrin and
ursolic acid up to 100 mM gave no MAPK activation
(Fig. 2B).
Activation of p42
MAPK by BAs was conﬁrmed by in-gel
kinase assays. Thus in agreement with the results
from above (Fig. 2A), cell stimulation by extracts of B.
serrata resin (3.8 mg/ml) and by AKBA (30 and 100 mM)
led to prominent kinase activity (Fig. 2C). Kinase ac-
tivities were rather low for cells treated with KBA,
b-BA and A-b-BA (100 mM each, not shown).
The dose responses for MAPK activation by KBA and
AKBA were determined. Both, p42
MAPK and p38 MAPK
became clearly activated in cells treated with 30 mM
AKBA for 1.5 min (Fig. 3A). In contrast, 100 mM KBA
was needed for a clear activation of p42
MAPK. However,
10 to 30 mM KBA gave substantial activation of p38
MAPK (Fig. 3A). Again, for b-BA and A-b-BA (100 mM
each) only weak MAPK activation was obtained (not
shown), indicating that the 11-keto group is a struc-
tural requirement for substantial activation of MAPKs.
Activation of both p42
MAPK and p38 MAPK by BAs was
rapid and occurred within 30 s, peaking around 1 to 2.5
min and declining after about 10 min (Fig. 3B). In this
respect, no appreciable differences between the various
BAs were observed.
Boswellic Acids Induce Ca
21 Mobilization in PMNL
We considered the possibility that BAs could induce
Ca
21 mobilization in PMNL, one of the hallmarks of
PMNL activation in response to various agonists. As
shown in Fig. 4, exposure of freshly isolated PMNL to
AKBA or KBA (30 mM, each) caused a rapid (within 10
to 15 s) and prominent elevation of intracellular Ca
21,
that was comparable to the effect of chemotactic fMLP,
used as a positive control. Thus, intracellular Ca
21
levels of unstimulated cells were about 40–50 nM,
rising to about 240 nM upon stimulation with 1 mM
fMLP. Upon exposure to 10 and 30 mM AKBA, intra-
cellular Ca
21 increased to about 120 and 230 nM, re-
spectively. Similarly, 10 and 30 mM KBA raised intra-
cellular Ca
21 to 105 and 145 nM. In contrast, b-BA,
A-b-BA, a-amyrin or ursolic acid (30 mM each) were
virtually not effective (not shown).
FIG. 3. Dose response and time course of MAPK activation by
AKBA and KBA. (A) Dose response. Freshly isolated PMNL (5 3 10
6
in 100 ml PGC buffer) were stimulated with the indicated amounts of
AKBA or KBA for 1.5 min at 37°C, ionophore A23187 (2.5 mM) was
used as positive control. (B) Time course. Freshly isolated PMNL
(5 3 10
6 in 100 ml PGC buffer) were stimulated with 30 mM AKBA or
100 mM KBA for the indicated times at 37°C. All incubations were
terminated by addition of the same volume of ice-cold SDS-b and
analyzed for dually phosphorylated p38 MAPK or p44/42
MAPK by WB.
FIG. 2. Activation of MAPK by extracts of B. serrata and isolated
BAs. To determine activation of p38 MAPK and p44/42
MAPK, freshly
isolated PMNL (5 3 10
6 in 100 ml PGC buffer) were stimulated with
the indicated amounts of B. serrata extracts (BS-extr) for 3 min at
37°C (A) or with BS-extr., and the compounds indicated in the ﬁgure
(B) for 1.5 min at 37°C. After addition of the same volume of ice-cold
SDS-b, samples were analyzed for dually phosphorylated p38 MAPK
(pp38) or p44/42
MAPK (pp44/42
MAPK) by WB. (C) Samples from above
were assayed for p42
MAPK activity by in-gel kinase assay using MBP
(0.5 mg/ml) as substrate. Puriﬁed recombinant active 42
MAPK (10 mU)
was used as positive control. The position of p42
MAPK (42 kDa) in the
gel is indicated. Results are representative of at least three separate
experiments.
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21, PKC, and PI 3-K in AKBA-Induced
MAPK Activation
We attempted to elucidate the upstream signaling
pathways leading to activation of p38 MAPK and
p42
MAPK induced by AKBA. Activation of MAPK by
various agonists [fMLP, platelet-activating factor
(PAF)] was shown to depend in part on Ca
21. Removal
of extracellular Ca
21 by EDTA and/or depletion of in-
tracellular Ca
21 by cell-permeable BAPTA/AM only
partially suppressed AKBA-induced activation of
p42
MAPK (Fig. 5A). Thus Ca
21 seems to play a minor role
in AKBA-induced MAPK activation.
Next, the involvement of protein kinase C (PKC) and
PI 3-K in MAPK activation was investigated. As de-
picted from Fig. 5B (WB) and C (in-gel kinase assay),
inhibition of PKC by RO-31-8425 (1 mM) slightly atten-
uated activation of p42
MAPK and p38 MAPK induced by
30 mM AKBA, whereas GF109203x (1 mM) rather en-
hanced p42
MAPK activation. Thus particular isoforms of
PKC (affected by RO-31-8425) could be partially in-
volved in activation of p42
MAPK and p38 MAPK. Wort-
mannin, an inhibitor of PI 3-K, was used to determine
a possible participation of PI 3-K in the upstream ac-
tivation of MAPKs. As shown in Figs. 5B and 5C,
wortmannin strongly attenuated p42
MAPK activation
evoked by 30 mM AKBA and reduced p38 MAPK acti-
vation, indicating an involvement of PI 3-K in the
upstream cascades required for AKBA-induced MAPK
signaling. Similar results were obtained when KBA
(100 mM) was used as stimulus (not shown).
DISCUSSION
Here we demonstrate that BAs the major constitu-
ents of extracts of B. serrata gum can stimulate impor-
tant cellular signaling pathways in isolated human
PMNL. Thus, 11-keto-BAs caused substantial activa-
tion of p42
MAPK and p38 MAPK, and induced the mobi-
lization of intracellular Ca
21. Recently, the tetracyclic
triterpene 3-oxo-tirucallic acid was identiﬁed in B. ser-
rata extracts as a component that enhanced 5-LO prod-
uct formation, accompanied with moderate Ca
21 mobi-
lization, and that increased phosphorylation of MEK-
1/2 (19).
Activation of p42
MAPK and p38 MAPK was deter-
mined by WB using speciﬁc AB that detect only the
dually phosphorylated (active) form of the kinases, and
was conﬁrmed by in-gel kinase assays using MBP as
substrate, a suitable method to detect p44/42
MAPK ac-
tivities in PMNL extracts (13). Activation of both
MAPKs by BAs was rapid and transient, and concen-
trations of 10 to 100 mM of AKBA or KBA necessary to
mobilize Ca
21 or to activate MAPKs, are in the range of
the concentrations required for various biological ef-
fects observed by others (1, 4). The presence of the
11-keto-group appears important for the effects of BAs,
since b-BA and A-b-BA were much less efﬁcient than
AKBA or KBA in MAPK activation, and only AKBA
and KBA caused Ca
21 mobilization in PMNL. Notably,
the keto group was also required for efﬁcient inhibition
of agonist-induced leukotriene formation in neutro-
phils (20) and for pronounced inhibitory effects on
DNA, RNA and protein synthesis in HL60 cells (21).
Although no receptors for BAs have been identiﬁed yet,
it is possible that 11-keto-BAs may bind a certain cell
surface receptor transducing the signal to the respec-
tive cellular target(s). The 11-keto group might be a
structural determinant for interaction with such a pu-
tative receptor(s).
The effects of BAs elicited in PMNL in this study re-
semble those evoked by chemotactic factors. Thus, simi-
lar as 11-keto-BAs, fMLP and PAF induced the activation
of p42
MAPK and p38 MAPK [but not of JNKs (22)] and
caused rapid mobilization of intracellular Ca
21 in PMNL
(23–26). The characteristics of fMLP-induced MAPK ac-
tivation, such as the time course, the partial dependence
on Ca
21 as well as on PKC, and the involvement of PI 3-K,
particularly in the activation of 42
MAPK (22, 25, 27, 28), are
conform with those induced by AKBA or KBA. Therefore,
BAs might share signal transduction pathways with
fMLP in PMNL. G-proteins couple the fMLP-receptor
interaction with subsequent biochemical and functional
responses (29) and it was concluded that fMLP-induced
activation of MAPK is a consequence of ligation of the
FIG. 4. BAs induce the mobilization of Ca
21. To Fura-2-loaded PMNL (1 3 10
7/ml PGC buffer) the indicated stimuli were added and the
ﬂuorescence was measured. Intracellular free Ca
21 was calculated as described. The monitored curves show one typical experiment of three
or four.
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that BAs could directly activate G-protein-coupled recep-
tors. Alternatively, BAs might act indirectly by stimula-
tion of mediator release that bind such receptors leading
to activation of MAPK. Future work is necessary to elu-
cidate such mechanisms.
PKC isoforms have been implicated as components
in the signal transduction cascade resulting in activa-
tion of p44/42
MAPK as well as of p38 MAPK in PMNL.
RO-31-8524 only partially inhibited AKBA-induced
MAPK activation, and GF109203x even increased the
effects of AKBA for unknown reasons. Similarly, minor
importance of PKC was proposed in the upstream reg-
ulation of fMLP-induced activation of p44/42
MAPK and
p38 MAPK in neutrophils (28). In PMNL, rapid acti-
vation of the PI 3-K occurs in response to various
agonists like fMLP or arachidonic acid (31), which for
example can regulate chemotaxis (32). It was shown
that in PMNL, PI 3-K is partially involved in agonist-
induced p44/42
MAPK activation (25, 28), but apparently
plays a minor role in the activation of p38 MAPK (28,
33). Wortmannin, a selective inhibitor of PI 3-K, con-
siderably suppressed the AKBA-induced activation of
p42
MAPK and also reduced p38 MAPK activation (Figs.
5B and 5C). Thus, PI 3-K might be an important com-
ponent in the signal transduction of p42
MAPK activation
induced by AKBA.
Rapid elevation of intracellular Ca
21 mediates many
PMNL responses to receptor agonists (34). Ca
21 has
been implicated in the regulation of protein phosphor-
ylation (35), and Ca
21 selective ionophores (ionomycin,
A23187) caused strong activation of p44/42
MAPK and
p38 MAPK in human neutrophils (36, 37). AKBA and
KBA rapidly increased intracellular Ca
21 levels in
PMNL, with comparable time courses and magnitudes
as observed for fMLP (Fig. 4) and this might be the
reason for AKBA-induced MAPK activation, as it was
observed after stimulation with Ca
21 ionophores. In
agreement with the results of Ferby et al. using PAF as
neutrophil agonist (25), depletion of Ca
21 reduced the
magnitude of AKBA-induced MAPK only partially, in-
dicating that alternative mechanisms than elevated
Ca
21 may contribute to MAPK activation by BAs.
In summary we could demonstrate, that extracts of
B. serrata gum and isolated 11-keto-BAs can mobilize
intracellular Ca
21 and stimulate the activation of
p42
MAPK and p38 MAPK in PMNL. Since these pivotal
signaling events regulate numerous effectors of PMNL,
such as superoxide production, phagocytosis of parti-
cles, release of lysosomal enzymes, and the release of
lipid mediators, it remains a future challenge to inves-
tigate whether BAs are capable of stimulating such
PMNL functions.
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2þ mobilisation and MAPK
activation to lipid metabolism and peroxide formation in human
leucocytes
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1 We have previously shown that 11-keto boswellic acids (11-keto-BAs), the active principles of
Boswellia serrata gum resins, activate p38 MAPK and p42/44
MAPK and stimulate Ca
2þ mobilisation in
human polymorphonuclear leucocytes (PMNL).
2 In this study, we attempted to connect the activation of MAPK and mobilisation of Ca
2þ to
functional responses of PMNL, including the formation of reactive oxygen species (ROS), release of
arachidonic acid (AA), and leukotriene (LT) biosynthesis.
3 We found that, in PMNL, 11-keto-BAs stimulate the formation of ROS and cause release of AA as
well as its transformation to LTs via 5-lipoxygenase.
4 Based on inhibitor studies, 11-keto-BA-induced ROS formation is Ca
2þ-dependent and is
mediated by NADPH oxidase involving PI 3-K and p42/44
MAPK signalling pathways. Also, the release
of AA depends on Ca
2þ and p42/44
MAPK, whereas the pathways stimulating 5-LO are not readily
apparent.
5 Pertussis toxin, which inactivates Gi/0 protein subunits, prevents MAPK activation and Ca
2þ
mobilisation induced by 11-keto-BAs, implying the involvement of a Gi/0 protein in BA signalling.
6 Expanding studies on differentiated haematopoietic cell lines (HL60, Mono Mac 6, BL41-E-95-A)
demonstrate that the ability of BAs to activate MAPK and to mobilise Ca
2þ may depend on the cell
type or the differentiation status.
7 In summary, we conclude that BAs act via Gi/0 protein(s) stimulating signalling pathways that
control functional leucocyte responses, in a similar way as chemoattractants, that is, N-formyl-
methionyl-leucyl-phenylalanine or platelet-activating factor.
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phosphatidylinositol 3-kinase; PKC, protein kinase C; PMA, phorbol myristate acetate; PMNL, polymorpho-
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Introduction
Extracts of Boswellia serrata gum resins have been tradition-
ally used as folk medicine to cure inflammatory and arthritic
diseases (Safayhi & Sailer, 1997). It was found that B. serrata
extracts suppress the formation of proinflammatory leuko-
trienes (LTs), and boswellic acids (BAs) were identified as the
active principles targeting 5-lipoxygenase (5-LO), the key
enzyme in LT biosynthesis (Safayhi et al., 1992; 1995). In
addition, human leucocyte elastase was found to be a target for
BAs (Safayhi et al., 1997). Aside of these anti-inflammatory
implications, BAs have been reported to influence the growth
and differentiation of tumour cells. Thus, B. serrata extracts or
isolated BAs induce the apoptosis of brain tumour cell lines
(Glaser et al., 1999), meningioma cells (Park et al., 2002), rat
gliomas (Winking et al., 2000), liver and colon cancer cell lines
(Liu et al., 2002a), and also of leukaemic cells (Hoernlein et al.,
1999). Caspase-8 (Liu et al., 2002a), topoisomerases (Hoern-
lein et al., 1999), and the p42/44
MAPK pathway (Park et al.,
2002) have been suggested as signalling molecules mediating
the apoptotic effects of BAs.
With respect to inhibition of 5-LO, 3-acetyl-11-keto-BA
(AKBA) was the most potent BA, whereas BAs lacking an 11-
keto-group were weak 5-LO inhibitors (Safayhi et al., 1992).
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www.nature.com/bjpThe IC50 values of AKBA for inhibition of 5-LO differ
between different groups and appear to depend also on the cell
type. Thus, the IC50 values were determined in the range of
1.5mM for 5-LO in rat neutrophils (Safayhi et al., 1992) and
12–15mM in differentiated HL60 and MM6 cells, respectively
(Werz et al., 1997). In cell-free systems, the IC50 values of
AKBA for 5-LO inhibition were around 50mM, implying that,
in intact cells, cellular components or mechanisms improve the
efficacy of AKBA (Werz et al., 1997). Finally, low concentra-
tions of ethanolic extracts of B. serrata potentiated 5-LO
product formation in PMNL induced by ionophore (Safayhi
et al., 2000), and 3-oxo-tirucallic acid, isolated from B. serrata
extracts, stimulated 5-LO product synthesis in resting and
agonist-challenged PMNL (Boden et al., 2001). Therefore,
until today, inhibition of 5-LO as the main principle for the
anti-inflammatory effects of B. serrata extracts, determined in
several in vivo models (Gupta et al., 1992; Krieglstein et al.,
2001) and pilot clinical studies (Gerhardt et al., 2001; Gupta
et al., 2001), remains a matter of debate.
Chemotactic agonists, such as platelet-activating factor
(PAF), N-formyl-methionyl-leucyl-phenylalanine (fMLP), or
LTB4, bind to their specific G protein-coupled receptors
(GPCR), leading to the activation of MAPK and the
mobilisation of Ca
2þ, which are pivotal signalling molecules
that regulate a number of functional processes of PMNL,
including chemotaxis, degranulation, formation of reactive
oxygen species (ROS), release of arachidonic acid (AA), and
LT biosynthesis (Herlaar & Brown, 1999; Belcheva & Coscia,
2002; Johnson & Druey, 2002). Recently, we showed that 11-
keto-BAs (AKBA, KBA, in the range of 10–30mM) are potent
activators of p42
MAPK and p38 MAPK, and stimulate Ca
2þ
mobilisation in PMNL (Altmann et al., 2002). Comparison of
these actions of BAs with those of chemotactic agonists led us
to conclude that BAs may possibly function as ligands of a
certain GPCR. In this study, we investigated if BAs are able to
induce the functional cellular responses in PMNL and if a Gi/0-
coupled heterotrimeric G protein mediates BA-induced
MAPK/Ca
2þ signalling. Finally, we demonstrate that BAs
induce signalling responses depending on the cell type.
Methods
Materials
A-b-BA, b-BA, AKBA, and KBA were purchased from
ChromaDex (Laguna Hills, CA, U.S.A.). Nycoprep was from
PAA Laboratories (Linz, Austria); diphenyleneiodonium
chloride (DPI), phorbol 12-myristate 13-acetate (PMA),
Ca
2þ-ionophore A23187, and fMLP were from Sigma
Chemical Co. (Deisenhofen, Germany); BAPTA/AM, LY-
294002, SB203580, U0126, and Fura-2/AM were from
Calbiochem (Bad Soden, Germany); RO-31-8425 was from
Alexis (Gru ¨ nberg, Germany); 20,70-dichlorofluorescein diace-
tate (DCF-DA) and lucigenin were from Molecular Probes
European BV (Leiden, Netherlands); and wortmannin from
Biotrend (Colonia, Germany). RPMI-1640 medium was from
Gibco-BRL (Grand Island, NY, U.S.A.), and fetal calf serum
was obtained from Boehringer Mannheim (Mannheim,
Germany). Human TGF-b1 was purified from outdated
platelets, as described (Werz et al., 1996). Calcitriol was kindly
provided by Dr H. Wiesinger (Schering AG). [
3H]AA was from
Biotrend (Colonia, Germany); and high-performance liquid
chromatography (HPLC) solvents were from Merck (Darm-
stadt, Germany).
Cells
Human PMNL were freshly isolated from leucocyte concen-
trates obtained at St Markus Hospital (Frankfurt, Germany).
In brief, venous blood was taken from healthy adult donors
and subjected to centrifugation for the preparation of
leucocyte concentrates. PMNL were immediately isolated by
dextran sedimentation, centrifugation on Nycoprep cushions,
and hypotonic lysis of erythrocytes, as described (Werz et al.,
2002a). PMNL were finally resuspended in PBS plus 1mgml
 1
glucose (PG buffer), or alternatively in PBS plus 1mgml
 1
glucose and 1mM CaCl2 (PGC buffer), as indicated.
HL60 cells were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum, 100mgml
 1 strepto-
mycin, and 100Uml
 1 penicillin. For differentiation towards
granulocytic cells, cells were seeded at a density of 2 10
5
cellsml
 1 and cultured in the presence of 1.5% (vv
 1)
dimethylsulphoxide, 500pM calcitriol, and 2ngml
 1 TGFb
for 4days.
Mono Mac (MM) 6 cells were cultured and differentiated
with TGFb and calcitriol, as described (Werz et al., 1996).
Determination of release of [
3H]-labelled AA from
PMNL
Freshly isolated PMNL were resuspended at 2 10
6 in 1ml
RPMI 1640 medium containing 4.8nM[
3H]AA (corresponding
to 0.25mCiml
 1, specific activity 200Cimmol
 1) and incu-
bated for 120min at 371Ci n5 %C O 2 atmosphere. Thereafter,
the cells were collected by centrifugation, washed once with
PBS and twice with PBS containing 2mgml
 1 fatty acid-free
albumin, to remove unincorporated [
3H]AA. Labelled PMNL
(5 10
6) were resuspended in 1ml PGC buffer containing
2mgml
 1 fatty acid-free albumin. The reaction was started by
addition of the indicated stimuli. After 5min at 371C, the
samples were placed on ice for 2min and cells were centrifuged
at 400 g for 5min at RT. Aliquots (100ml) of the super-
natants were measured in a beta-counter (Micro Beta Trilux,
Perkin Elmer, Foster City, CA, U.S.A.) to detect the amounts
of [
3H]-labelled AA released into the medium.
Determination of cellular peroxide formation
Measurement of peroxides was conducted using the peroxide-
sensitive fluorescence dye DCF-DA. Freshly isolated PMNL
(1 10
7), HL 60 cells (1 10
7), or MM6 cells (5 10
6) were
resuspended in 1ml PGC buffer and preincubated with DCF-
DA (1mgml
 1 for PMNL and MM6; 10mgml
 1 for HL 60
cells) for 2min at 371C in a thermally controlled (371C)
fluorimeter cuvette in a spectrofluorometer (Aminco-Bowman
series 2, Thermo Spectronic, Rochester, NY, U.S.A.) with
continuous stirring. The fluorescence emission at 530nm was
measured after excitation at 485nm. The mean fluorescence
data measured 5min after stimulus addition are given as
arbitrary units.
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Freshly isolated PMNL (2 10
5) were resuspended in 200mlo f
100mM NaCl, 5mM KCl, 25mM NaHCO3,2 0 m M HEPES,
pH 7.4, and transferred to a 96-well plate. Lucigenin (25mM,
final concentration) and 1mM CaCl2 were added and cells were
stimulated with the indicated stimuli. After stirring, samples
were measured in duplicates at 371C. The chemiluminescence
(CL) was recorded using a Micro Luminat Plus LB 96V
(Berthold, Bad Wildbad, Germany) at intervals of 6s (two
cycles) in a total detection time of 3min. The detected CL was
summarised over two intervals and plotted versus blank values.
Measurement of intracellular Ca
2þ levels
The determination of intracellular Ca
2þ levels was performed
as described previously (Werz, 2002a). In brief, freshly isolated
PMNL (1 10
7), HL 60 cells (1 10
7 buffer), or MM6 cells
(3 10
6) were resuspended in 1ml PGC buffer and incubated
with 2mM Fura-2/AM for 30min at 371C. After washing, cells
were finally resuspended in 1ml PGC buffer and transferred
into a thermally controlled (371C) fluorimeter cuvette in a
spectrofluorometer (Aminco-Bowman series 2, Thermo Spec-
tronic, Rochester, NY, U.S.A.) with continuous stirring. The
fluorescence emission at 510nm was measured after excitation
at 340 and 380nm, respectively. Intracellular Ca
2þ levels were
calculated according to the method of Grynkiewicz et al.
(1985), whereas Fmax (maximal fluorescence) was obtained by
lysing the cells with 0.5% Triton-X 100 and Fmin by chelating
Ca
2þ with 10mM EDTA.
Determination of MAPK activation by SDS–PAGE and
Western blotting
Freshly isolated PMNL, HL60, or MM6 cells (5 10
6 each)
were resuspended in PGC buffer; the final volume was 100ml.
After addition of the indicated stimuli, samples were incubated
at 371C and the reaction was stopped by addition of 100mlo f
ice-cold 2  sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) sample-loading buffer (SDS-b;
20mM Tris/HCl, pH 8, 2mM EDTA, 5% SDS (wv
 1), 10%
b-mercaptoethanol), vortexed and heated for 6min at 951C.
Total cell lysates (20ml) were mixed with 4ml of glycerol/0.1%
bromophenolblue (1:1, vv
 1) and analysed by SDS–PAGE
using a Mini Protean system (Bio-Rad, Hercules, CA, U.S.A.)
on a 10% gel. After electroblot to nitrocellulose membrane
(Amersham Pharmacia, Little Chalfont, U.K.), membranes
were blocked with 5% nonfat dry milk in 50mM Tris/HCl, pH
7.4, and 100mM NaCl (Tris-buffered saline (TBS)) plus 0.1%
Tween 20 for 1h at RT. Membranes were washed and then
incubated with primary antibody (AB) overnight at 41C.
Phospho-specific ABs recognising p44/42
MAPK (Thr202/
Tyr204) and p38 MAPK (Thr180/Tyr182) were obtained from
New England Biolabs (Beverly, MA, U.S.A.), and used as
1:2000 dilution. The membranes were washed and incubated
with 1:1000 dilution of alkaline phosphatase-conjugated
immunoglobulin G (Sigma Chemical Co.) for 2h at RT. After
washing with TBS and TBS plus 0.1% NP-40, proteins were
visualised with nitro blue tetrazolium and 5-bromo-4-chloro-3-
indolylphosphate (Sigma Chemical Co.) in detection buffer
(100mM Tris/HCl, pH 9.5, 100mM NaCl, 5mM MgCl2).
Determination of 5-LO product formation in PMNL
To determine 5-LO product formation in intact cells, 1 10
7
freshly isolated PMNL were finally resuspended in 1ml PG
buffer. When 5-LO product formation was assayed in the
absence of Ca
2þ, PMNL were finally resuspended in 1ml PG
buffer and 1mM EDTA and 30mM BAPTA/AM were added.
The reaction was started by simultaneous addition of
exogenous AA with the indicated BAs. After 10min at 371C,
the reaction was stopped with 1ml of methanol, and 30mlo f
1 N HCl, and 200ng prostaglandin B1 and 500ml of PBS were
added. Formed AA metabolites were extracted using C-18
solid-phase extraction columns and analysed by HPLC as
described (Werz et al., 1997). 5-LO product formation is
expressed as ng of 5-LO products per 10
6 cells, which includes
LTB4 and its all-trans isomers, 5(S),12(S)-di-hydroxy-6,10-
trans-8,14-cis-eicosatetraenoic acid (5(S),12(S)-DiHETE),
5(S)-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-
HETE), and 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosate-
traenoic acid (5-HPETE). 5-HETE and 5-HPETE coelute as
one major peak; integration of this peak represents both
eicosanoids. Cysteinyl LTs (LTC4,D 4, and E4) were not
detected and oxidation products of LTB4 were not determined.
Statistics
The results are presented as mean7s.e. The program
‘GraphPad PRISM 3.0’ was used for statistical comparisons.
Statistical evaluation of the data was performed using Student´s
t-test for unpaired observations. A P-value of o0.05 was
considered significant.
Results
11-Keto-BAs stimulate the release of superoxide anion
and ROS in PMNL
In order to explore the effects of BAs on PMNL, we sought to
determine whether BAs are capable of eliciting functional
processes connected to Ca
2þ mobilisation and MAPK
activation. Phagocytes undergo an oxidative burst in response
to different agonists, resulting in the release of ROS via the
NADPH oxidase. PMNL, preloaded with the ROS-sensitive
dye DCF-DA, were stimulated with BAs (30mM, each) and for
comparison with 1mM fMLP, 2.5mM ionophore A23187, and
100nM PMA. After 5min, ROS formation was determined by
analysing the fluorescence of the oxidised dye. In agreement
with the literature (Roos et al., 1976; Simchowitz & Spilberg,
1979), fMLP, ionophore A23187, or PMA caused a rapid
formation of ROS in PMNL (Figure 1). AKBA and KBA
strongly upregulated the formation of ROS, whereas b-BA and
A-b-BA had only moderate effects (Figure 1). Notably, the
magnitude of AKBA- (or KBA-) induced ROS formation was
much more pronounced as compared to fMLP, being in a close
range of the efficacy of ionophore and PMA. Similar results
were obtained when the formation of superoxide anion (O2
 )
was determined by measuring the chemiluminescence of the
metabolised lucigenin. Thus, stimulation of PMNL with 30mM
AKBA resulted in a 12-fold increase in O2
  formation
compared to unstimulated cells, whereas fMLP (1mM) and
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(not shown).
AKBA-induced ROS formation involves NADPH
oxidase, PI 3-K, and p42/44
MAPK, and requires Ca
2þ
To further dissect the signalling pathways leading to ROS
formation, pharmacological inhibitors of potential signalling
molecules were examined using the DCF-DA fluorescence
assay. PMA, used as a control, binds to PKC isoenzymes,
stimulating NADPH oxidase by multiple phosphorylations of
p47
phox (Heyworth & Badwey, 1990). DPI, a direct inhibitor of
NADPH oxidase (Hancock & Jones, 1987), almost completely
abolished PMA- as well as AKBA-induced ROS formation
(Figure 2a). Also, chelation of Ca
2þ by 30mM BAPTA/AM
and 1mM EDTA clearly reduced AKBA- or PMA-induced
ROS formation (Figure 2a). As shown in Figure 2b, PMA-
induced ROS formation was only slightly affected by
wortmannin (50nM) or LY-294002 (30mM), inhibitors of
phosphatidylinositol 3-kinase (PI 3-K), or by the p38 MAPK
inhibitor SB203580 (10mM). However, U0126 (3mM) that
blocks the activation of p42/44
MAPK partially reduced ROS
generation and the PKC inhibitor RO-318425 (1mM) totally
abolished the effects of PMA. In contrast, AKBA-induced
ROS formation was not at all affected by PKC inhibition (RO-
318425), but was clearly reduced by wortmannin or LY-
294002, and by U0126, implying an involvement of PI 3-K and
p42/44
MAPK, respectively (Figure 2b). Also, for AKBA-
induced ROS formation, a role for p38 MAPK is not
apparent.
11-Keto-boswellic acids cause the release of [
3H]AA from
PMNL
In PMNL, AA is released from phospholipids upon cell
stimulation by the cytosolic PLA2 (cPLA2). Since cPLA2 is
activated by phosphorylation at serine residues by members of
the MAPK family and/or elevation of the intracellular Ca
2þ
levels (Gijon & Leslie, 1999), BAs were tested for their ability
to elevate the liberation of AA from PMNL. AKBA and KBA
considerably enhanced the release of [
3H]-labelled AA, whereas
b-BA and A-b-BA showed only weak effects (Figure 3). Also,
under these experimental settings, AKBA and KBA caused
even more pronounced responses as compared to 1mM fMLP.
The fMLP- as well as the AKBA-induced AA release was
completely abolished when Ca
2þ was removed by chelation
using EDTA and BAPTA/AM (not shown). Experiments
using SB203580 (10mM) and U0126 (3mM), in order to inhibit
p38 MAPK and p42/44
MAPK activities, respectively, were
performed to estimate the importance of these MAPK for
AA liberation. The effect of AKBA was partially suppressed
by U0126 (5374.6%), but was unaffected by SB203580 (not
shown), implying that p42/44
MAPK, but apparently not p38
MAPK, may contribute to the AKBA-induced AA release.
Effects of 11-keto-boswellic acids on cellular 5-LO
product formation in PMNL
In intact cells, 5-LO can be activated upon elevation of the
intracellular Ca
2þ levels and/or phosphorylation by p38
MAPK-regulated MAPKAPKs and p42/44
MAPK (Werz et al.,
2000; 2002a,b). Although 11-keto BAs are direct inhibitors of
5-LO (Safayhi et al., 1992; 1995), we speculated that, due to
their potential to mobilise Ca
2þ and to activate MAPK, BAs
could also stimulate 5-LO in intact cells. As shown in
Figure 1 11-Keto-BAs induce the generation of ROS in PMNL.
Freshly isolated PMNL (5 10
6 in 1ml PGC buffer) were
preincubated with DCF-DA (1mgml
 1) for 2min at 371C, prior
addition of the indicated stimuli. The generation of peroxides was
measured as described. Data determined 5min after addition of
stimuli are expressed as the mean of the fluorescence given in
arbitrary units 7s.e., n¼4. Student’s t-test; **Po0.01.
Figure 2 AKBA-induced ROS formation involves NADPH oxi-
dase, PI 3-K, and p42/44
MAPK, and requires Ca
2þ. PMNL (5 10
6 in
1ml PGC buffer) were preincubated with the indicated compounds
for 20min at RT, prior addition of DCF-DA (1mgml
 1). After
another 2min, AKBA (30mM) or PMA (100nM) were added and the
generation of peroxides was measured as described above. (a) Effects
of DPI and Ca
2þ depletion. Data determined 5min after addition of
stimuli are expressed as the mean of the fluorescence given in
arbitrary units7s.e., n¼3. Student’s t-test; **Po0.01. (b) Effects of
pharmacological protein kinase inhibitors. Data were determined
5min after addition of stimuli and expressed as the percentage of the
mean fluorescence7s.e., n¼4, of control. Student’s t-test; *Po0.05,
**Po0.01. The control values (100%) in the absence of inhibitors
for cells stimulated with AKBA were 425757, and for PMA
6757103 arbitrary fluorescence units.
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with 20mM AA, AKBA and KBA (30mM each) caused 3.8- and
2.4-fold increases in 5-LO product formation versus control
cells that had been stimulated with AA alone, whereas no
upregulatory effects were observed for b-BA and A-b-BA.
Notably, such upregulatory effects of the 11-keto-BAs were
most prominent when Ca
2þ was chelated by EDTA and
BAPTA/AM, whereas, in the presence of Ca
2þ, AKBA
increased 5-LO product formation only by 1.9-fold. Expand-
ing the preincubation period with BAs prior addition of AA
(41min) strongly reduced the effects of BAs (not shown). The
dose–response curve shown in Figure 4b reveals that, at higher
concentrations (100mM), AKBA fails to stimulate 5-LO,
possibly due to direct inhibitory enzyme interaction. In order
to determine if p38 MAPK and/or p42/44
MAPK are required for
AKBA-induced 5-LO activation, PMNL were preincubated
with 3mM U0126 and/or 10mM SB203580 prior stimulation.
Upregulation of 5-LO product formation by AKBA (in the
absence of Ca
2þ) was not significantly suppressed by these
inhibitors (not shown), suggesting that MAPK are not
determinants for AKBA-induced 5-LO activation.
Prolonged exposure of 5-LO to elevated Ca
2þ or oxidants
such as ROS leads to a rapid inactivation of 5-LO (Ford-
Hutchinson et al., 1994). Hence, it appeared possible, that the
potent 5-LO inhibition by AKBA in intact cells after longer
preincubation periods (30min) prior cell stimulation is related
to the prominent Ca
2þ mobilisation and the accompanied
Figure 3 11-Keto-BAs elicit the liberation of AA in PMNL.
Freshly isolated PMNL (2 10
6 in 1ml RPMI 1640 medium) were
prelabelled with 0.25mCiml
 1 [
3H]AA for 120min at 371C and 5%
CO2. After unincorporated [
3H]AA was removed, cells (5 10
6 in
1ml PGC buffer, containing 2mgml
 1 fatty acid-free albumin) were
treated with the indicated additives and incubated for 5min at 371C.
Free (nonesterified) [
3H]AA was determined as described in
Methods. Results are given as mean7s.e. (n¼4). Student’s t-test;
*Po0.05; **Po0.01.
Figure 4 Effects of 11-keto-BAs on the formation of 5-LO
metabolites. (a) Freshly isolated PMNL (5 10
6) were resuspended
in 1ml PG buffer containing 1mM EDTA and preincubated with
30mM BAPTA/AM for 15min. Then, cells were stimulated with
20mM AA alone or together with the indicated BAs (30mM, each).
After 10min at 371C, 5-LO products were determined by HPLC.
Results are given as meanþs.e., n¼4–6. Student’s t-test; **Po0.01.
(b) Dose–response curve of AKBA. PMNL (5 10
6) were resus-
pended in 1ml PG buffer containing 1mM EDTA and preincubated
with 30mM BAPTA/AM for 15min. Then, cells were stimulated with
20mM AA alone or together with the indicated amounts of AKBA.
After 10min at 371C, 5-LO products were determined. Results are
given as meanþs.e., n¼4–5. (c) Inhibition of 5-LO. PMNL
(5 10
6) were resuspended in either 1ml PGC buffer or PG buffer
containing 1mM EDTA and 30mM BAPTA/AM. After 15min at
371C, AKBA was added, and cells were incubated for another
30min at 371C. Then, CaCl2 was adjusted to 1mM in all incubations
and cells were immediately stimulated with 2.5mM ionophore and
40mM AA. After 10min, 5-LO products were determined. Results
are given as meanþs.e., n¼3.
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AKBA in the presence of Ca
2þ, which results in Ca
2þ
mobilisation and ROS formation. Alternatively, Ca
2þ was
removed by 1mM EDTA and 30mM BAPTA/AM during this
preincubation period, conditions where ROS release does not
occur. Subsequently, after preincubation, all samples were
adjusted to 1mM Ca
2þ and cells were immediately stimulated
with ionophore and AA to induce 5-LO product formation in
intact cells. As can be seen from Figure 4c, the efficacy of
AKBA to inhibit 5-LO product formation was strongly
impaired when cells were preincubated in the absence of
Ca
2þ (IC50 approx. 50mM), as compared to conditions when
Ca
2þ was present (IC50 approx. 8mM). Thus, potent 5-LO
inhibitory effects of AKBA in intact cells by may require
Ca
2þ-mediated processes, such as ROS formation.
Pertussis toxin (PTX) attenuates boswellic acid-induced
mobilisation of Ca
2þ and MAPK activation in PMNL
The proximal signalling pathways involved, as well as the
kinetics for Ca
2þ mobilisation and MAPK activation,
resembled those of chemotactic factors, such as fMLP, that
act via G protein-coupled receptors (GPCR). In order to
determine a possible role of Gi or G0 proteins in the AKBA-
induced Ca
2þ release and MAPK activation, the effects of
PTX, an irreversible inhibitor of Gai/0 subunits of hetero-
trimeric G proteins, were assessed in human isolated PMNL.
As shown in Figure 5a, PTX (2mgml
 1) suppressed the Ca
2þ
response induced by 30mM AKBA in a similar fashion as
compared to fMLP stimulation. Similarly, PTX clearly
reduced the activation of p42
MAPK in PMNL, stimulated with
AKBA or KBA, whereas activation of p38 MAPK was only
moderately reduced (Figure 5b). In control experiments
(Table1 and Figure 5b), PTX also partially decreased the
fMLP-induced activation of MAPK and Ca
2þ mobilisation,
whereas MAPK activation (not shown) and Ca
2þ mobilisation
(Table 1) induced by ionomycin (that circumvents G protein
signalling) were not suppressed by PTX.
Moreover, PTX (2mgml
 1) partially inhibited AKBA-
induced ROS formation (21.177.6%), but did not at all affect
ROS production in PMNL stimulated by PMA. On the other
hand, PTX caused only marginal suppression (8.374.1%) of
AKBA-induced 5-LO activity in PMNL.
Cell type-dependent induction of MAPK activation, Ca
2þ
mobilisation and ROS generation by BAs
The effects of BAs on the mobilisation of Ca
2þ, activation of
MAPK and formation of ROS were further investigated in
various haematopoietic cell lines. For monocytic MM6 cells
differentiated with calcitriol and TGFb, none of the four
different BAs (up to 100mM) induced Ca
2þ mobilisation or
activation of MAPK, and also no significant induction of ROS
formation was observed (not shown). In control experiments,
PAF, LTB4 or fMLP caused pronounced elevation of
intracellular Ca
2þ, demonstrating that G protein-coupled
Ca
2þ mobilisation is operative in these cells. Similarly, BAs
also failed to activate the B-lymphocytic cell line BL41-E-95-A
in this respect (not shown).
In contrast, the effects of BAs in differentiated granulocytic
HL60 cells resembled those observed in PMNL from human
blood. Thus, AKBA considerably induced mobilisation of
Ca
2þ, stimulated activation of p38 MAPK and p42
MAPK, and
upregulated the formation of ROS (Figure 6). Interestingly,
KBA was less effective, whereas b-BA and A-b-BA also
stimulated HL60 cells for MAPK activation and release of
ROS. Nevertheless, b-BA and A-b-BA failed to substantially
mobilise Ca
2þ in differentiated HL60 cells. It should be noted
Figure 5 PTX suppresses Ca
2þ mobilisation and activation of
MAPK in PMNL induced by boswellic acids. (a) Ca
2þ mobilisation.
Freshly isolated PMNL (1710
7ml
 1 PGC buffer) were loaded with
2mM Fura-2 for 30min at 371C. Then, cells were preincubated with
or without 2mgml
 1 PTX for 60min at 371C. After addition of
30mM AKBA, the fluorescence was measured and intracellular free
Ca
2þ was calculated as described. The monitored curves show one
typical experiment out of four. (b) MAPK activation. Freshly
isolated PMNL (5 10
6 in 100ml PGC buffer) were preincubated
with or without 2mgml
 1 PTX for 60min at 371C and then
stimulated with 30mM AKBA, 30mM KBA, 1mM fMLP, or left
untreated. After 1.5min at 371C, incubations were terminated by
addition of the same volume of ice-cold SDS-b. Samples were
electrophoresed and analysed for dually phosphorylated p38 MAPK
or p44/42
MAPK by Western blotting.
Table 1 Effects of PTX on Ca
2+ mobilisation
Stimulus Ca
2+ mobilisation (percentage of control)
Ionomycin (2.5mM) 94.178.3
fMLP (100nM) 39.679.7
AKBA (30mM) 43.8716.8
Freshly isolated PMNL (1 10
7ml
 1 PGC buffer) were
loaded with 2mM Fura-2 for 30min at 371C. Then, cells were
preincubated with or without 2mgml
 1 PTX for 60min at
371C. After addition of the indicated stimuli, the fluorescence
was measured and intracellular free Ca
2+ was calculated as
described. Values (mean7s.e., n¼4) are given as the
percentage of Ca
2+ mobilisation of PTX-treated cells versus
control cells that received no PTX.
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nor to the other BAs (not shown), implying that a certain
signalling component(s), induced during differentiation, is
required to transduce the effects of BAs.
Discussion
We have recently reported that 11-keto-BAs potently stimulate
the elevation of intracellular Ca
2þ levels and activate p38
MAPK as well as p42
MAPK (Altmann et al., 2002), which are
pivotal signalling events that regulate numerous effectors of
PMNL. In the present study, we show that 11-keto-BAs in fact
elicit functional responses of PMNL or granulocytic HL60
cells such as ROS generation, increased liberation of AA, and
its subsequent metabolism by 5-LO. Investigation of the
signalling molecules involved and comparison of the kinetics
with those of chemotactic ligands for leukocytes, that is,
fMLP, PAF or LTB4, led us to conclude that 11-keto-BAs may
transduce their signals in a common way as chemotactic
ligands that involve GPCR signalling (see Altmann et al.
(2002) and references therein). Since elevated levels of AA and
ROS are critical inducers of caspase-mediated apoptosis
(Hampton et al., 1998; Taketo & Sonoshita, 2002), our
findings may also provide a molecular basis for the 11-keto-
BA-induced caspase activation (Liu et al., 2002a,b) and the
apoptotic effects observed in various cancer cell lines (Shao
et al., 1998; Glaser et al., 1999; Hoernlein et al., 1999; Jing
et al., 1999; Liu et al., 2002a,b).
O2
  is the precursor of ROS, which are essential for the host
defence against microorganisms. The NADPH oxidase of
leucocytes is the major source of O2
  released upon agonist
challenge (Chanock et al., 1994). Activation of NADPH
oxidase requires the presence of Ca
2þ and multiple phospho-
rylations of the subunit p47
phox by certain PKC isoenzymes or
other kinases (Heyworth & Badwey, 1990; Chanock et al.,
1994; Dewas et al., 2000). We demonstrate that, according to
their ability to stimulate Ca
2þ mobilisation and MAPK
activation (compare Altmann et al., 2002), 11-keto-BAs, but
not BAs lacking the 11-keto group, induced a rapid and robust
formation of O2
  and of ROS in PMNL, as determined by
lucigenin chemiluminescence and the oxidation of DCF-DA,
respectively. Since the NADPH oxidase inhibitor DPI (Han-
cock & Jones, 1987) abolished ROS formation, ROS derived
from the NADPH oxidase system may indeed be responsible.
Pharmacological targeting of the proximal signalling pathways
revealed that AKBA-induced ROS formation seemingly
depends on PI 3-K and on the p42/44
MAPK pathway, but does
not require p38 MAPK or PKC. In this context, it is interesting
that the fMLP-induced phosphorylation of the p47
phox
component in neutrophils was suppressed by inhibition of
p42
MAPK (Dewas et al., 2000) and PI 3-K (Ding et al., 1995),
but not when p38 MAPK was blocked by SB203580 (Dewas
et al., 2000). In contrast, our control experiments utilising PMA
as a direct activator of PKC confirm the findings by others,
showing that PKC, and to a minor extent also p42
MAPK,a r e
required for NADPH oxidase-dependent ROS formation (Cox
et al., 1985; Heyworth & Badwey, 1990; Dewas et al., 2000),
whereas a role of PI 3-K or p38 MAPK is not readily apparent.
Notably, Ca
2þ signalling pathways are determinants for ROS
formation, since chelation of Ca
2þ strongly suppressed the
signals induced by AKBA and also by PMA. Together, 11-keto
BAs may stimulate ROS formation by mobilisation of Ca
2þ
and by activation of p42/44
MAPK, apparently involving PI 3-K.
The release of free AA by leukocytes is an important step in
the onset of inflammatory reactions and the cPLA2, which is
regulated by Ca
2þ and phosphorylation by MAPK, appears to
play a major role for AA liberation in PMNL (Gijon & Leslie,
1999). 11-keto BAs, but not b-BA and A-b-BA, induced the
release of considerable amounts of AA, with a similar efficacy
as fMLP. The doses of the respective BAs were somewhat
higher than those needed for the formation of ROS, which
might be due to the fact that cPLA2 favours a sustained Ca
2þ
influx (Qiu et al., 1998), which in turn requires higher
Figure 6 Effects of BAs on Ca
2þ release, MAPK activation, and
ROS production in granulocytic HL60 cells. HL60 cells were
differentiated towards granulocytic cells in the presence of 1.5%
DMSO, 2ngml
 1 TGFb, and 500pM calcitriol for 4days. (a)
Mobilisation of Ca
2þ. Cells (10
7ml
 1 PGC buffer) were loaded with
2mM Fura-2 for 30min at 371C. After addition of BAs (50mM, each)
or 1mM fMLP, the fluorescence was measured and intracellular free
Ca
2þ was calculated as described. The monitored curves show one
typical experiment out of 4–5, respectively. (b) MAPK activation.
Cells (5 106/100ml PGC buffer) were stimulated with 30mM of
BAs, 1mM fMLP, or left untreated. After 1.5min at 371C,
incubations were terminated by addition of the same volume of
ice-cold SDS-b. Samples were electrophoresed and analysed for
dually phosphorylated p38 MAPK or p44/42
MAPK by Western
blotting. (c) ROS formation. Cells (5 10
7ml
 1 PGC buffer) were
preincubated with DCF-DA (10mgml
 1) for 2min at 371C prior
addition of the indicated stimuli. The generation of peroxides was
measured as described. Data determined 5min after addition of
stimuli are expressed as the mean of the fluorescence given in
arbitrary units7s.e., n¼4. Student’s t-test; *Po0.05; **Po0.01.
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In agreement with findings reported for ligands acting via
GPCR (Qiu et al., 1998), AKBA-induced AA liberation also
depended on Ca
2þ and p42/44
MAPK.
Although BAs have been initially reported as direct-type
inhibitors of the 5-LO enzyme, without reducing or iron-
chelating properties (Safayhi et al., 1992; 1995), we demon-
strate that AKBA can paradoxically stimulate cellular 5-LO,
when added to PMNL concomitantly with AA. Also, it was
reported that low concentrations of B. serrata extracts
enhanced ionophore-stimulated 5-LO product synthesis in
PMNL (Safayhi et al., 2000), and 3-oxo-tirucallic acid, that
acts as a direct 5-LO inhibitor in cell-free systems, induced and
upregulated 5-LO activity in human neutrophils (Boden et al.,
2001). In intact cells, mobilisation of Ca
2þ, and also
phosphorylation by MAPKAPKs and by p42/44
MAPK, acti-
vates 5-LO for product formation (Werz et al., 2000; 2002a,b).
Interestingly, AKBA-induced 5-LO activation was most
prominent in the absence of Ca
2þ, and was not sensitive to
MAPK inhibitors and hardly sensitive to PTX. Thus,
additional unknown factors or pathways induced by AKBA
seem operative, which still remain to be determined.
A discrepancy in the efficacy of AKBA is evident for
suppression of 5-LO in intact cells (IC50E2–5mM) and cell-free
systems (IC50E15–50mM) (Safayhi et al., 1995; Werz et al.,
1997; 1998). Thus, in intact cells, additional factors are
operative for the suppression of 5-LO. Since prolonged
exposure to elevated Ca
2þ or oxidants rapidly inactivates
5-LO (Ford-Hutchinson et al., 1994), it appeared possible that
the potent 5-LO inhibition by AKBA in intact cells is related
to the prominent ROS release occurring during preincubation
periods (15–30min) prior cell stimulation. In fact, Ca
2þ
depletion, that prevents ROS formation, impaired the efficacy
of AKBA in intact cells (Figure 4c), and the respective IC50
value fits well with those obtained in cell-free systems (Werz
et al., 1998). Intriguingly, the efficacy of AKBA for suppres-
sion of 5-LO in MM6 cells (IC50E15mM), that are unable to
mobilise Ca
2þ and to produce ROS in response to AKBA, is
significantly reduced as compared to PMNL (IC50E2–5mM).
Upon ligation of their specific GPCR, chemoattractants
elicit various functional responses of different leucocytes
involving Ca
2þ mobilisation and activation of MAPK
(Herlaar & Brown, 1999; Belcheva & Coscia, 2002). The
putative BA receptor, operative in PMNL and mature HL60
cells, seems to be induced during differentiation towards
granulocytic cells, since undifferentiated HL60 cells did not
respond to BAs with Ca
2þ mobilisation, MAPK activation or
ROS formation. Along these lines, it was found that, in HL60
cells, the G protein-coupled fMLP receptor is also first induced
after differentiation (Perez et al., 1992). Nevertheless, differ-
entiated monocytic MM6 cells apparently do not possess any
BA-inducible signalling pathways or BA receptor(s), although
these cells respond to diverse ligands of GPCR (fMLP, LTB4
or PAF), implying intact G protein signalling pathways in
differentiated MM6 cells. Intriguingly, differentiated MM6
cells also failed to mobilise Ca
2þ in response to 5(S)-HETE or
5-oxo-ETE, which on the other side caused significant Ca
2þ
mobilisation in PMNL (unpublished observations). Accord-
ingly, even the expression of the putative G protein coupled 5-
oxo-ETE receptor was found to be cell type-dependent
(O’Flaherty et al., 2000). Thus, we conclude that the expression
of the target (–receptor) of AKBA may be restricted to certain
cell types. Finally, it should be noted that, in contrast to
PMNL, in differentiated HL60 cells also b-BA and A-b-BA
caused cell stimulation (Figure 6a and b), suggesting that, at
least in HL60 cells, putative receptor subtypes (not present in
PMNL) may exist that accept BAs lacking the 11-keto group.
Our experiments using PTX suggest that a Gi/0-subunit of a
heterotrimeric G protein mediates the effects of 11-keto-BAs in
PMNL. Remarkably, the activation of p38 MAPK and of 5-
LO was less affected by PTX, implying that, for example,
PTX-insensitive Gq subunits, as in the case of the PAF
receptor (Shimizu et al., 1996), are involved. Also, the PI 3-K
inhibitor wortmannin differentially suppressed the activation
of p38 MAPK and p42
MAPK induced by AKBA (Altmann
et al., 2002). It is yet unclear whether 11-keto-BAs act via a
GPCR or alternatively interfere directly with a G protein.
Notably, modulation of G proteins by low molecular weight
compounds in the absence of a GPCR, both in a positive or a
negative way, has been described (see Breitweg-Lehmann et al.
(2002) and references therein).
The data presented here imply that BAs, at least in
concentrations X10mM, are potent immunocompetent agents
that might be regarded as proinflammatory stimuli. By
contrast, cellular and pilot clinical studies indicate the anti-
inflammatory effects of B. serrata extracts and BAs (Gupta
et al., 1992; 2001; Gerhardt et al., 2001; Krieglstein et al.,
2001). It is conceivable that, at low concentrations, BAs may
have antagonistic activity within certain signalling pathways
induced by a second stimulus. In fact, at low concentrations,
AKBA (2–8mM) inhibited the activation of p42/44
MAPK in
meningioma cells stimulated with platelet-derived growth
factor (Park et al., 2002), and, in our hands, BAs (0.3–1mM)
significantly suppressed the PAF-induced Ca
2þ mobilisation
in platelets (unpublished results). Further studies are required
to identify the receptor(s) of BAs and the defined mechanisms
leading to Ca
2þ and MAPK signalling, and to reveal if BAs
can act as partial agonists at receptors relevant for inflamma-
tory processes. Such knowledge may help to unravel the
molecular mechanisms of the anti-inflammatory actions of
BAs, and may provide new concepts for the pharmacological
intervention with inflammatory diseases.
We thank Astrid Neu and Sven George for expert technical
assistance. This study was supported by grants from the Fonds der
Chemischen Industrie, the EU (LEUCHRON, QLRT-2000-01521),
and the Deutsche Pharmazeutische Gesellschaft.
References
ALTMANN, A., FISCHER, L., SCHUBERT-ZSILAVECZ, M.,
STEINHILBER, D. & WERZ, O. (2002). Boswellic acids activate
p42(MAPK) and p38 MAPK and stimulate Ca(2+) mobilization.
Biochem. Biophys. Res. Commun., 290, 185–190.
BELCHEVA, M.M. & COSCIA, C.J. (2002). Diversity of G protein-
coupled receptor signaling pathways to ERK/MAP kinase. Neuro-
signals, 11, 34–44.
230 A. Altmann et al Activation of leucocytes by boswellic acids
British Journal of Pharmacology vol 141 (2)BODEN, S.E., SCHWEIZER, S., BERTSCHE, T., DUFER, M., DREWS,
G. & SAFAYHI, H. (2001). Stimulation of leukotriene synthesis in
intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-
oxo-tirucallic acid. Mol. Pharmacol., 60, 267–273.
BREITWEG-LEHMANN, E., CZUPALLA, C., STORM, R., KUDLACEK,
O., SCHUNACK, W., FREISSMUTH, M. & NURNBERG, B. (2002).
Activation and inhibition of G proteins by lipoamines. Mol.
Pharmacol., 61, 628–636.
CHANOCK, S.J., EL BENNA, J., SMITH, R.M. & BABIOR, B.M. (1994).
The respiratory burst oxidase. J. Biol. Chem., 269, 24519–24522.
COX, J.A., JENG, A.Y., SHARKEY, N.A., BLUMBERG, P.M. &
TAUBER, A.I. (1985). Activation of the human neutrophil
nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase
by protein kinase C. J. Clin. Invest., 76, 1932–1938.
DEWAS, C., FAY, M., GOUGEROT-POCIDALO, M.A. & EL-BENNA, J.
(2000). The mitogen-activated protein kinase extracellular signal-
regulated kinase 1/2 pathway is involved in formyl-methionyl-
leucyl-phenylalanine-induced p47phox phosphorylation in human
neutrophils. J. Immunol., 165, 5238–5244.
DING, J., VLAHOS, C.J., LIU, R., BROWN, R.F. & BADWEY, J.A.
(1995). Antagonists of phosphatidylinositol 3-kinase block activa-
tion of several novel protein kinases in neutrophils. J. Biol. Chem.,
270, 11684–11691.
FORD-HUTCHINSON, A.W., GRESSER, M. & YOUNG, R.N. (1994). 5-
LIPOXYGENASE. Annu. Rev. Biochem., 63, 383–417.
GERHARDT, H., SEIFERT, F., BUVARI, P., VOGELSANG, H. &
REPGES, R. (2001). Therapy of active Crohn disease with Boswellia
serrata extract H 15. Z. Gastroenterol., 39, 11–17.
GIJON, M.A. & LESLIE, C.C. (1999). Regulation of arachidonic acid
release and cytosolic phospholipase A2 activation. J. Leukoc. Biol.,
65, 330–336.
GLASER, T., WINTER, S., GROSCURTH, P., SAFAYHI, H., SAILER,
E.R., AMMON, H.P., SCHABET, M. & WELLER, M. (1999).
Boswellic acids and malignant glioma: induction of apoptosis but
no modulation of drug sensitivity. Br. J. Cancer, 80, 756–765.
GRYNKIEWICZ, G., POENIE, M. & TSIEN, R.Y. (1985). A new
generation of Ca2+ indicators with greatly improved fluorescence
properties. J. Biol. Chem., 260, 3440–3450.
GUPTA, I., PARIHAR, A., MALHOTRA, P., GUPTA, S., LUDTKE, R.,
SAFAYHI, H. & AMMON, H.P. (2001). Effects of gum resin of
Boswellia serrata in patients with chronic colitis. Planta Med., 67,
391–395.
GUPTA, O.P., SHARMA, N. & CHAND, D. (1992). A sensitive and
relevant model for evaluating anti-inflammatory activity-papaya
latex-induced rat paw inflammation. J. Pharmacol. Toxicol.
Methods, 28, 15–19.
HAMPTON, M.B., FADEEL, B. & ORRENIUS, S. (1998). Redox
regulation of the caspases during apoptosis. Ann. N.Y. Acad. Sci.,
854, 325–328.
HANCOCK, J.T. & JONES, O.T. (1987). The inhibition by diphenyle-
neiodonium and its analogues of superoxide generation by
macrophages. Biochem. J., 242, 103–107.
HERLAAR, E. & BROWN, Z. (1999). p38 MAPK signalling cascades in
inflammatory disease. Mol. Med. Today, 5, 439–447.
HEYWORTH, P.G. & BADWEY, J.A. (1990). Protein phosphorylation
associated with the stimulation of neutrophils. Modulation of
superoxide production by protein kinase C and calcium.
J. Bioenerg. Biomembr., 22, 1–26.
HOERNLEIN, R.F., ORLIKOWSKY, T., ZEHRER, C., NIETHAMMER,
D., SAILER, E.R., SIMMET, T., DANNECKER, G.E. & AMMON,
H.P. (1999). Acetyl-11-keto-beta-boswellic acid induces apoptosis in
HL-60 and CCRF-CEM cells and inhibits topoisomerase I.
J. Pharmacol. Exp. Ther., 288, 613–619.
JING, Y., NAKAJO, S., XIA, L., NAKAYA, K., FANG, Q., WAXMAN, S.
& HAN, R. (1999). Boswellic acid acetate induces differentiation
and apoptosis in leukemia cell lines. Leuk. Res., 23, 43–50.
JOHNSON, E.N. & DRUEY, K.M. (2002). Heterotrimeric G protein
signaling: role in asthma and allergic inflammation. J. Allergy Clin.
Immunol., 109, 592–602.
KRIEGLSTEIN, C.F., ANTHONI, C., RIJCKEN, E.J., LAUKOTTER, M.,
SPIEGEL, H.U., BODEN, S.E., SCHWEIZER, S., SAFAYHI, H.,
SENNINGER, N. & SCHURMANN, G. (2001). Acetyl-11-keto-beta-
boswellic acid, a constituent of a herbal medicine from Boswellia
serrata resin, attenuates experimental ileitis. Int. J. Colorectal Dis.,
16, 88–95.
LIU, J.J., NILSSON, A., OREDSSON, S., BADMAEV, V. & DUAN, R.D.
(2002b). Keto- and acetyl-keto-boswellic acids inhibit proliferation
and induce apoptosis in Hep G2 cells via a caspase-8 dependent
pathway. Int. J. Mol. Med., 10, 501–505.
LIU, J.J., NILSSON, A., OREDSSON, S., BADMAEV, V., ZHAO, W.Z. &
DUAN, R.D. (2002a). Boswellic acids trigger apoptosis via a
pathway dependent on caspase-8 activation but independent on
Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcino-
genesis, 23, 2087–2093.
O’FLAHERTY, J.T., TAYLOR, J.S. & KUROKI, M. (2000). The coupling
of 5-oxo-eicosanoid receptors to heterotrimeric G proteins.
J. Immunol., 164, 3345–3352.
PARK, Y.S., LEE, J.H., BONDAR, J., HARWALKAR, J.A., SAFAYHI,
H. & GOLUBIC, M. (2002). Cytotoxic action of acetyl-11-keto-beta-
boswellic acid (AKBA) on meningioma cells. Planta Med., 68,
397–401.
PEREZ, H.D., KELLY, E. & HOLMES, R. (1992). Regulation of formyl
peptide receptor expression and its mRNA levels during differ-
entiation of HL-60 cells. J. Biol. Chem., 267, 358–363.
QIU, Z.H., GIJON, M.A., DECARVALHO, M.S., SPENCER, D.M. &
LESLIE, C.C. (1998). The role of calcium and phosphorylation of
cytosolic phospholipase A(2) in regulating arachidonic acid release
in macrophages. J. Biol. Chem., 273, 8203–8211.
ROOS, D., GOLDSTEIN, I.M., KAPLAN, H.B. & WEISSMANN, G.
(1976). Dissociation of phagocytosis, metabolic stimulation and
lysosomal enzyme release in human leukocytes. Agents Actions, 6,
256–259.
SAFAYHI, H. & SAILER, E.R. (1997). Anti-inflammatory actions of
pentacyclic triterpenes. Planta Med., 63, 487–493.
SAFAYHI, H., BODEN, S.E., SCHWEIZER, S. & AMMON, H.P. (2000).
Concentration-dependent potentiating and inhibitory effects of
Boswellia extracts on 5-lipoxygenase product formation in stimu-
lated PMNL. Planta Med., 66, 110–113.
SAFAYHI, H., MACK, T., SABIERAJ, J., ANAZODO, M.I., SUBRAMANIAN,
L.R. & AMMON, H.P. (1992). Boswellic acids: novel, specific, non-
redox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther., 261,
1143–1146.
SAFAYHI, H., RALL, B., SAILER, E.R. & AMMON, H.P. (1997).
Inhibition by boswellic acids of human leukocyte elastase. J.
Pharmacol. Exp. Ther., 281, 460–463.
SAFAYHI, H., SAILER, E.R. & AMMON, H.P. (1995). Mechanism of 5-
lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol.
Pharmacol., 47, 1212–1216.
SHAO, Y., HO, C.T., CHIN, C.K., BADMAEV, V., MA, W. & HUANG,
M.T. (1998). Inhibitory activity of boswellic acids from Boswellia
serrata against human leukemia HL-60 cells in culture. Planta Med.,
64, 328–331.
SHIMIZU, T., MORI, M., BITO, H., SAKANAKA, C., TABUCHI, S.,
AIHARA, M. & KUME, K. (1996). Platelet-activating factor and
somatostatin activate mitogen-activated protein kinase (MAP
kinase) and arachidonate release. J. Lipid Mediat. Cell. Signal.,
14, 103–108.
SIMCHOWITZ, L. & SPILBERG, I. (1979). Generation of superoxide
radicals by human peripheral neutrophils activated by chemotactic
factor. Evidence for the role of calcium. J. Lab. Clin. Med., 93,
583–593.
TAKETO, M.M. & SONOSHITA, M. (2002). Phospholipase A2 and
apoptosis. Biochim. Biophys. Acta, 1585, 72–76.
WERZ, O., BRUNGS, M. & STEINHILBER, D. (1996). Purification of
transforming growth factor beta1 from human platelets. Pharmazie,
51, 893–896.
WERZ, O., BUERKERT, E., FISCHER, L., SZELLAS, D., DISHART, D.,
RA ˚ DMARK, O., SAMUELSSON, B. & AND STEINHILBER, D.
(2002b). Extracellular signal-regulated kinases phosphorylate 5-
lipoxygenase and stimulate 5-lipoxygenase product formation in
leukocytes. FASEB J., 16, 1441–1443.
WERZ, O., BUERKERT, E., SAMUELSSON, B., RA ˚ DMARK, O. & AND
STEINHILBER, D. (2002a). Activation of 5-lipoxygenase by cell
stress is calcium-independent in human polymorphonuclear leuko-
cytes. Blood, 99, 1044–1052.
WERZ, O., KLEMM, J., SAMUELSSON, B. & RA ˚ DMARK, O. (2000).
5-Lipoxygenase is phosphorylated by p38 kinase depen-
dent MAPKAP kinases. Proc. Natl. Acad. Sci. U.S.A., 97,
5261–5266.
A. Altmann et al Activation of leucocytes by boswellic acids 231
British Journal of Pharmacology vol 141 (2)WERZ, O., SCHNEIDER, N., BRUNGS, M., SAILER, E.R., SAFAYHI,
H., AMMON, H.P.T. & STEINHILBER, D. (1997). A test system for
leukotriene synthesis inhibitors based on the in-vitro differentiation
of the human leukemic cell lines HL-60 and Mono Mac 6. Naunyn-
Schmiedeberg’s Arch. Pharmacol., 356, 441–445.
WERZ, O., SZELLAS, D., HENSELER, M. & STEINHILBER, D. (1998).
Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase
for efficient inhibition of 5-lipoxygenase activity. Mol. Pharmacol.,
54, 445–451.
WINKING, M., SARIKAYA, S., RAHMANIAN, A., JODICKE, A. &
BOKER, D.K. (2000). Boswellic acids inhibit glioma growth: a new
treatment option? J. Neurooncol., 46, 97–103.
(Received August 28, 2003
Revised October 13, 2003
Accepted October 29, 2003)
232 A. Altmann et al Activation of leucocytes by boswellic acids
British Journal of Pharmacology vol 141 (2)Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  1 
Inhibitors of actin polymerisation stimulate arachidonic 
acid release and 5-lipoxygenase activation by 
upregulation of Ca
2+ mobilisation in polymorphonuclear 
leukocytes involving Src family kinases 
 
Lutz Fischer, Eva Bürkert, Dieter Steinhilber, and Oliver Werz 
Institute of Pharmaceutical Chemistry, University of Frankfurt, D-60439 Frankfurt, Germany 
 
Abstract:  Here we show, that agents that 
block actin polymerisation such as latrunculin B 
(LB), and to a minor extent also cytochalasin D 
(Cyt D), enhance the release of arachidonic acid 
(AA) as well as nuclear translocation of 5-
lipoxygenase (5-LO) and 5-LO product synthesis 
in human polymorphonuclear leukocytes 
(PMNL), challenged with thapsigargin (TG). 
The concentration-dependent effect of LB (EC50 
? 200 nM) declined with prolonged 
preincubation (> 3 min) prior TG and was 
barely detectable when PMNL were stimulated 
with Ca
2+-ionophores.  
Investigation of the stimulatory mechanisms 
revealed that LB (or Cyt D) elicits Ca
2+ 
mobilisation and potentiates agonist-induced 
elevation of intracellular Ca
2+, regardless of the 
nature of the agonist. LB caused rapid but only 
moderate activation of p38 mitogen-activated 
protein kinase (MAPK) and extracellular signal-
regulate kinase (ERK)2. The selective Src family 
kinase inhibitors PP2 and SU6656, blocked LB- 
or Cyt D-mediated Ca
2+ mobilisation, and 
suppressed the upregulatory effects on AA 
release and 5-LO product synthesis, without 
affecting AA metabolism evoked by ionophore 
alone. We conclude that in PMNL, inhibitors of 
actin polymerisation cause enhancement of 
intracellular Ca
2+ levels through Src family 
kinase signaling, thereby facilitating the release 
of AA and 5-LO product formation, elicited by 
agonists that moderately induce Ca
2+ 
mobilisation. 
 
Key words: leukotriene, polymorphonuclear leukocyte, 
latrunculin, cytochalasin, inflammation, cytoskeleton. 
 
INTRODUCTION 
 
Massive formation and release of leukotrienes 
(LTs) occurs mainly in phagocytes upon 
stimulation, and is initiated by the oxygenation of 
free arachidonic acid (AA) via 5-lipoxygenase (5-
LO) [1]. 5-LO and its products have been 
implicated in a variety of pathophysiological events 
and contribute to a number of inflammatory and 
allergic disorders including asthma, arthritis, 
psoriasis and cardiovascular diseases such as 
atherosclerosis, myocardial infarction and stroke [1-
3]. Therefore, the understanding of the mechanisms 
regulating the biosynthesis of 5-LO product 
synthesis attracts particular attention, but is still 
incompletely understood. 
For 5-LO product  synthesis in phagocytes, the 
liberation of AA by the cytosolic phospholipase 
(cPL)A2 is one of the rate-limiting steps. Ca
2+ 
and/or phosphorylation at serine residues are of 
importance for cPLA2 activation, depending on the 
cell type and the stimulus [4]. In analogy to cPLA2, 
also 5-LO can be activated by Ca
2+ and/or 
phosphorylation [5-7]. cPLA2 and 5-LO translocate 
from a soluble cellular locale to the nuclear 
membrane [8, 9], where 5-LO activating protein 
(FLAP) serves as an AA-binding protein, believed 
to facilitate AA transfer to 5-LO [10]. 
It was shown that a threshold level of [Ca
2+]i is 
required for activation and translocation of cPLA2, 
and it was proposed that phosphorylation may 
reduce the requirement for Ca
2+ [11]. Also for 5-LO 
activation, Ca
2+ and phosphorylation may act in 
conjunction [5, 6, 12, 13]. In fact, Ca
2+-ionophores 
that cause prominent and rapid elevation of [Ca
2+]i 
induce substantial release of AA and LTs, which is 
also evident when phosphorylation is blocked [5, 
11]. Agents, including thapsigargin (TG), N-
formyl-methionyl-leucyl-phenylalanine (fMLP) or 
zymosan that elicit only moderate and/or transient 
Ca
2+ mobilisation are poor inducers of the AA 
cascade.  
Previous studies have proposed a regulatory role of 
the cytoskeleton for the capacity of leukocytes to 
form LTs. For example, it was shown that 
preincubation of polymorphonuclear leukocytes 
(PMNL) with cytochalasins (Cyt) upregulates LT 
formation induced by fMLP [14-16]. Moreover, 5-
LO is able to bind to actin [17] and interacts with 
the actin-binding protein coactosin-like protein 
(CLP) [18, 19]. On the other hand, 5-LO interferes 
with actin polymerisation and a modulatory role for 
5-LO in actin dynamics was suggested [19]. Thus, 
there are several indications that reorganization of 
the actin skeleton, may have impact on the 
regulation of LT biosynthesis.  
In the present study the effects of latrunculin B 
(LB) and Cyt D, inhibitors of actin polymerisation, 
on 5-LO product release from  PMNL  were 
investigated and the underlying mechanism were 
explored. We found that the LB- or Cyt D-mediated 
upregulation of 5-LO product synthesis depended 
on the stimulus and was primarily due to an Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  2 
increased liberation of AA, but also to an enhanced 
translocation of 5-LO to the nucleus. Analysis of 
the signaling and activation pathways of these 
processes suggest that LB and Cyt D mediate their 
effects by elevation of [Ca
2+]i, through Src family 
kinase signaling. 
 
MATERIALS AND METHODS 
 
The 5-LO antibody (AK-7, 1551) was kindly 
provided by Dr. Olof Rådmark, Karolinska Institute 
Stockholm, Sweden. RPMI 1640 medium was from 
GibcoBRL, Life Technologies (Rockville, MD). 
Fetal calf serum, Ca
2+-ionophore A23187, 
ionomycin, AA, TG, fMLP, Sigma (Deisenhofen, 
Germany); LB, PP2, PP3, SU6656, Calbiochem 
(San Diego, USA); Cyt D, Fura-2, Alexis 
(Grünberg, Germany); [
3H]AA, GE Healthcare Bio-
Sciences (Freiburg, Germany); HPLC solvents, 
Merck (Darmstadt, Germany). 
 
Cells 
 
PMNL were freshly isolated from leukocyte 
concentrates obtained at St Markus Hospital 
(Frankfurt, Germany) as described [5]. In brief, 
venous blood was taken from healthy adult donors 
and leukocyte concentrates were prepared by 
centrifugation at 4000  ? g/20 min/20°C. PMNL 
were immediately isolated by dextran 
sedimentation, centrifugation on Nycoprep 
cushions (PAA Laboratories, Linz, Austria), and 
hypotonic lysis of erythrocytes. PMNL (10
7 cells 
/ml; purity > 96-97%) were finally resuspended in 
PBS containing 1 mg/ml glucose, and 1 mM CaCl2 
(PGC buffer) or 1 mM EDTA (PG buffer) was 
added, as indicated. 
 
Measurement of intracellular Ca
2+ levels 
 
Freshly isolated PMNL (10
7/ml PGC buffer)were 
incubated with 2 µM Fura-2/AM for 30 min at 
37°C, washed, resuspended in 1 ml PGC buffer and 
transferred into a thermally controlled (37°C) 
fluorimeter cuvette in a spectrofluorometer 
(Aminco-Bowman series 2) with continuous 
stirring. The fluorescence emission at 510 nm was 
measured after excitation at 340 and 380 nm, 
respectively. [Ca
2+]i was calculated according to the 
method of Grynkiewicz et al. [20]. Fmax (maximal 
fluorescence) was obtained by lysing the cells 
w0ith 1% Triton-X 100 and Fmin by chelating Ca
2+ 
with 10 mM EDTA. 
 
Determination of 5-LO product 
synthesis 
 
Freshly  isolated PMNL (7.5 × 106) were finally 
resuspended in 1 ml PGC buffer.  After 
preincubation with the indicated compounds at 
37°C, 5-LO product formation was started by the 
addition of the indicated stimuli (DMSO, final 
concentration = 0.3 % (vol/vol), was used as 
solvent) with or without exogenous AA as 
indicated. After 10 min at 37°C, the reaction was 
stopped with 1 ml of methanol and 30 µl of 1 N 
HCl, 200 ng prostaglandin B1 and 500 µl of PBS 
were added. Formed 5-LO metabolites were 
extracted and analyzed by HPLC as described [5]. 
5-LO product formation is expressed as ng of 5-LO 
products per 106 cells which includes LTB4 and its 
all-trans isomers, 5(S),12(S)-di-hydroxy-6,10-trans-
8,14-cis-eicosatetraenoic acid (5(S),12(S)-
DiHETE), and 5(S)-hydro(pero)xy-6-trans-8,11,14-
cis-eicosatetraenoic acid (5-H(p)ETE). Cysteinyl 
LTs (LTC4, D4 and E4) were not detected and 
oxidation products of LTB4 were not determined. 
 
SDS-PAGE and Western blotting 
 
Freshly isolated PMNL (5 ? 10
6) were resuspended 
in PGC buffer, final volume was 100 µl. After 
addition of the indicated stimuli, samples were 
incubated at 37°C and the reaction was stopped by 
addition of 100 µl of ice-cold 2 ? sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample loading buffer (SDS-b; 20 mM 
Tris/HCl, pH 8, 2 mM EDTA, 5% SDS (w/v), 10% 
?-mercaptoethanol), vortexed and heated for 6 min 
at 95°C. Total cell lysates (20 µl) were mixed with 
4 µl of glycerol/0.1% bromphenolblue (1:1, 
vol/vol) and analyzed by SDS-PAGE on a 10% gel. 
Correct loading of the gel and transfer of proteins to 
the nitrocellulose membrane was confirmed by 
Ponceau staining. After electroblot to nitrocellulose 
membrane (Amersham Pharmacia), blocking with 5 
% non fat dry milk for 1 h at RT, membranes were 
washed and incubated with primary antibodies 
(ABs) overnight at 4°C. Phospho-specific 
antibodies (AB) recognizing  ERK1/2 
(Thr202/Tyr204) or p38 MAPK (Thr180/Tyr182) 
were obtained from New England Biolabs. All ABs 
were used as 1:2,000 dilution. The membranes were 
washed and incubated with 1:1,000 dilution of 
alkaline phosphatase conjugated IgGs (Sigma) for 2 
h at RT. After washing, proteins were visualized 
with nitro blue tetrazolium and 5-bromo-4-chloro-
3-indolylphosphate (Sigma) in detection buffer. 
 
Determination of release of [
3H]-labeled 
arachidonic acid from PMNL 
 
Freshly isolated PMNL were resuspended at 2 ? 10
6 
in 1 ml RPMI 1640 medium containing 4.8 nM 
[
3H]AA (corresponding to 0.25 µCi/ml, specific 
activity 200 Ci/mmol) and incubated for 120 min at 
37
oC in 5 % CO2 atmosphere. Thereafter, cells were 
collected by centrifugation, washed once with PBS 
and twice with PBS containing 2 mg/ml fatty acid 
free albumin, to remove unincorporated [
3H]AA. 
Labeled PMNL (10
7) were resuspended in 1 ml 
PGC buffer containing 2 mg/ml fatty acid free Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  3 
albumin. The reaction was started by addition of the 
indicated stimuli. After 5 min at 37°C, the samples 
were placed on ice for 2 min and cells were 
centrifuged at 400 ? g for 5 min at rt. Aliquots (100 
µl) of the supernatants were measured in a beta-
counter (Micro Beta Trilux, Perkin Elmer, Foster 
City, CA) to detect the amounts of [
3H]-labeled AA 
released into the medium.  
 
Subcellular fractionation by detergent 
lysis 
 
Subcellular localization of 5-LO was investigated 
as described previously [21]. In brief, freshly 
isolated PMNL (3 × 10
7) in 1 ml PGC buffer were 
incubated at 37°C for 10  min with the indicated 
stimuli and chilled on ice. Nuclear and non-nuclear 
fractions were obtained after cell lysis by 0.1% NP-
40. Aliquots of these fractions were immediately 
mixed with the same volume of SDS-b, heated for 6 
min at 95°C, and analyzed for  5-LO protein by 
SDS-PAGE and immunoblotting. 
 
Statistics 
 
The program “GraphPad PRISM 3.0” was used for 
statistical comparisons. Statistical evaluation of the 
data was performed using Student´s  t test for 
unpaired observations. A  P  value of < 0.05 was 
considered as significant. 
 
 
 
 
RESULTS 
 
LB and Cyt D elevate TG-induced 5-LO 
product synthesis from endogenous 
AA. 
 
Addition of TG (0.01 to 10 µM) to isolated human 
PMNL resuspended in PGC buffer induced a 
concentration-dependent induction of 5-LO product 
formation (EC50 ? 2 µM, fig. 1A). When extra- and 
intracellular Ca
2+ was removed using 1 mM EDTA 
and 30 µM BAPTA/AM, respectively, no 5-LO 
product formation was detectable (not shown), 
implying that Ca
2+ is absolutely required for TG-
induced 5-LO activation.  Depending on the 
concentration of TG, co-addition of 3 µM LB 
caused an up to 18-fold increase in 5-LO product 
synthesis (fig. 1A). Again, when Ca
2+ was chelated 
by EDTA and BAPTA/AM, no 5-LO product 
synthesis was observed in response to TG plus LB 
(not shown). The magnitude of the stimulatory 
effect of LB was most prominent when low 
concentrations of TG (0.01 to 1 µM) were used for 
PMNL challenge. In contrast, LB failed to 
upregulate 5-LO product synthesis at 10 µM TG. 
Addition of LB to PMNL alone caused no 
significant 5-LO product synthesis (not shown). 
Concentration-response experiments revealed an 
EC50 of  ? 0.2 µM LB, maximal effects were 
obtained at 3 µM (fig. 1B). Moreover, LB gave the 
best effect when added simultaneously with TG, 
whereas the upregulatory effects of LB decreased 
over time. Thus, preincubation with 3 µM LB for 
30 min caused an only two-fold increase of TG-
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Fig. 1 Latrunculin B upregulates 5-LO product synthesis induced by thapsigargin.  
For all experiments freshly isolated PMNL (7.5 × 10
6 in 1 ml PGC buffer) were used. Results are given as mean + S.E., n = 5-6. Student t 
test; *P< 0.05; **P< 0.01. (A) PMNL were incubated with or without 3 µM LB together with the indicated concentrations of TG at 37°C for 
10 min and 5-LO products were determined by HPLC as described in the Methods section. (B) Cells were incubated with 1 µM TG  together 
with the indicated concentrations of LB at 37°C for 10 min and 5-LO products were determined. (C) PMNL were preincubated with 3 µM 
LB for the indicated periods at 37°C. Then, 1 µM TG was added and after another 10 min, and 5-LO products were determined. (D) PMNL 
were incubated with 1 µM TG, 2.5 µM ionophore, or 1 µM fMLP together with or without 3 µM LB at 37°C for 10 min, and 5-LO products 
were determined. (E) PMNL were incubated with 1 µM TG together with or without 3 µM LB at 37°C. Incubations were stopped by addition 
of the same volume of methanol after the times indicated and 5-LO products were determined. Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  4 
induced 5-LO product synthesis (fig. 1C).  
Next, LB was coincubated with other stimuli 
known to induce 5-LO product formation. LB 
caused only a slight increase of 5-LO product 
synthesis when ionophore A23187 (2.5 µM, 
optimized concentration [21]) was used as agonist 
and upregulated fMLP-induced 5-LO activity only 
about 1.6-fold (fig. 1D). Interestingly, upregulation 
of TG-induced 5-LO product synthesis by LB was 
obvious only when endogenous substrate was 
converted by 5-LO, thus, in the presence of 
exogenous AA (10 µM), LB caused no significant 
enhancements (not shown). Moreover, LB not only 
increased the total amount of 5-LO products 
formed, it also significantly shortened the lag-phase 
of 5-LO product synthesis from about 160 to 70 sec 
(fig. 1E). Together, LB selectively upregulates TG-
induced 5-LO product formation from endogenous 
substrate. 
In addition to LB, also the actin polymerisation 
inhibitor Cyt D (10 µM) caused upregulation of 5-
LO product synthesis induced by TG and slightly 
also by fMLP, but not by ionophore. However, the 
magnitude of these upregulatory effects of Cyt D (? 
3.6-fold) on top of TG were less pronounced as 
compared to LB (? 18-fold, see fig. 1A), which fits 
to the potency of these compounds to inhibit actin 
polymerisation [22].  
 
LB elevates TG-induced AA release. 
 
In accordance with 5-LO product formation, LB 
upregulates AA release from PMNL induced by 
TG, but only marginally when induced by fMLP, 
and fails in response to ionophore (fig. 2A). Again, 
the release of AA was less efficiently increased by 
Cyt D as compared to LB (not shown). In analogy 
to 5-LO product synthesis, effects of LB on the 
release of AA were most pronounced at suboptimal 
concentrations of TG (0.01 to 1 µM), whereas LB 
failed at TG concentrations >3 µM (fig. 2B). The 
EC50 for upregulation of TG-induced AA release 
was 0.2 µM LB, maximal effects were obtained at 3 
µM LB (fig. 2C), and prolonged preincubation with 
LB prior TG reduced the stimulatory effect of LB 
(not shown). 
 
LB promotes the translocation of 5-LO 
to the nuclear membrane. 
 
In order to determine, if LB influences 5-LO 
redistribution, PMNL were challenged with TG or 
ionophore and subcellular localisation of 5-LO was 
determined. Stimulation of PMNL with TG (1 µM) 
caused only moderate translocation of 5-LO to the 
nucleus, but co-addition of LB caused significant 
enrichment of 5-LO in this locale (fig. 3). LB alone 
had no effect. In contrast, ionophore (2.5 µM) 
induced substantial 5-LO translocation which was 
not further increased by LB (fig. 3). 
LB induces Ca
2+ mobilisation and 
augments agonist-induced elevation of 
[Ca
2+]i. 
 
Elevation of [Ca
2+]i is a determinant for the release 
of AA by cPLA2 as well as for 5-LO product 
synthesis [23]. It appeared possible that LB 
upregulates AA liberation and 5-LO activation by 
increasing [Ca
2+]i. Ionomycin, a Ca
2+-ionophore 
related to A23187, was used, since A23187 
possesses fluorescent properties and is not suitable 
for measurement of [Ca
2+]i using Fura-2. At 1 µM, 
TG induced a moderate and rather delayed increase 
in [Ca
2+]i from 60 +/- 8 to 230 +/- 15 nM) as 
compared to ionomycin (from 60 +/- 8 to 869 +/- 
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Fig. 2 Latrunculin B upregulates the release of AA induced by thapsigargin. 
Freshly isolated PMNL (2 ? 10
6 in 1 ml RPMI 1640 medium) were prelabeled with 0.25 µCi/ml [
3H]AA for 120 min at 37°C and 5 % CO2. 
Unincorporated [
3H]AA was removed, and cells (10
7) were resuspended in 1 ml PGC buffer, containing 2 mg/ml fatty acid-free albumin and 
incubated as described below. (A) Cells were stimulated with 1 µM TG, 2.5 µM ionophore A23187, or 1 µM fMLP together with or without 
3 µM LB for 5 min at 37°C and free (nonesterified) [
3H]AA was determined as described in the Methods section. (B) Cells were stimulated 
with the indicated concentrations of TG with or without 3 µM LB. After 5 min at 37°C, free [
3H]AA was determined. (C) Cells were 
incubated with 1 µM TG together with the indicated concentrations of LB. After 5 min at 37°C, free [
3H]AA was determined. Results are 
given as mean ± S.E. (n = 4). Student t test; *P< 0.05; **P< 0.01. 
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Fig. 3 Latrunculin B enhances 5-LO redistribution to the 
nucleus. Freshly isolated PMNL (3 × 10
7 in 1 ml PGC buffer) 
were stimulated with 2.5 µM A23187 or 1 µM TG together with 
or without 3 µM LB for 5 min at 37°C. 5-LO was detected in 
nuclear and non-nuclear fractions by immunoblotting after 
subcellular fractionation. Similar results were obtained in two 
additional independent experiments. Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  5 
313 nM) within 110 sec of measurement (fig. 4A). 
Interestingly, LB (3 µM) alone elevated the [Ca
2+]i 
from 60 +/- 6 to 218 +/- 26 nM, with a delay of 
about 40 sec (fig. 4A). Similarly, Cyt D caused 
elevation of [Ca
2+]i, although to a minor extent (82 
+/- 34 nM). Co-addition of LB or Cyt D with TG 
gave additive effects resulting in enhanced [Ca
2+]i 
(462 +/- 50 and 349 +/- 77 nM, respectively). Such 
additive signals of Cyt D or LB were also observed 
with ionomycin, where again, LB was more 
effective as compared to Cyt D (fig. 4A). 
Concentration-response studies regarding 
augmentation of TG-induced elevation of [Ca
2+]i 
determined an EC50 for LB at 0.2 µM with maximal 
effects at 3 µM (fig. 4B). The enhancement of 
[Ca
2+]i  induced by TG alone was concentration-
dependent (fig. 4C). However, in combination with 
LB a clear concentration-dependent effect was not 
readily apparent. It should be noted that the values 
of [Ca
2+]i given in fig. 4C were recorded 220 sec 
after addition of TG and 120 sec after stimulation 
with TG plus LB, reflecting [Ca
2+]i at the time 
points where the velocity of 5-LO product 
formation is close to maximum (see fig. 1E). 
Obviously, at low TG concentrations (< 0.1 µM), 
[Ca
2+]i  enters a plateau (fig. 4D), which is followed 
by a second raise at higher concentrations of TG. 
The PLC inhibitor U-73122 (but not its inactive 
analogue U-73343, not shown) blocked LB-induced 
Ca
2+ mobilisation as well as the upregulatory effect 
of LB, but did not reduce TG-induced Ca
2+ 
mobilisation (table 1). Finally, LB elicited [Ca
2+]i 
also in the absence of extracellular Ca
2+ (presence 
of 1 mM EDTA), which was more rapid but only 
about 10 to 15 % of the signal obtained in the 
presence of extracellular Ca
2+, and also this effect 
was abolished by U-73122 (not shown). Therefore, 
it appears that LB evokes mobilisation of Ca
2+ from 
internal stores involving PLC. 
Effect of LB on the activation of MAP 
kinases. 
 
Release of AA by cPLA2  and 5-LO activation is 
regulated also by p38 MAPK and ERK1/2 [4-7]. 
Addition of LB to PMNL rapidly induced 
activation of ERK2 and p38 MAPK within 15 to 30 
sec, and subsequently slightly declined (fig. 5A). 
Maximum activation was determined at 3 µM of 
thapsigargin [µM]
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Fig. 4 Latrunculin B and cytochalasin D induce Ca
2+ mobilisation and upregulate agonist-induced Ca
2+ mobilisation. Freshly isolated 
PMNL (1 × 10
7/ml PGC buffer) were loaded with 2 µM Fura-2 for 30 min at 37°C. After washing, cells (1 × 10
7) were resuspended in PGC 
buffer, the fluorescence was measured, and [Ca
2+]i was calculated as described. Values are given as mean + S.E., n = 3-5; curves are 
representative for 3-5 experiments. (A) Cyt D (10 µM), LB (3 µM), TG (1 µM), and ionomycin (1 µM) were added alone or combined as 
indicated 25 s after the measurement was started. As control, the solvent (DMSO) was added that gave no significant signal. The monitored 
curves show one typical experiment out of four. (B) Cells were stimulated with 1 µM TG together with the indicated concentrations of LB. 
The maximal [Ca
2+]i after stimulation was determined within 125 s of measurement.  (C) Cells were stimulated with the indicated 
concentrations of TG with or without 3 µM LB. The maximal values obtained with TG alone or with TG plus LB were recorded after 220 or 
120 sec, respectively. (D) TG was added at the indicated concentrations. A second raise of [Ca
2+]i,100 sec after TG was added is observed at 
TG concentrations = 0.1 µM. 
Table 1 Effects of U-73122 on elevation of  [Ca
2+]i.  Freshly 
isolated PMNL (1 × 10
7/ml PGC buffer) were loaded with 2 µM 
Fura-2 for 30 min at 37°C. After washing, cells (1 × 10
7) were 
resuspended in PGC buffer and preincubated with or without 3 
µM U-73122, prior stimulation with LB and TG as indicated. 
The fluorescence was measured, and intracellular free Ca
2+ was 
calculated as described. The maximal [Ca
2+]i after stimulation 
was determined within 130 s of measurement. Values are given 
as mean + S.E., n = 3. 
stimulus  increase in [Ca
2+]i (nM) 
  w/o  + 3 µM U-73122 
LB  187 ± 26  21 ± 3 
TG  207 ± 18  210 ± 10 
TG + LB  565 ± 100  198 ± 12 
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LB (not shown). However, compared to fMLP or 
ionophore, MAPK activation elicited by LB was 
only moderate (fig. 5B). Moreover, LB did not 
potentiate activation of ERK2 or p38 MAPK 
induced by ionophore, fMLP, or TG (fig. 5B). 
Together, MAPK may play only a minor role in 
transmitting signals by LB. 
Src family kinases mediate the 
stimulatory effects of LB on Ca
2+ 
mobilisation. 
 
It was reported that LB or Cyt D evoke activation 
of members of the Src family kinases in certain cell 
types [24, 25], and Src family kinases in turn are 
involved in activation of PLC? that mediates 
mobilisation of Ca
2+ from internal storage sites 
[26]. We investigated the involvement of Src family 
kinases in LB-mediated Ca
2+ responses using the 
selective Src family kinase inhibitors PP2 [27], and 
for control the negative analogue PP3, as well as 
SU6656 [28]. PP2 acts as a competitive inhibitor of 
ATP-binding, with IC50 values of  4 - 20 nM for 
crude p56
lck, p59
fynT, and Hck in vitro, whereas for 
cellular studies, much higher concentrations of PP2 
(IC50 = 0.55 µM) are required, probably due to high 
[ATP]i compared with low concentrations used in 
in vitro kinase assays [27]. Neither PP2 (and PP3, 2 
µM, each) nor SU6656 (5 µM) caused suppression 
of TG-induced elevation of [Ca
2+]i  (fig. 6). 
However, PP2 (but not PP3) or SU6656 
substantially reduced Ca
2+ mobilisation elicited by 
LB (or Cyt D, not shown). Importantly, also the 
upregulatory  effects of LB on top of TG were 
reduced by PP2 (but not by PP3) or by SU6656 
(fig. 6). Thus, selective inhibition of  Src family 
kinases prevents LB effects regarding Ca
2+ 
mobilisation. 
 
Inhibition of  Src family kinases 
prevents the stimulatory effects of LB 
on AA release, 5-LO product synthesis, 
and 5-LO translocation. 
 
Next, the involvement of Src family kinases in LB-
mediated stimulation of AA release, 5-LO product 
synthesis, and 5-LO translocation was evaluated. 
As shown in  fig. 7A, PP2 and SU6656 (but not 
PP3) strongly blocked the upregulated 5-LO 
product synthesis by 3 µM LB in PMNL stimulated 
with TG. In control experiments, PP2 and SU6656 
failed to significantly suppress 5-LO product 
synthesis induced by ionophore alone (fig. 7B), 
indicating that Src family kinases are not generally 
involved in 5-LO activation and that the inhibitors 
do not interfere with 5-LO catalytic activity. 
A similar pattern of the effects of  Src family 
kinases inhibitors was found when the release of 
AA (fig. 7C and D) and 5-LO translocation (fig. 8) 
were investigated. Thus, PP2 and SU6656 (but not 
PP3) abolished the stimulatory effects of 3 µM LB 
on top of TG, but failed to reduce ionophore-
evoked responses.  
 
DISCUSSION 
 
Although previous studies have demonstrated that 
inhibitiors of actin polymerisation augment the 
capacity of agonist-challenged PMNL to release 
AA metabolites [14-16], the underlying 
mechanisms and the signaling molecules involved 
have not been defined thus far. Here we show that 
treatment of human PMNL with the actin 
polymerisation inhibitors LB or Cyt D leads to an 
elevation of basal and agonist-induced [Ca
2+]i, 
involving Src family kinases. The elevated [Ca
2+]i  
appears to contribute to an increased availability of 
free AA and to an enhanced nuclear 5-LO 
translocation. Both processes together might be 
attributable for substantial 5-LO product synthesis.  
For 5-LO product synthesis, AA must be liberated 
from phospholipids, implying that activation of the 
Ca
2+-dependent cPLA2 is a determinant [29, 30]. 
0 15 30 45 60 90 120 180 240 sec.
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Fig. 5 Effects of latrunculin B on MAPK activation. Freshly 
isolated PMNL (5 × 10
6 in 100 µl PGC buffer) were stimulated 
as indicated and described below. Incubations were terminated 
by addition of the same volume of ice-cold SDS-b. Samples 
were electrophoresed and analyzed for dually phosphorylated 
p38 MAPK or ERK2 by Western blotting. (A) Cells were 
stimulated with 3 µM LB for the indicated times at 37°C. (B) 
Cells were stimulated with 1 µM fMLP, 2.5 µM ionophore 
A23187, or 1 µM TG, together with or without 3 µM LB at 
37°C for 1.5 min. The results shown are representative for 3-4 
experiments. 
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Fig. 6 Effects of Src family kinase inhibitors on Ca
2+ 
mobilisation. Freshly isolated PMNL (1 × 10
7/ml PGC buffer) 
were loaded with 2 µM  Fura-2 for 30 min at 37°C. After 
washing, cells (1 × 10
7) were resuspended in PGC buffer and 
preincubated with PP2, PP3 (2 µM, each), or SU6656 (5 µM) for 
15 min at 37°C and then stimulated with TG (1 µM) and LB (3 
µM) as indicated. The fluorescence was measured and [Ca
2+]i 
was calculated as described. The maximal [Ca
2+]i after 
stimulation was determined within 130 s of measurement. Values 
are given as mean + S.E., n = 3-5. Student t test; *P< 0.05; **P< 
0.01. Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  7 
Agonists that induce the release of AA by cPLA2 
and the subsequent conversion via 5-LO encompass 
a variety of agents, which are all capable to raise 
[Ca
2+]i. These stimuli include ionophores, TG, G 
protein-coupled receptor (GPCR) agonists such as 
fMLP, cytokines like IL-8, and phagocytic particles 
like zymosan or urate crystals [23]. The extent of 
LT synthesis correlates to the ability to elevate 
[Ca
2+]i. Thus, Ca
2+-ionophores cause strong AA 
release and LT formation, whereas naturally-
occurring ligands, which moderately raise [Ca
2+]i, 
are much less efficient [31-34]. In our study, 
ionophore elevated [Ca
2+]i to about 800 nM and 
caused a much stronger AA liberation and 5-LO 
product synthesis as compared to TG that increased 
[Ca
2+]i to only 230 nM.  Accordingly, LB 
augmented AA release and metabolism only in 
combination with TG, but not  together with 
ionophore, although [Ca
2+]i was upregulated by LB 
regardless of the stimulus. Previous studies have 
addressed the Ca
2+ requirement of cPLA2 and 5-LO 
in PMNL, and it was found that cPLA2 requires a 
threshold level of approx. 350 to 400 nM [Ca
2+]i 
[31], whereas 5-LO showed a linear dependence on 
Ca
2+ and saturates below these concentrations [31]. 
Obviously, co-stimulation of TG plus LB, raising 
[Ca
2+]i to approx. 460 nM, is required for efficient 
AA release (and subsequent 5-LO product 
synthesis), since the [Ca
2+]i levels obtained with TG 
alone do not reach the threshold level (350-400 nM 
[Ca
2+]i) needed for cPLA2 activation. The [Ca
2+]i, 
levels after ionophore stimulation (approx. 800 nM) 
are high enough for cPLA2 activation and 
augmentation by LB (to > 1000 nM) causes no 
significant further enhancements. Moreover, the 
duration of the lag-phase in 5-LO product synthesis 
(fig. 1E) correlates to the period of time required to 
reach the threshold levels of [Ca
2+]i for AA release 
and 5-LO product synthesis. Thus, a correlation 
between the ability of these stimuli to elevate 
[Ca
2+]i and to recruit cPLA2 and 5-LO is apparent. 
However, since high concentrations of TG (?1 µM) 
cause substantial formation of 5-LO products (fig. 
1A) without inducing a further increase of [Ca
2+]i as 
compared to TG at 0.1 or 0.3 µM (fig. 4C), other 
unknown effectors than Ca
2+ may amplify AA 
release and conversion by 5-LO. Nevertheless, Ca
2+ 
seems to be absolutely required for TG-induced 5-
LO product formation, since TG (0.01 up to 10 µM) 
was not effective  in the absence of intra and 
extracellular Ca
2+.  
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Fig. 7 Effects of Src family kinase inhibitors on AA release and 5-LO product synthesis. 
(A  and B)  Effects of PP2, PP3, and SU6656 on  5-LO product synthesis. Freshly isolated PMNL (7.5 × 10
6/ml PGC buffer) were 
preincubated with PP2, PP3 (2 µM, each), or SU6656 (5 µM) for 15 min at 37°C and then either stimulated with 1 µM TG plus 3 µM LB 
(left panel), or with 2.5 µM ionophore A23187 (right panel). After 10 min at 37°C, 5-LO products were extracted and determined by HPLC 
as described. (C and D) Effects of PP2, PP3, and SU6656 on AA release. Freshly isolated PMNL (2 ? 10
6/ml RPMI 1640 medium) were 
prelabeled with 0.25 µCi/ml [
3H]AA for 120 min at 37°C and 5 % CO2. Unincorporated [
3H]AA was removed and cells (5 ? 10
6) were 
resuspended in 1 ml PGC buffer, containing 2 mg/ml fatty acid-free albumin. Cells were preincubated with PP2, PP3 (2 µM, each), or 
SU6656 (5 µM) for 15 min at 37°C and then stimulated with 1 µM TG plus 3 µM LB (left panel), or with 2.5 µM ionophore A23187 (right 
panel). After 5 min at 37°C, free [
3H]AA was determined. Results are given as mean ± S.E., n = 4. Student t test; **P< 0.01. Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  8 
Besides Ca
2+, phosphorylation of serine residues by 
members of the MAPK family regulates activation 
of cPLA2 [4] but also of 5-LO [6, 7, 21], in 
particular when  [Ca
2+]i is low, whereas enzyme 
phosphorylation is less important when Ca
2+ 
mobilisation is substantial [5, 11]. Since LB caused 
only moderate enhancement of MAPK activation 
but at the same time strongly elevated [Ca
2+]i, we 
conclude that phosphorylation plays a minor role in 
transmitting the upregulatory effects of LB or Cyt 
D to cPLA2 and 5-LO.  
In the presence of exogenous AA, LB was unable to 
upregulate TG-induced 5-LO product synthesis, 
again implying that LB elevates 5-LO product 
synthesis mainly by affecting cPLA2. Also others 
found that moderate elevation of [Ca
2+]i by natural 
“weak” agonists is sufficient to induce substantial 
formation of 5-LO products from exogenous 
substrate [31, 32]. Hence, an  insufficient AA 
release  at suboptimal  [Ca
2+]i levels is mainly 
attributable for low 5-LO product formation, 
implying that cPLA2 rather than 5-LO is the rate-
limiting enzyme. Nevertheless, LB had a clear 
stimulatory effect on 5-LO, inasmuch as it 
promoted translocation to the nucleus.  
LB is a potent monomer-sequestering and F-actin-
depolymerizing drug that  in vivo disrupts 
microfilament organization and inhibits 
microfilament-mediated processes [22]. LB is about 
10- to 100-fold more potent than Cyts in several 
experimental cell-based models and the 
mechanisms of how the drugs disrupt actin 
microfilaments differ [22]. Thus, Cyts act primarily 
by binding to the fast-growing or barbed end of the 
actin filament [35], whereas LB binds to 
monomeric actin, thereby  preventing actin 
polymerisation [36]. All the effects of LB in our 
study were concentration-dependent with a 
consistent EC50 ? 0.2 µM and maximal efficacy at 
concentrations around 3 µM, which fits to the 
effective concentrations of LB reported to suppress 
actin polymerisation [22, 36]. 
Dynamic reorganization of the actin skeleton is 
central to a variety of PMNL functions, including 
locomotion, adhesion spreading and phagocytosis 
(for review, see [37]). Most stimuli activating the 
AA pathway also evoke actin polymerisation with 
similar kinetics, implying that these processes may 
influence each other. In fact, both cPLA2 as well as 
5-LO bind to certain cytoskeletal proteins. cPLA2 
was found to interact with vimentin [38], and 5-LO 
can bind alpha-actinin, actin [17] and  CLP [18, 
19]. Regarding the modulation of the AA pathway, 
positive as well as negative regulatory effects of 
actin polymerisation were reported. Thus, in fMLP-
stimulated PMNL, actin polymerisation suppresses 
AA metabolism, visualized by a Cyt-evoked 
increase in LTB4 formation [14-16]. Also, 
suppression of the basal F-actin content and of 
stimulus-induced actin assembly by botulinum 
toxin C2 increased 5-LO product formation in 
response to soluble chemoattractants, paralleled by 
a loss of motile and phagocytotic functions [39]. In 
accordance with our findings, Cyts increased the 
[Ca
2+]i in human PMNL after stimulation with 
fMLP [40]. Similarly, in LB-treated RBL-2H3 mast 
cells exposed to antigen, an increased extend in the 
[Ca
2+]i was measured, accompanied by enhanced 
AA release [41].  
On the other hand, actin polymerisation may 
positively influence the AA pathway. Thus, Cyts 
inhibited the release and metabolism of AA in 
thrombin- or collagen-stimulated platelets [42, 43]. 
Notably, in human platelets, inhibition of actin 
polymerisation by Cyt D or latrunculin A inhibited 
the TG-evoked Ca
2+ entry [44]. Also in 
complement-stimulated glomerular epithelial cells 
[45] or zymosan-challenged macrophage-like 
P388D1 cells [46], Cyt D or LB reduced cPLA2 
activity and AA release. Together, the effect of 
actin polymerisation on the AA pathway seemingly 
depends on the cell type, the nature of the stimulus, 
and the transmitting signaling pathways, but 
appears to be tightly connected to the [Ca
2+]i.   
Analysis of the pathways mediating the 
enhancement of [Ca
2+]i  by LB suggests a role of 
PLC isoenzymes and Src family kinases. U-73122 
(that inhibits PLC) is capable to inhibit receptor-
coupled Ca
2+ mobilisation from internal stores [47]. 
U-73122 blocked the LB-evoked rise in [Ca
2+]i, 
suggesting that LB leads to release of Ca
2+ from 
internal stores through the PLC pathway. Among 
the PLC isoenzymes, the PLC?1 and -2 isotypes are 
expressed in hematopoietic cells [48] and are 
activated in response to chemoattractants by 
tyrosine phosphorylation involving nonreceptor 
protein tyrosine kinases (PTKs) such as Src family 
kinases [49, 50]. The selective Src family kinase 
inhibitors PP2 [27] and SU6656 [28] selectively 
blocked the effects of LB on Ca
2+ mobilisation, AA 
release, 5-LO  product synthesis, and 5-LO 
translocation, indicating the involvement of Src 
family kinases. It should be noted that the 
structurally related PP3 used as negative control for 
PP2 had no such effects, and PP2 or SU6656 did 
not block PMNL responses evoked by TG or 
ionophore in the absence of LB, excluding 
inhibitory effects on the enzymatic machinery of 
AA metabolism. Among the Src family kinase 
members, Fgr, Hck, and Lyn are expressed in 
PMNL [51], and using double knockout hck-/- fgr-
/- PMNL or PP1-treated cells a role of these kinases 
in Cyt B-induced degranulation was evident [52]. 
Also, there are indications that actin polymerisation 
signals through Src family kinases. For example, 
the nonreceptor PTKs Fer and Fyn are activated by 
LB-induced actin depolymerisation in CHO cells 
[24], and actin disassembly stimulates the 
nonreceptor PTK c-Abl in fibroblasts [53, 54] and 
c-Src in smooth muscle cells [25].  
In conclusion our data indicate that inhibitors of 
actin polymerization have a prominent influence on 
the release of AA and the subsequent conversion to 
proinflammatory 5-LO products by modulating the Fischer et al. Actin polymerisation inhibitors and leukotriene synthesis  9 
[Ca
2+]i  through Src family kinase/PLC signaling. 
Since PMNL migration and adhesion to sites of 
inflammation is connected to an extensive 
cytoskeleton remodeling [37], the committed 
polymerisation of actin may be regarded as a 
regulatory process, limiting Ca
2+-dependent PMNL 
functions in response to natural occurring 
inflammatory stimuli, down regulation of the 
biosynthesis of proinflammatory 5-LO products 
might be one example. 
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